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Abstract
Large portions of mammalian genomes are packaged into structurally compact heterochromatin, which
protects genome integrity and suppresses transcription of lineage-inappropriate genes. Characterization
of heterochromatic regions has relied on genomic mapping of associated histone modifications, such as
H3K9me3 and H3K27me3, and purification of proteins interacting with these modifications.
Heterochromatic regions marked by H3K9me3 have been shown to impede gene activation during
reprogramming to pluripotency, and I find that H3K9me3 domains can similarly impede conversion of
fibroblasts to hepatocytes. However, both H3K9me3 and H3K27me3 can be found in transcriptionally
active chromatin, limiting the accuracy of histone marks alone for identifying heterochromatin domains or
bound proteins that impede reprogramming. I developed a biophysical method to purify heterochromatic
regions, using sucrose gradients to isolate chromatin fragments that are resistant to sonication.
Sequencing of the purified material (Gradient-seq) revealed the genomic landscape of structural
heterochromatin in human fibroblasts, which is transcribed at low levels and contains largely distinct
H3K9me3 and H3K27me3 domains, as well as unmarked regions. Gradient-seq also uncovered subtypes
of H3K9me3 and H3K27me3 domains that are structurally euchromatic, a distinction corroborated by
increased gene transcription, hypomethylation at CpG islands, decreased association with the nuclear
lamina, and increased activation during hepatic reprogramming. Using quantitative proteomics, we found
172 proteins associated with heterochromatin after gradient sedimentation and H3K9me3-directed IP.
The identified proteins include known transcriptional repressors and are enriched for proteins shown to
impede reprogramming to pluripotency. We show that the RNA-binding protein RBMX, one of the proteins
most enriched by gradient sedimentation and H3K9me3 IP, is a functional regulator of heterochromatin.
RBMX and the related protein RBMXL1 are required for silencing of select heterochromatinized genes,
and depletion of these proteins in fibroblasts renders H3K9me3-marked hepatocyte genes more
competent for activation during reprogramming to the hepatic lineage. Thus, our biophysical method for
heterochromatin isolation has allowed us to create a genome-wide map of chromatin compaction in
human cells, to identify chromatin domain subtypes that impede conversion between differentiated
lineages, and to discover novel heterochromatin proteins that contribute to this reprogramming barrier.
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ABSTRACT
THE HUMAN HETEROCHROMATIN LANDSCAPE: GENOMIC SUBTYPES,
BOUND PROTEINS, AND CONTRIBUTIONS TO CELL IDENTITY
Justin S. Becker
Kenneth S. Zaret

Large portions of mammalian genomes are packaged into structurally compact
heterochromatin, which protects genome integrity and suppresses transcription of lineageinappropriate genes. Characterization of heterochromatic regions has relied on genomic
mapping of associated histone modifications, such as H3K9me3 and H3K27me3, and
purification of proteins interacting with these modifications. Heterochromatic regions
marked by H3K9me3 have been shown to impede gene activation during reprogramming
to pluripotency, and I find that H3K9me3 domains can similarly impede conversion of
fibroblasts to hepatocytes. However, both H3K9me3 and H3K27me3 can be found in
transcriptionally active chromatin, limiting the accuracy of histone marks alone for
identifying heterochromatin domains or bound proteins that impede reprogramming. I
developed a biophysical method to purify heterochromatic regions, using sucrose
gradients to isolate chromatin fragments that are resistant to sonication. Sequencing of
the purified material (Gradient-seq) revealed the genomic landscape of structural
heterochromatin in human fibroblasts, which is transcribed at low levels and contains
largely distinct H3K9me3 and H3K27me3 domains, as well as unmarked regions.
Gradient-seq also uncovered subtypes of H3K9me3 and H3K27me3 domains that are
structurally euchromatic, a distinction corroborated by increased gene transcription,
hypomethylation at CpG islands, decreased association with the nuclear lamina, and
v

increased activation during hepatic reprogramming. Using quantitative proteomics, we
found 172 proteins associated with heterochromatin after gradient sedimentation and
H3K9me3-directed IP. The identified proteins include known transcriptional repressors
and are enriched for proteins shown to impede reprogramming to pluripotency. We show
that the RNA-binding protein RBMX, one of the proteins most enriched by gradient
sedimentation and H3K9me3 IP, is a functional regulator of heterochromatin. RBMX and
the related protein RBMXL1 are required for silencing of select heterochromatinized
genes, and depletion of these proteins in fibroblasts renders H3K9me3-marked
hepatocyte genes more competent for activation during reprogramming to the hepatic
lineage. Thus, our biophysical method for heterochromatin isolation has allowed us to
create a genome-wide map of chromatin compaction in human cells, to identify chromatin
domain subtypes that impede conversion between differentiated lineages, and to discover
novel heterochromatin proteins that contribute to this reprogramming barrier.
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PREFACE
This dissertation is a series of chapters organized around published and submitted
manuscripts of which I am the primary author. Chapter 2 presents a review article that was
published in TRENDS in Genetics in January 2016. Chapter 4 presents a research
manuscript that has been submitted for publication. The experimental and analytical
methods used during my thesis research, in particular for the manuscript in Chapter 4, are
presented Chapter 3. These chapters all closely resemble the text of the submitted or
published work, with alterations to reflect the format and organization of the thesis. The
opening chapter discusses the relevant literature for the topics in covered in this
dissertation, including a description of gaps in the field prior to my work, which goes
beyond the more limited scope of the review in Chapter 2. Meanwhile, Chapter 5 presents
the major conclusions from my thesis research and contextualizes them in relation to
existing literature, while also presenting avenues for future investigation. Included as an
Appendix at the end of the document is an additional manuscript to which I contributed as
third author during my graduate work, which was published in Genes and Development.
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CHAPTER 1: INTRODUCTION
In multicellular organisms, a fixed complement of chromosomes is able to instruct
the development of the hundreds of different cell types, each with distinct morphologies
and functions, which makes possible the complex physiologies of eukaryotes. As an
organism develops, there is generally no change in the sequence of DNA or the number
of genes, and thus the diversity of cell fates must be achieved through the selective
activation and repression of different groups of genes, with each cell type having a
different signature of gene activity. In humans, it is estimated that less than 60 percent of
the genomic sequence with evidence for transcription is copied into RNA in a given specific
cell type (Djebali et al., 2012). Thus, the mechanisms that selectively induce or suppress
gene activity are central to understanding how diverse cell types are produced during the
course of normal development or tissue regeneration (Zaret, 2008; Hemberger et al.,
2009; Adam and Fuchs, 2016). Subsequent conversion of cells to a different cell type of
interest, such as for therapeutic replacement of tissue destroyed by disease (Wu and
Hochedlinger, 2011), requires a rewiring of the gene expression signatures that are
established during development, to activate genes required for the function of the new cell
type and extinguish expression of inappropriate genes (Vierbuchen and Wernig, 2012;
Papp and Plath, 2013).
A gene’s activity in any given cell type is closely related to the physical structure
of the chromatin fiber, with active regions being associated with a more open and
accessible conformation, while transcriptionally silent regions of DNA exhibit a denser
packaging of nucleosomes. Physical compaction of chromatin is understood to play a
causal role in gene silencing, by reducing the accessibility of the DNA template to binding
1

by transcription factors and other machinery necessary for transcription (Workman and
Kingston, 1998; Li et al., 2007). On the spectrum of chromatin accessibility, regions with
the highest level of compaction are termed “heterochromatin,” which classically have been
identified cytologically by their enhanced uptake of DNA dyes and dark appearance in an
electron microscope (Heitz, 1928; Brown, 1966; Underwood et al., 2016). By contrast,
“euchromatin” refers to the portion of chromatin that has a more open or decondensed
physical structure, appearing light in electron micrographs, and where the majority of
transcriptional activity is confined.
Heterochromatin formation occurs and has been most frequently studied at highly
repetitive, noncoding regions of the genome, such as regions flanking mammalian
centromeres and telomeres (Pardue and Gall, 1970; Fanti et al., 1998; Guenatri et al.,
2004; Probst and Almouzni, 2008), or at sequences with propensity for parasitic selfduplication, such as DNA- or RNA-based transposable elements (Pimpinelli et al., 1995;
Kazazian, 2004). The packaging of such loci into dense heterochromatin structures
prevents mutagenic recombination between repetitive sequences (Fanti et al., 1998;
Peters et al., 2001) and suppresses the activity of transposons (Slotkin and Martienssen,
2007; Montoya-Durango et al., 2009). Thus, heterochromatin serves to protect genome
integrity in addition to silencing inappropriate transcription (Eden et al., 2003; Peng and
Karpen, 2008). In metazoans, such repeat-rich regions form heterochromatin in most or
all cell types in the body, and thus are termed “constitutive heterochromatin” (Brown, 1966;
Saksouk et al., 2015). By contrast, regions of “facultative heterochromatin” are dynamic
during development, forming at particular stages or in a lineage-specific fashion (Brown,
1966; Trojer and Reinberg, 2007). One classic example of facultative heterochromatin is
the inactivation of one of the two X chromosomes in females, which is silenced in early
2

development to maintain proper gene dosage and which appears as a compacted,
electron dense Barr body (Heard, 2005; Peters et al., 2002; Rego et al., 2008). Facultative
heterochromatin also plays an important role in cell fate control, by stably repressing
lineage-inappropriate gene expression (Trojer and Reinberg, 2007; Allan et al., 2012; Xu
et al., 2014a; Snitow et al., 2016). The hallmark chromatin staining pattern of particular
cell types, such as the “clock-faced chromatin” of antibody-secreting plasma cells (JinnFei and el-Labban, 1986), illustrates the dramatic and specific rearrangements in
condensed heterochromatin that can accompany cell differentiation.

1.1 Properties of heterochromatin and role in cell identity
Defining features of heterochromatin include its physically dense structure and reduced
transcriptional output. Early biophysical studies showed that the darkly staining
heterochromatin masses in vertebrate nuclei had a structure that was more resistant to
mechanical shearing with a sonifier or pressure cell, and that these regions could be
physically isolated from the more heavily sheared euchromatic fibrils by differential
centrifugation (Doenecke and McCarthy, 1975; Frenster et al., 1963). These studies
showed that the shearing-resistant heterochromatin structures had minimal transcriptional
activity, contained repetitive DNA satellites, had a higher ratio of histone protein to DNA,
and were dependent on linker histone for their resistance to shearing (Doenecke and
McCarthy, 1975; Duerksen and McCarthy, 1971; Frenster et al., 1963). The condensed
nature of heterochromatic sequences is more typically assessed by resistance to cleavage
by nucleases such as DNase I and II and micrococcal nuclease (MNase) (Gottesfeld et
al., 1975; Wallrath and Elgin, 1995; Hamid et al., 1996), where the limited activity of the
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nucleases is assumed to mirror inaccessibility to transcriptional machinery. Moreover,
genetic studies of position-effect variegation (PEV) showed that compact heterochromatic
structures, when placed adjacent to active genes via chromosomal rearrangement, can
spread laterally along chromosomes into nearby loci and dominantly suppress
transcription (Tartof et al., 1984; Wallrath and Elgin, 1995). This phenomenon was
classically observed in the case of the white gene in Drosophila fruit flies, where
juxtaposition of the gene near pericentromeric or telomeric sequences caused a mosaic
pattern of gene expression and eye color in the developing fly (Tartof et al., 1984; Wallrath
and Elgin, 1995). More recent work has recapitulated this phenomenon in mammalian
systems using reporter transgenes that can be silenced by proximity to both repetitive and
gene-containing forms of heterochromatin (Ayyanathan et al., 2003; Tchasovnikarova et
al., 2015). Additional conserved properties of heterochromatin include spatial proximity to
the nuclear lamina (Csink and Henikoff, 1996; Guelen et al., 2008; Poleshko et al., 2013)
or nucleoli (Sadoni et al., 1999; van Koningsbruggen et al., 2010), as well as replication
late in S phase (O’Keefe et al., 1992).
Among the diverse post-translational modifications that are observed on histone
tails, di- and tri-methylation at the specific residue histone 3 lysine 9 (H3K9me2 and
H3K9me3) is highly enriched over repeat-rich heterochromatic sequences in organisms
ranging from Schizosaccharomyces pombe to humans (Nakayama et al., 2001; Schotta
et al., 2002; Peters et al., 2003; Martens et al., 2005). The gene Su(var)3-9 was discovered
as a powerful suppressor of PEV in Drosophila with dominance over most PEV enhancers
(Tschiersch et al., 1994), and it encodes a SET domain-containing enzyme that catalyzes
the demethylation and trimethylation of H3K9, with a particular role in pericentromeric
H3K9me3 (Rea et al., 2000; Czermin et al., 2001; Schotta et al., 2002). There are two
4

mammalian homologues of this enzyme, SUV39H1 and SUV39H2, which are required for
the integrity of pericentromeric heterochromatin, the silencing of satellite repeat
transcription, and the accuracy of mitotic and meiotic chromosome segregation (Aagaard
et al., 1999; Peters et al., 2001). Suv39h1/h2 double-mutant mice show perinatal lethality
after E12.5, reduced size, hypogonadism in males, and increased tumorigenesis (Peters
et al., 2001). In mammals, in addition to the SUV39H proteins, the enzyme SETDB1/ESET
also catalyze H3K9me2 and H3K9me3 deposition (Schultz et al., 2002), while
G9a/EHMT2 and GLP/EHMT1 contribute to H3K9me2 only (Tachibana et al., 2001, 2002,
2005). SETDB1 plays in important role in pluripotent cells by repressing transcription
factor genes for developmental lineages and trophectoderm (Bilodeau et al., 2009; Yeap
et al., 2009; Yuan et al., 2009; Lohmann et al., 2010), while G9a and GLP are required for
the stable silencing of pluripotency genes like Oct3/4 during early differentiation (Feldman
et al., 2006; Epsztejn-Litman et al., 2008; Liu et al., 2015). Consistent with these
observations, deletion of Setdb1 in mice causes lethality around the time of implantation
(Dodge et al., 2004), while loss of either G9a or GLP in mice is lethal by day E12.5
(Tachibana et al., 2002, 2005).
The H3K9me2/3 marks are not known to directly interfere with RNA transcription
or directly affect chromatin structure, but rather serve as a “landing platform” for
complexes involved in various aspects of transcriptional repression (Beisel and Paro,
2011; Black et al., 2012). The methylated lysine 9 residue is directly bound by the
chromodomain of Heterochromatin Protein 1 (HP1) (Bannister et al., 2001; Lachner et al.,
2001), which is a suppressor of PEV in Drosophila (Eissenberg et al., 1990) and has three
isoforms in mammals: HP1α/CBX5, HP1β/CBX1, and HP1γ/CBX3 (Fodor et al., 2010).
HP1 has the ability to self-oligomerize and interact simultaneously with more than one
5

nucleosome, features that may help to directly drive chromatin compaction (Canzio et al.,
2011). Moreover, HP1 proteins interact directly with a variety of repressive chromatin
modifiers, such as DNA methyltransferases (DNMTs) and histone deacetylases (HDACs)
(Eissenberg and Elgin, 2014). This is consistent with observations that H3K9 methylation
are epistatic to DNA methylation at CpG nucleotides and histone deacetylation at
pericentromeric repeats and embryonically silenced genes, sites where these three
chromatin features coincide (Lehnertz et al., 2003; Epsztejn-Litman et al., 2008). HP1
further interacts with the co-repressor KAP1/TRIM28/TIF1β (Ryan et al., 1999); both
proteins not only localize to H3K9me3-marked chromatin but also can in turn recruit H3K9
methyltransferases to act on nearby nucleosomes (Schultz et al., 2002; Eissenberg and
Elgin, 2014), providing a mechanism for heterochromatin spread (Al-Sady et al., 2013).
Importantly, forced tethering of the fission yeast methyltrasferase Clr4 to chromatin is
sufficient to drive gene repression, and when an H3K9 demethylase is ablated, this
repression is stable through multiple mitotic and meiotic generations even after removal
of the tethered Clr4 (Audergon et al., 2015; Ragunathan et al., 2015). These findings
establish the potential of H3K9me3 to function in epigenetic inheritance and its causal role
in gene silencing. Similar results have been obtained in mammalian cell culture systems,
where ectopic recruitment of HP1 or KAP1 can drive heritable H3K9me3 spreading and
gene silencing over distances of multiple kilobases (Ayyanathan et al., 2003; Groner et
al., 2010; Hathaway et al., 2012).
In addition to H3K9me3, trimethylation of a different histone 3 residue, lysine 27
(H3K27me3), also has important roles in transcriptional repression and chromatin
compaction (Margueron and Reinberg, 2011). H3K27 methylation is exclusively catalyzed
by a single protein complex, Polycomb Repressive Complex 2 (PRC2), which in mammals
6

can contain either of two methyltransferases EZH1 or EZH2 (Müller et al., 2002; Czermin
et al., 2002; Kuzmichev et al., 2002; Ferrari et al., 2014). This complex was named
‘Polycomb’ because its genetic disruption in Drosophila led to improper body
segmentation (Lewis, 1978), associated with aberrant de-repression of Hox transcription
factor genes (Lewis, 1978; Duncan, 1982). Recent genome-wide mapping studies have
revealed a global correlation between H3K27me3 and transcriptional repression (Barski
et al., 2007), and genes marked by H3K27me3 are markedly enriched for transcription
factors involved in cell fate transitions, a result corroborated in diverse organisms and
developmental lineages (Lee et al., 2006; Boyer et al., 2006; Schwartz et al., 2006;
Bracken et al., 2006; Xu et al., 2014a). H3K27me3 generated by PRC2 promotes binding
by the chromodomain-containing Polycomb Repressive Complex 1 (PRC1) (Lee et al.,
2007), which can directly compact nucleosome arrays in vitro (Francis et al., 2004).
However, other studies have found that the chromatin structure of H3K27me3-marked
promoters can remain accessible to binding by general transcription factors and RNA
polymerase II (Breiling et al., 2001; Dellino et al., 2004). These and other studies have
suggested that H3K27me3-associated repression is mediated at least partially through
blocking the transcriptional initiation or elongation of an engaged RNA polymerase
(Breiling et al., 2001; Dellino et al., 2004; Stock et al., 2007; Kanhere et al., 2010). Thus,
it remains unclear to what extent the H3K27me3 mark is associated with the highly
compact chromatin structure that is characteristic of heterochromatin.
Although the term “facultative heterochromatin” is more frequently associated in
the literature with H3K27me3 (eg, (Trojer and Reinberg, 2007)), regions marked by
H3K9me3 show substantial developmental rearrangement. Differentiated human cells
have megabase-sized domains of H3K9me3 that are expanded in both size and number
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in comparison to pluripotent embryonic stem (ES) cells (Hawkins et al., 2010), consistent
with a large increase in total H3K9me3 levels by mass spectrometry (Sridharan et al.,
2013). Differentiation-specific H3K9me3 domains encompass several genes required for
pluripotency, as well as numerous gene family clusters (encoding zinc finger transcription
factors, adhesion proteins, olfactory receptors, and mediaters of neurotransmission) with
cell type-specific function (Hawkins et al., 2010; Soufi et al., 2012; Vogel et al., 2006).
These large H3K9me3 domains are observed in diverse human cell lines and tissues, with
substantial regions of overlap as well as divergence when comparing different tissues
(Soufi et al., 2012; Becker et al., 2016). H3K9me3 is also strongly enriched with domains
mapped by their association with the nuclear lamina (lamina-associated domains, or
LADs), which also undergo developmental rearrangement (Guelen et al., 2008).
Meanwhile, H3K27me3-enriched regions can span hundreds of kilobases and, similar to
H3K9me3-marked regions, cover a larger fraction of the genome in differentiated cells
compared to ES cells (Pauler et al., 2009; Hawkins et al., 2010). Comparison of H3K9me3
and H3K27me3 domains in somatic cells reveals some regions of overlap but largely
distinct positioning in the genome (Hawkins et al., 2010; Chandra et al., 2012). This is
similar to the observation that H3K9me3 and H3K27me3 both contribute to silencing on
the inactive X chromosome but occupy distinct spatial domains (Chadwick and Willard,
2004; Heard, 2005; Nozawa et al., 2013). Comparable to findings for H3K9me3, earlier
studies suggested that coverage for the dimethyl mark H3K9me2 increases after exit from
pluripotency (Wen et al., 2009). Other groups have challenged this result, arguing that it
is dependent on the threshold set for defining H3K9me2-enriched regions (Filion and van
Steensel, 2010), though mass spectrometry data also reveals an increase in H3K9me2
levels in mouse fibroblasts compared to ES cells (Sridharan et al., 2013). Regardless,
8

enrichment of H3K9me2 can be found in common among H3K9me3- and H3K27me3marked regions (Chandra et al., 2012), suggesting that the two trimethyl marks allow more
specific delineation of two flavors of repressive chromatin.

1.2 Heterochromatin as a barrier to cell reprogramming
The epigenetic mechanisms that enforce cell type-specific transcription programs must be
overcome when cells are “reprogrammed” or converted to other cell fates, such as
pluripotency (Graf and Enver, 2009; Vierbuchen and Wernig, 2012). In 2006, it was shown
that overexpression of four genes is sufficient to convert differentiated cells, such as skin
fibroblasts, to induced pluripotent stem (iPS) cells, which closely resemble ES cells and
have the ability to give rise to any cell type in the embryo (Takahashi and Yamanaka,
2006; Takahashi et al., 2007). The four genes overexpressed in the original iPS
technique—OCT4, SOX2, KLF4, and CMYC (henceforth, “OSKM”)— all encode master
transcription factors expressed in pluripotent ES cells (Boyer et al., 2005; Takahashi and
Yamanaka, 2006). Additional combinations of genes are capable of generating iPS cells
(Buganim et al., 2012; Shu et al., 2013), with all such methods fundamentally relying on
lineage-specifying transcription factors to rewire gene expression programs toward a
desired fate (van Oevelen et al., 2013).
Among cellular conversion techniques, iPS cells represent a highly successful
example of reprogramming, as the cells produced closely resemble non-reprogrammed
ES cells on the functional, transcriptional, and epigenetic level (Maherali et al., 2007;
Wernig et al., 2007; Cahan et al., 2014). The technique also has tremendous utility in
biomedicine, since iPS cells derived from a patient can be differentiated to a cell type of
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interest, enabling the production of patient-specific cells for therapeutic transplantation
(Wu and Hochedlinger, 2011; Hanna et al., 2007; Wang et al., 2015) or for modeling of
diseases affecting tissues that cannot be cultured ex vivo (Moretti et al., 2010; Toma et
al., 2015). Nonetheless, transcription factor-driven iPS reprogramming remains a highly
inefficient process, with only a small fraction of the starting cell population (generally
<0.1%) reaching the iPS state, through a process that appears to be stochastic (Hanna et
al., 2009), and the duration of the process lasts over one month for human cells
(Vierbuchen and Wernig, 2012; Papp and Plath, 2013). Although expression of the iPS
reprogramming factors for a few days is sufficient to cause widespread downregulation of
the somatic transcriptional program in the majority of cells, activation of the pluripotency
network is more delayed (Brambrink et al., 2008; Stadtfeld et al., 2008; Polo et al., 2012;
Tanabe et al., 2013). Among genes repressed in the starting cell type, a particular subset
of pluripotency markers—so-called “late-reprogramming genes”—are only expressed in
the final stages of the reprogramming process and are highly predictive of successful iPS
conversion (Buganim et al., 2012; Polo et al., 2012).
Our laboratory previously mapped the genome-wide binding of the OSKM factors
after 48 hours of expression in human fibroblasts (Soufi et al., 2012). This work showed
that the factors are able to engage their gene targets in a range of chromatin contexts. Yet
there are megabase-sized stretches of chromatin that lack binding for all four factors, even
though the factors were able to bind such sites in ES cells (Soufi et al., 2012). These
regions, defined by their differentiation-specific impediment to OSKM binding, were
termed “Differentially Bound Regions” (DBRs) (Soufi et al., 2012). The DBRs, which
average ~2 MB in size, closely correspond to domains of H3K9me3 present in fibroblasts
and absent in pluripotent ES cells. In addition to H3K9me3, the DBRs have several other
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features of heterochromatin: resistance to DNase-I digestion, transcriptional repression,
overlap with LADs, and an enrichment for repetitive elements (Soufi et al., 2012). The
DBRs also contain genes essential for pluripotency, including NANOG, SOX2, DPP2,
DPPA4, GDF3, and ZFP42. Strikingly all of these genes were previously shown to be
delayed in activation until the late stages of reprogramming (Buganim et al., 2012; Polo
et al., 2012), suggesting that a failure of the reprogramming factors to access the DNA
within heterochromatic DBRs was a key underlying mechanism for the inefficiency of iPS
conversion. Indeed, reducing H3K9me3 levels through knockdown of SUV39H1/H2
methyltransferase caused an increase in OCT4 and SOX2 binding within DBRs (Soufi et
al., 2012), concomitant with an increase in the rate and number of human iPS colonies
formed (Onder et al., 2012; Soufi et al., 2012). In the murine system, similar results have
been shown for shRNA against SETDB1, which caused one of the largest increases in
iPS colony formation in a screen of 615 chromatin-related genes (Cheloufi et al., 2015).
Mouse iPS reprogramming is also enhanced by inhibition or knockdown of the H3K9me2related enzymes G9a and GLP (Shi et al., 2008; Sridharan et al., 2013), as well as by
knockdown of HP1 isoforms, with the strongest effect seen for HP1γ/CBX3 (Sridharan et
al., 2013). Thus, perturbation of H3K9me3-related heterochromatin has emerged as a
major strategy for enhancing conversion to pluripotency.
Heterochromatin structures over core pluripotency loci not only impede the rate of
the reprogramming process, but also are a major cause for cells arresting in nonpluripotent states. In a plate of cells expressing the reprogramming factors, many go on
to become “partially reprogrammed” cells, which express a subset of undifferentiated
markers and can be stably propagated, but lack expression of many late reprogramming
genes and have limited developmental potential (Mikkelsen et al., 2008; Fussner et al.,
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2011). In partially reprogrammed cells, core pluripotency genes retain H3K9me3 (Chen et
al., 2013), high levels of DNA methylation (Mikkelsen et al., 2008; Fussner et al., 2011),
and a compact chromatin structure (Fussner et al., 2011). Erasure of heterochromatin
marks by knockdown of SETDB1 or SUV39H1, overexpression of the H3K9 demethylase
KDM4B, or inhibition of DNA methyltransferases are sufficient to drive partially
reprogrammed cells to the iPS state (Chen et al., 2013; Mikkelsen et al., 2008). These
findings reveal that failure to convert H3K9me3-marked heterochromatin to active
euchromatin is a major restriction point on the path to the iPS state. Moreover, even in
fully reprogrammed human iPS cells, there exist large domains with aberrant non-CpG
methylation compared to compared to ES cells (Lister et al., 2011), and 21 out of 22 of
these domains fall within heterochromatic DBRs (Soufi et al., 2012). Thus,
heterochromatin contributes to the persistent epigenetic signatures that remain in iPS
cells, highlighting the challenge of activating these regions of chromatin during
transcription factor-mediated reprogramming.
Moreover, the barrier imposed by H3K9me3-marked heterochromatin on
reprogramming

is

not

specific

to

particular

transcription

factor

combinations.

Reprogramming to pluripotency can also be carried out by somatic cell nuclear transfer
(SCNT), a long-established technique (Gurdon et al., 1958) involving transfer of a nucleus
from a differentiated cell into an enucleated egg in order to restore the developmental
potential of the donor nucleus. SCNT allows for the cloning of mice to produce viable
offspring (Wakayama et al., 1998), but most of the resulting embryos arrest at an early
developmental stage (Pasque et al., 2011a). By generating transcriptomic data for twocell mouse embryos, Zhang and colleagues curated large genomic regions called
“Reprogramming Resistant Regions” (RRRs), which become acquire transcriptional
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activity in normal fertilized embryos but remain aberrantly silenced in SCNT-derived
embryos (Matoba et al., 2014). The RRRs, which ranged from 100 to 800 kilobases in
size, had high levels of H3K9me3 in the donor nuclei and were enriched for LINE and LTR
repeat elements (Matoba et al., 2014), similar to the DBRs discovered for human iPS
reprogramming (Soufi et al., 2012). Knockdown of SUV39H1/H2 or overexpression of the
H3K9 demethylase KDM4D ameliorated the RRR expression defect and allowed as much
as 80% of the embryos to reach the blastocyst stage, compared to less than 20% in
controls (Matoba et al., 2014). This dramatic improvement in the viability and
developmental competence of SCNT is consistent with previous results after deletion of
G9a methyltransferase (Epsztejn-Litman et al., 2008). Moreover, these findings suggest
that H3K9me2/3-marked regions pose an impediment not only to the activity of the OSKM
factors but also to the coordinated action of the diverse components of the egg cytoplasm.
In addition to influencing the kinetics of the reprogramming process, dissolution of
heterochromatin may be instrumental to the pluripotent state itself. Electron spectroscopic
imaging (ESI) allows high-resolution analysis of chromatin structures, including detection
of nucleosomes, calculation of inter-fiber distances, and distinguishing of chromatin from
protein-based complexes (Ahmed et al., 2010). In pluripotent cells of the developing
embryonic epiblast, ESI reveals a dispersed network of 10-nm fibers and an absence of
blocks of highly compacted chromatin, which is seen at later stages of development in the
primitive endoderm or trophectoderm cells (Ahmed et al., 2010). These densely packed
heterochromatin fibers are also absent in cultured ES or iPS cells, while they remain in
partially reprogrammed cells (Fussner et al., 2011). ES cells also lack dense
heterochromatin structures detected by electron microscopy (Underwood et al., 2016)
and, compared to differentiated cells, have fewer and less intense H3K9me3 foci
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(Meshorer and Misteli, 2006). These observations, along with the finding that ES-cell
chromatin has a higher rate of exchange of linker histone and HP1 (Meshorer and Misteli,
2006), has led to the conclusion that pluripotency represents a more globally accessible
chromatin state (Gaspar-Maia et al., 2011). This model is supported by the elevated global
transcriptional output of ES cells, leaky transcription of tissue-specific genes, and
expression of satellite repeats and LINE and SINE retrotransposons (Efroni et al., 2008),
which demonstrates that heterochromatin function—in addition to structure—is different
between pluripotent and differentiated cells.
Given the reduction or absence of traditional hallmarks of heterochromatin in
pluripotent cells, it is currently unclear whether the profound influence of H3K9me3
removal on reprogramming to pluripotency will apply generally to other cell-conversion
techniques, or whether it is purely a byproduct of the unique features of the pluripotent
state. A variety of methods exist for reprogramming somatic cells directly to another
differentiated lineage, without going to through a pluripotent intermediate, by
overexpressing tissue-specific transcription factors (Ladewig et al., 2013). Before the iPS
era, Weintraub and colleagues showed that ectopic MyoD expression was sufficient to
convert fibroblasts to muscle progenitors (Davis et al., 1987), and now diverse
transcription factor combinations have been discovered for converting fibroblasts to
cardiomyocytes (Ieda et al., 2010), neurons (Vierbuchen et al., 2010), hepatocytes (Sekiya
and Suzuki, 2011; Huang et al., 2011), as well as for causing cells to switch lineages within
the hematopoietic (Xie et al., 2004) or pancreatic (Zhou et al., 2008) compartments.
Directly reprogrammed cells are typically shown to have undergone a cell fate change by
their morphology, expression of characteristic marker genes, and rescue of tissue function
in vivo in transplantation experiments (Zhou et al., 2008; Sekiya and Suzuki, 2011; Huang
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et al., 2011). However, in nearly all cases, transcriptome-wide assessment reveals
substantial differences between directly reprogrammed cells and the native cell types they
mimic (Cahan et al., 2014; Morris et al., 2014).. Transcriptomes of engineered cell types
reveal persistent expression of genes specific to the starting cell type, failure to completely
induce the gene networks of the desired cell population, and, in some cases, aberrant
induction of genes for additional developmental lineages that share some of the same
transcription factors (Marro et al., 2011; Cahan et al., 2014; Morris et al., 2014). Thus,
whereas iPS reprogramming is an inefficient but highly faithful conversion to the
pluripotent state, directed conversion methods often achieve high yields of reprogrammed
cells but are – as a class – less faithful to their intended lineage (Cahan et al., 2014).
There is great interest in developing techniques to generate large numbers of
functional human hepatocytes in vitro, which could allow therapeutic transplantation of
patient-derived cells for metabolic liver disease (Haridass et al., 2008; Asgari et al., 2013)
and improved screening of pharmaceuticals for pharmacokinetics and toxicity (Sahi et al.,
2010). Two recent reports describe the reprogramming of human fibroblasts to a
hepatocyte-like state, which they termed human induced hepatocytes (hiHeps), using
different combinations of endodermal transcription factors that both included HNF1A and
HNF4A (Huang et al., 2014; Du et al., 2014). The resulting cells exhibit hepatocyte
morphology, express marker genes like albumin and α-1-antitrypsin, and demonstrate
aspects of normal liver metabolism like glycogen synthesis, LDL update, and detoxification
of certain xenobiotic drugs (Huang et al., 2014; Du et al., 2014). However, analysis of
hiHep transcriptomes reveal widespread differences compared to native hepatocytes in
culture, including hepatocyte-specific transcription factor and metabolic genes that remain
uninduced in the reprogrammed cells (Huang et al., 2014; Du et al., 2014). The hiHep
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cells are capable of engrafting in the livers of mouse models of liver failure (Huang et al.,
2014; Du et al., 2014), including fumarylacetoacetate hydrolase (FAH)-deficient animals
(Azuma et al., 2007), which represents an improvement over previous work using cells
differentiated from pluripotent stem cells (Ji et al., 2013; Du et al., 2014; Vallier, 2014).
However, in vivo engraftment and expansion has only been demonstrated in hiHep cells
after cell immortalization with to disable cell-cycle checkpoints (tumorigenic manipulations
that preclude therapeutic use), and, even so, the engrafted hiHep cells secreted an order
of magnitude less albumin (Du et al., 2014) or required an order of magnitude more
transplanted cells to rescue mouse survival (Huang et al., 2014) compared to native fetal
hepatocytes. A particular challenge in the differentiation or reprogramming of cells to the
mature hepatic fate is the activation of a panel genes encoding enzymes of the
cytochrome P450 family, which are critical for drug metabolism and excretion (Vallier,
2014). However, the role of H3K9me3 or heterochromatin in impeding activation of these
gene classes has not been explored, and no manipulations of chromatin state have been
shown to improve conversion to the hepatic lineage.

1.3 The regulation and composition of mammalian heterochromatin
Given the role of H3K9me3-dependent heterochromatin in impeding cell reprogramming,
the mechanisms that control H3K9me3 deposition—and, in particular, the processes that
establish H3K9me3 domains in a cell type-specific manner—might be targeted in order to
influence reprogramming efficiency or allow access to specific cell fates. However, very
little is known about the protein machinery that mediates the observed dynamics in
H3K9me3 domains among developmental stages and different lineages (Allan et al., 2012;
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Soufi et al., 2012; Becker et al., 2016). Since H3K9me3 methyltransferases are
constitutively expressed and do not themselves recognize specific DNA sequences
(Aagaard et al., 1999; Tachibana et al., 2001; Marmorstein, 2003), additional mechanisms,
such as transcription factor- or RNA-mediated recruitment of methyltransferases, are
required to explain the selectivity of H3K9me3 deposition.
Several transcription factors have been shown to play a role in heterochromatin
establishment, though in many cases such mechanisms were described for constitutively
heterochromatic repeats as opposed to gene-containing domains. Gfi1b, Sall1, Zeb1, and
certain Pax family transcription factors all bind to pericentromeric satellites, which contain
sequence motifs for each of these factors within the repeated unit (Vassen et al., 2006;
Yamashita et al., 2007; Bulut-Karslioglu et al., 2012). Gfi1b is known to directly interact
with SUV39H1 and G9a, suggesting a direct role in H3K9me3 deposition (Vassen et al.,
2006). Meanwhile, Pax3 and Pax9 are required in mouse fibroblasts for the silencing of
major satellite transcription and for the integrity of pericentromeric heterochromatin, but
the mechanism by which their binding leads to repression rather than persistent activity is
unclear and may involve a transient state of transcript generation (Bulut-Karslioglu et al.,
2012). The roles of Gfi1b, Pax3, and Pax9 in constitutive heterochromatin is surprising
given the cell type-specific expression of these factors (Vassen et al., 2006; BulutKarslioglu et al., 2012), suggesting that alternative mechanisms maintain pericentromeric
heterochromatin depending on the lineage and the factors expressed.
An important regulator of H3K9me3 recruitment is Krüppel-associated box
(KRAB)-associated protein 1 (KAP1), also known as TRIM28 or TIF1β (Iyengar and
Farnham, 2011). KAP1 is the obligate co-repressor for KRAB domain-containing zinc
finger transcription factors (KRAB-ZNFs), a family of hundreds of recently evolved
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transcription factors that are specific to tetrapods (Friedman et al., 1996; Kapopoulou et
al., 2016). KAP1 interacts directly with both HP1 and SETDB1, and thus it acts as a
molecular link between the sequence-specific binding of KRAB-ZNFs and the subsequent
deposition and propagation of H3K9me3 (Ryan et al., 1999; Schultz et al., 2002; Iyengar
and Farnham, 2011). Phosphorylation of KAP1 at serine 824, which occurs in response
to DNA damage, causes a global reduction in chromatin compaction (Ziv et al., 2006), and
mutations mimicking constitutive phosphorylation of this residue promote iPS
reprogramming (Seki et al., 2010) Ectopic tethering of KAP1 or a KRAB domain is
sufficient to induce spreading of H3K9me3 over distances of tens of kilobases and
mitotically heritable gene silencing (Ayyanathan et al., 2003; Groner et al., 2010; Gilbert
et al., 2014). However, recent findings suggest that KRAB-ZNF mediated recruitment of
KAP1 may not have a widespread role in heterochromatin domain formation. Deletion of
KAP1’s RBCC domain, which is required for KAP1-KRAB interaction, predominantly
affects KAP1 binding at the 3’ end of ZNF genes (Iyengar et al., 2011). These genes
represent a small subset of KAP1’s chromatin binding, do not significantly change
expression upon loss of KAP1 (Iyengar et al., 2011), and may not be heterochromatic
given evidence of transcriptional elongation (Blahnik et al., 2011). While KAP1 is required
for the silencing of endogenous retroviruses (Rowe et al., 2010; Ecco et al., 2016), no
study has reported the elimination of a large (>10 kb) H3K9me3 domain upon loss of a
specific KRAB-ZNF or even KAP1 itself.
Indeed, a challenge for transcription factor-dependent models of H3K9me3
domain formation is the sheer size of these domains. While lateral propagation of
H3K9me3 from a single nucleation site, such as a transcription factor binding motif, is
compatible with experimental evidence (Groner et al., 2010; Hathaway et al., 2012) and
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mathematical modeling (Hodges and Crabtree, 2012) for distances of tens of kilobases,
such mechanisms to not account for the creation of H3K9me3 domains of multiple
megabases, as is observed in differentiated human cells (Hawkins et al., 2010; Chandra
et al., 2012; Soufi et al., 2012). The formation of such domains may involve the
coordinated action of many reiterated transcription factor binding events, or may
alternatively involve mechanisms unrelated to local sequence motifs.
In addition to transcription factor-dependent mechanisms, it has been shown that
nucleation and maintenance of heterochromatin domains in some cases depends upon
noncoding RNA (ncRNA). Such RNA-based mechanisms have been best elucidated in
the fission yeast S. pombe, where maintenance of pericentromeric heterochromatin
requires the RNA interference (RNAi) pathway (Volpe et al., 2002), which is activated by
low-level transcription of the pericentromeric repeats themselves (Djupedal et al., 2005;
Kato et al., 2005). Repeat-derived ncRNAs are processed into small interfering RNAs
(siRNAs) and stay tethered to the site of nascent heterochromatin transcription by RNARNA base pairing; this creates a binding platform for the recruitment of additional
machinery involved in transcriptional silencing, including an H3K9me3 methyltransferase
(Bühler et al., 2006; Zhang et al., 2008; Bayne et al., 2010). More recently, additional
ncRNA-based mechanisms that are distinct from RNAi, such as those involving RNA
processing factors and the RNA exosome, have been implicated in heterochromatin
establishment in fission yeast (Bühler et al., 2007; Reyes-Turcu et al., 2011).
Whether RNAi contributes to heterochromatin in mammals remains controversial,
in part owing to inconsistent evidence for heterochromatin-derived siRNAs (Saksouk et
al., 2015). However, accumulating data suggest that other forms of ncRNA may have a
substantial role in regulating mammalian heterochromatin. Several groups have observed
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that, at some heterochromatin regions, the presence of H3K9me3 is compatible with
simultaneous low-level transcription (Martens et al., 2005; Terranova et al., 2005; Lu and
Gilbert, 2007). HP1a binds directly to RNA, including transcripts derived from satellite
repeats, and this interactions is required for its localization to and function at
pericentromeric heterochromatin (Maison et al., 2002; Muchardt et al., 2002; Maison et
al., 2011). In normal mouse embryogenesis, pericentromeric heterochromatin formation
requires an early burst of transcription from these regions (Probst et al., 2010; Casanova
et al., 2013), and ectopic addition of satellite-derived dsRNAs is sufficient to rescue
defective heterochromatin formation in an H3.3 mutant (Santenard et al., 2010). Away
from the centromere, LINE-1 retrotransposons undergo a similar early developmental
burst in transcription that precedes their silencing (Fadloun et al., 2013), and regions of
persistent LINE-1 transcription on the X chromosome are found in close proximity to genes
silenced by X inactivation, suggesting a possible direct role in silencing (Chow et al.,
2010). Finally, a ribosomal-derived ncRNA has been shown not only to participate in
silencing of ribosomal DNA, but also to initiate widespread heterochromatin formation and
loss of pluripotency when ectopically expressed in human ES cells (Savić et al., 2014).
The mechanisms and protein machinery that link the transcription of such ncRNAs to
H3K9me3 deposition and chromatin compaction are largely undefined. Moreover, it
remains to be determined what are the relative contributions of RNA-based versus
transcription factor-based mechanisms in the formation of the megabase-scale domains
of facultative heterochromatin that emerge during mammalian development (Hawkins et
al., 2010).
To identify new proteins involved in the regulation of H3K9me3, some groups have
performed chromatin immunoprecipitation (ChIP) to isolate H3K9me3-marked chromatin
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fragments, followed by mass spectrometry (MS) to define the protein content of those
fragments (Soldi and Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015). An alternative
approach is the use of MS-based proteomics after pulldown of soluble complexes with an
H3K9me3 peptide bait, which has been used to identify “reader” complexes interacting
directly with the mark (Vermeulen et al., 2010; Eberl et al., 2013). Each of these studies
profiled interacting proteins for multiple histone modifications, and the H3K9me3associated proteins were not further studied to investigate a functional role in H3K9me3
or gene repression, nor were their genomic locations mapped (Vermeulen et al., 2010;
Eberl et al., 2013; Soldi and Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015).
Nonetheless, large numbers of H3K9me3-associated proteins were identified with no
previously characterized role in heterochromatin. The identified H3K9me3 readers
included several transcription factors with zinc finger domains (non-KRAB), including
POGZ, CHAMP1/ZNF828, ZNF282D, ANDP, and ZMYM4, which were also shown to
interact directly or indirectly with HP1 isoforms (Eberl et al., 2013; Vermeulen et al., 2010).
Other groups have shown, by ChIP-MS, that H3K9me3-marked chromatin fragments are
enriched for components of the nuclear scaffold/matrix, including Scaffold Attachment
Factor (SAF)-A/HNRNPU, SAFB1, SAFB2, and SAFB-like transcriptional modulator, as
well as Matrin3 (MATR3) (Soldi and Bonaldi, 2013), consistent with a tethering of
heterochromatin to nuclear structures. Surprisingly, simple inspection of these H3K9me3related proteomic datasets reveals large number of RNA-binding proteins. A published list
of H3K9me3 readers (Vermeulen et al., 2010) includes several heterogeneous
ribonucleoproteins (HNRNPs) (HNRNPA1, HNRNPA2, HNRNPA2B1, HNRNPK, and
HNRNPL) as well as the RNA-binding proteins NONO and SFPQ, which are involved in
splicing but have also been shown to act as corepressors for hormone receptors (Mathur
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et al., 2001; Dong et al., 2009). A H3K9me3-directed ChIP-MS study in the same cell type
identified all of these same proteins as well as scores of additional RNA-processing factors
(Transformer-2 protein homologs A and B; serine/arginine-rich splicing factors (SRSFs) 1,
2, 3, 6, and 7; RNA binding motif protein, X-linked (RBMX); etc) (Soldi and Bonaldi, 2013).
The specific RNA-binding protein HNRNPK has recently been found to interact with
SETDB1 and KAP1, promote H3K9me3 deposition at gene promoters and endogenous
retroviruses, and impede iPS reprogramming (Bao et al., 2015; Thompson et al., 2015).
However, for the larger set of H3K9me3-associated RNA-binding proteins, their role in
heterochromatic silencing is unexplored, as is whether RNA interaction is required for the
interaction with H3K9me3-marked chromatin. These studies suggest that the composition
and regulation of mammalian heterochromatin is likely to involve a wider diversity of
factors than the canonical chromodomain proteins and repressive histone modifiers.

1.4 H3K9me3 outside of heterochromatin and avenues for investigation
Although H3K9me3 is enriched at both repetitive and gene-containing regions of
repressed heterochromatin, care must be taken when inferring the relationship between
H3K9me3-associated proteins and heterochromatin per se. First, two of the most
comprehensive ChIP-MS datasets (Engelen et al., 2015; Ji et al., 2015) were prepared
using murine ES cells, which appear to completely lack the highly compacted chromatin
structures present in differentiated cells (Meshorer and Misteli, 2006; Fussner et al., 2011;
Underwood et al., 2016). These findings illustrate that H3K9me3 deposition can in the
absence of the high levels of physical compaction that are typically thought to define
heterochromatic regions. Second, even in differentiated cells, the H3K9me3 mark is
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present in actively transcribed regions of chromatin. Work in both Drosophila and
mammalian cells has shown an increase in H3K9me3 and HP1 within in gene bodies upon
transcriptional induction (Piacentini et al., 2003; Vakoc et al., 2005), and indeed HP1
appears to promote transcriptional elongation at least some genes (Piacentini et al., 2003,
2009; Riddle et al., 2012), with certain phosphorylated forms of mammalian HP1γ
localizing preferentially to active chromatin (Lomberk et al., 2006).
In general, levels of H3K9me3 within transcribed gene bodies are quantitatively
lower than regions of constitutive heterochromatin (Vakoc et al., 2005). However, specific
regions have a seemingly paradoxical chromatin configuration with high levels of
H3K9me3 coincident with gene transcription (Blahnik et al., 2011; Riddle et al., 2012). In
human cells, this has been observed at clusters of KRAB-ZNF genes on chromosome 19,
which feature large domains of H3K9me3 and HP1 binding (Vogel et al., 2006)
overlapping with H3K36me3 (Blahnik et al., 2011), a mark that is associated with
transcription elongation (Vakoc et al., 2006). Analysis of SNPs in RNA-seq data confirms
that both alleles of the H3K9me3-marked ZNF genes are expressed (Blahnik et al., 2011).
These clusters of genes are the same sites where KAP1 binding was observed to be most
dependent upon interaction with KRAB domains (Iyengar et al., 2011), suggesting that
KAP1 recruitment by KRAB-ZNF proteins to their own genes, previously proposed to be
a negative feedback mechanism (O’Green et al., 2007), is compatible with gene
expression (Blahnik et al., 2011; Valle-García et al., 2016) and therefore does not
necessitate formation of repressive heterochromatin. The KRAB-ZNF clusters on
chromosome 19 were also shown to have a distinct pattern of three-dimensional genomic
contacts and, compared to other H3K9me3-marked regions, were classified as forming a
distinct architectural subcompartment (Rao et al., 2014). Of note, this finding required
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targeted analysis of chromosome 19 alone, and the approach lacked sensitivity to detect
similar regions genome-wide (Rao et al., 2014). A similar chromatin state, with strong
enrichment for H3K9me3 and HP1 coinciding with H3K36me3-marked, transcribed genes,
has been observed on Drosophila chromosome 4 (Riddle et al., 2012). At present, no
study has comprehensively defined regions of H3K9me3 that are permissive to
transcription or have an accessible chromatin structure, and it is unknown whether such
domains exist on human chromosomes other than chr19 or affect non-ZNF human genes.
The finding of the H3K9me3 mark in the context of transcriptionally active
chromatin suggests a limitation of approaches dependent upon this modification, such has
H3K9me3 ChIP-MS (Soldi and Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015), to
define with confidence the protein composition of repressive heterochromatin. Further
work is necessary to determine whether, for example, the large number of RNA-binding
proteins found to bind or co-precipitate with H3K9me3 (Vermeulen et al., 2010; Soldi and
Bonaldi, 2013) are “contaminants” from euchromatic forms of H3K9me3 domains, or
alternatively

whether

such

proteins

indeed

contribute

to

highly

compacted

heterochromatin in mammalian cells, similar to RNA-based mechanisms known to
regulate yeast or fly heterochromatin (Grewal and Elgin, 2007; Bühler et al., 2007; ReyesTurcu et al., 2011). A second limitation of H3K9me3-dependent approaches to define the
heterochromatin proteome is the exclusion of heterochromatic regions marked by
H3K27me3, as exemplified by regions on the inactive X chromosome (Plath et al., 2003;
Rego et al., 2008), or possibly regions of heterochromatin that might exist despite the
absence of either mark (as suggested by computational clustering of Drosophila and
human chromatin states (Filion et al., 2010; Zhu et al., 2013)). Although some evidence
suggests that H3K27me3-marked chromatin is more accessible to transcription factor
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binding and hence may be less heterochromatic than H3K9me3-marked chromatin
(Breiling et al., 2001; Dellino et al., 2004), this model would be best tested by a method
that defined heterochromatic regions genome-wide based on chromatin structure,
independent form histone mark, which could then be compared to H3K9me3 and
H3K27me3 ChIP-seq profiles. Physical isolation of structurally compact regions as intact
chromatin fragments would allow simultaneous analysis of their genomic localization and
proteomic composition. Finally, to the extent that regions with heterochromatic structure
diverge from H3K9me3 or H3K27me3 domains, it is important to assess the combinations
of chromatin structures and histone marks that impart resistance to gene activation during
cellular reprogramming, to gain insight into the barriers to cell fate conversion.
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CHAPTER 2. H3K9ME3-DEPENDENT HETEROCHROMATIN:
BARRIER TO CELL FATE CHANGES (REVIEW ARTICLE)

The following chapter contains a review article that was published in TRENDS in Genetics
in January 2016 (Vol. 32(1), pages 29-41). The content of the paper focuses on the
connection between H3K9me3-marked heterochromatin and cell fate control, with
particular emphasis on H3K9me3 as a barrier to cell reprogramming. The paper was cowritten by myself and Dario Nicetto, Ph.D. (co-first authors), with guidance from Dr. Zaret
(senior author).
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2.1 Modes of developmental gene silencing
The diverse repertoire of cell types in multicellular organisms is achieved by the differential
regulation of gene expression. While much effort has been expended to study how genes
are activated, less is known about mechanisms by which cell type-inappropriate genes
are repressed, even though this is a crucial aspect of cell fate control (Fisher and
Merkenschlager, 2002; Hemberger et al., 2009; Meister et al., 2011). It has been long
been appreciated that genetic material in the nucleus can be partitioned into two general
categories: open ‘euchromatin,’ which has a relatively low density of DNA and high rates
of gene transcription, and ‘heterochromatin,’ which has a relatively high density of DNA
and low rates of gene transcription. Heterochromatin was originally discerned cytologically
by the intensity of dark staining with DNA dyes (Heitz, 1928). The physically condensed
state of these regions, reflected by their increased resistance to nucleases (Wallrath and
Elgin, 1995) and their compact properties in biophysical assays (Frenster et al., 1963;
Gilbert and Allan, 2001), is mechanistically linked to gene silencing, since compaction
renders the DNA template less accessible to binding by the transcriptional machinery.
Heterochromatin also has the property of spreading along chromosomes, which is
illustrated by the compaction and silencing of transgenes integrated proximal to
endogenous heterochromatin regions (Wallrath and Elgin, 1995; Elgin and Reuter, 2013).
A large fraction of mammalian genomes is taken up by repeat-rich sequences—
including tandem-repeat satellites near centromeres and telomeres, retrotransposons,
and endogenous retroviruses—which pose a risk to genome integrity through their
potential for illicit recombination and self-duplication. Thus, in all cell types, there is utility
in keeping such regions physically inaccessible and, consequently, transcriptionally silent,
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by packaging them in condensed heterochromatin. Such repeat-rich regions are classified
as ‘constitutive’ heterochromatin, as their silencing is universal across developmental
lineages (Saksouk et al., 2015). By contrast, ‘facultative’ heterochromatin refers to regions
whose compaction and silencing is dynamic in development, such as at cell type-specific
genes and enhancers (Trojer and Reinberg, 2007).
In organisms ranging from the fission yeast Schizosaccharomyces pombe to
humans, repeat-rich constitutive heterochromatin is marked by dimethylation and
trimethylation of histone 3 lysine 9 (H3K9me2 and H3K9me3) (Rea et al., 2000; Nakayama
et al., 2001; Martens et al., 2005). In mammals, these covalent modifications are catalyzed
by five members of the SET-domain containing family of methyltransferases. SETDB1 and
the related enzymes SUV39H1 and SUV39H2 contribute to both H3K9me2 and H3K9me3
(Rea et al., 2000; Schultz et al., 2002), while GLP and G9a (also called EHMT1 and
EHMT2, respectively) catalyze H3K9me1 and H3K9me2 (Tachibana et al., 2001, 2002,
2005). H3K9me2/me3 are bound by the chromodomain of Heterochromatin Protein 1
(HP1, three isoforms in mammals), which can self-oligomerize and recruit repressive
histone modifiers, contributing to heterochromatin compaction and spread (Bannister et
al., 2001; Lachner et al., 2001; Canzio et al., 2011). The methyltransferases that deposit
H3K9me2 and H3K9me3 are required to establish high levels of DNA methylation at CpG
dinucleotides and low levels of histone acetylation, two other hallmarks of heterochromatin
(Epsztejn-Litman et al., 2008; Lehnertz et al., 2003). By contrast, cell type-specific
repression of many genes requires trimethylation of a different H3 residue, lysine 27
(H3K27me3), which is catalyzed by the Polycomb repressive complex 2 (PRC2) (Boyer et
al., 2006; Ezhkova et al., 2009; Lee et al., 2006; Xu et al., 2014a). This mode of
“facultative” silencing is particularly prominent at many lineage-specifying transcription
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factor genes, such as the homeobox (HOX) family (for detailed review of the role of PRC2
and H3K27me3 in development, see: (Margueron and Reinberg, 2011; Beisel and Paro,
2011)).
The presence of H3K27me3 over gene promoters is highly correlated with gene
repression (Hawkins et al., 2010; Margueron and Reinberg, 2011), yet it has been shown
that H3K27me3-marked promoters remain accessible to binding by general transcription
factors and a paused RNA polymerase (Breiling et al., 2001; Dellino et al., 2004). This
contrasts with chromatin marked by H3K9me3, which occludes the DNA from binding by
transcription factors with diverse DNA-binding domains (Soufi et al., 2012). Thus,
H3K9me3-dependent and H3K27me3-dependent silencing appear to be mechanistically
different based on the extent to which the chromatin is accessible to other factors (see
Table 2-1).
Although the H3K9me3 modification has been most often studied in the context of
constitutive heterochromatin, genome-wide mapping studies have made clear its role in
cell type-specific regulation of facultative heterochromatin (Hawkins et al., 2010; Vogel et
al., 2006; O’Geen et al., 2007; Zhu et al., 2013). In differentiated human cells, H3K9me3
forms large contiguous domains ranging in size from the kilobase to the megabase scale
(Hawkins et al., 2010; Soufi et al., 2012; Vogel et al., 2006) (Figure 2-1). These domains
or ‘patches’ expand in both number and size during differentiation from pluripotency, and
they span numerous genes repressed in a cell type-specific manner (Hawkins et al.,
2010). In particular, there is enrichment for H3K9me3 over gene family clusters, such as
those for zinc finger transcription factors, olfactory receptors, and neurotransmitter-related
genes (in non-neuronal cell types) (Hawkins et al., 2010; Vogel et al., 2006; O’Geen et al.,
2007), raising the possibility that H3K9me3 protects repetitive gene clusters from illicit
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recombination similar to noncoding repeats, while also suppressing transcription. Such
H3K9me3 domains are largely exclusive of the H3K27me3 domains that also expand
during development (Hawkins et al., 2010; Pauler et al., 2009; Chandra et al., 2012),
highlighting the different functions of these marks, although some developmental
transcription factor genes are decorated by both modifications (Hawkins et al., 2010).
The related repressive modification, H3K9me2, similarly forms megabase-scale
domains that include genes; the domains have been called Large Organized Chromatin
K9 modifications (LOCKs) (Wen et al., 2009). Interestingly, binding sites for the insulator
protein CTCF were detected at the boundaries of these large domains, suggesting that
presence of such H3K9me2-decorated patches might be intimately connected to higherorder chromatin structures maintained by CTCF (Wen et al., 2009). Whether the
boundaries of these H3K9me2 domains expand during differentiation from pluripotency
has been a matter of dispute (Wen et al., 2009; Filion and van Steensel, 2010; Lienert et
al., 2011), with some groups favoring a model of mostly invariant domains during
development but local gain of H3K9me2 over select genes (Lienert et al., 2011).
Nevertheless, the dimethyl mark is important for the silencing of lineage-inappropriate
genes during differentiation (Wen et al., 2009; Lienert et al., 2011; Liu et al., 2015b), and
mass spectrometry-based quantification of histone marks reveals an increase in both
H3K9me3 and H3K9me2 in mouse fibroblasts compared with pluripotent cells (Sridharan
et al., 2013).

Taken together, the findings in this section indicate that H3K9me2/3

deposition is patterned according to cell identity and must be reset to specify new fates.
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2.2 Heterochromatin: a barrier to cell reprogramming and cell fate plasticity
The hallmarks of cell identity are erased when differentiated cells are reprogrammed to
induced pluripotent stem (iPS) cells (see Box 1 - Methods of Cellular Reprogramming)
(Takahashi and Yamanaka, 2006). This conversion process requires that reprogramming
transcription factors bind to their targets in DNA and reactivate pluripotency genes that
were silenced in development, suggesting that accessing heterochromatic regions is a
necessary step to fully reprogram cells. However, only a minor fraction of the starting cells
(<0.1%) successfully complete this process (Papp and Plath, 2013; Vierbuchen and
Wernig, 2012), raising the question of what chromatin features contribute to such
inefficiency.

H3K9me3 heterochromatin impedes iPS reprogramming
Insights into chromatin impediments to reprogramming emerged from determining where
the canonical iPS reprogramming factors (Oct4, Sox2, Klf4, and cMyc; henceforth OSKM)
first bind the genome shortly after they are expressed in human fibroblasts (Soufi et al.,
2012). All four factors target open chromatin sites, but only OSK, while not M, also target
sites containing nucleosomes and lacking evident histone marks, making them pioneer
factors (Iwafuchi-Doi and Zaret, 2014; Soufi et al., 2012, 2015). However, there are
megabase-scale chromatin regions in which none of the four factors can target DNA in
fibroblasts, even though these same domains have binding sites for the factors in
pluripotent cells (Soufi et al., 2012). Thus, the domains were called Differentially Bound
Regions (DBRs). The DBRs overlap with domains enriched for H3K9me3 in fibroblasts
but not in embryonic stem (ES) cells (see Figure 2-1), suggesting that H3K9me3
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heterochromatin may mediate the impediment to OSKM binding. Indeed, knockdown of
the SUV39H1/H2 methyltransferases increases Oct4 and Sox2 binding in these regions
(Soufi et al., 2012).
The DBRs encode diverse genes and repeat elements, including transcription
factor genes essential for pluripotency, such as NANOG, SOX2, DPPA2, DPPA4, GDF3,
and ZFP42 (Boyer et al., 2005; Soufi et al., 2012). Strikingly, all of these genes were
independently shown to be delayed in activation until the late phases of reprogramming
(Buganim et al., 2012; Polo et al., 2012), with endogenous SOX2 and NANOG highly
restricted to cells that successfully reprogram (Buganim et al., 2012). The discovery that
all four OSKM factors fail to bind within large patches of H3K9me3 heterochromatin (Soufi
et al., 2012) that include key pluripotency genes provides mechanistic insight into the
observation that these genes are more refractory to activation than others (Polo et al.,
2012; Buganim et al., 2012). The DBRs also encompass 21 out of 22 of the domains found
to have aberrant non-CpG methylation in human iPS cells, compared with ES cells (Soufi
et al., 2012; Lister et al., 2011). This indicates that some H3K9me3 domains, in addition
to impeding the rate or efficiency of reprogramming, have a persistent effect in the final
reprogrammed state of iPS cells, rendering the conversion to the ES state incomplete.
These findings suggested that H3K9me3 removal might be an effective strategy to
enhance the efficiency of reprogramming. Indeed, knockdown of the SUV39H1/H2
methyltransferases, thereby reducing H3K9me3, causes a dramatic increase in the
number and rate of appearance of human iPS colonies (Soufi et al., 2012). Independently,
in a screen of 22 chromatin modifiers, short hairpin RNA (shRNA) against SUV39H1 was
found to cause the strongest increase in human iPS colony formation (Onder et al., 2012).
Similar results have been obtained for the other H3K9 methyltransferases, in that
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reprogramming efficiency is improved in murine neural progenitor cells after G9a inhibition
(Shi et al., 2008) and in murine fibroblasts after depletion of G9a, GLP, or SETDB1 (with
additive effects in combination) (Sridharan et al., 2013).

It is thus unclear which

methyltransferase is most responsible for stabilizing the differentiated state. The yield of
fully reprogrammed murine iPS colonies is also enhanced by perturbation of other
heterochromatin components, such as knockdown of individual HP1 isoforms (e.g.,
HP1g/Cbx3) (Sridharan et al., 2013), inhibition of histone deacetylases (Huangfu et al.,
2008; Liang et al., 2010; Mali et al., 2010), or inhibition of DNA methylation (Mikkelsen et
al., 2008). Loss of DNA methylation enhances removal of H3K9me3 in the presence of a
transcriptional stimulus (Hathaway et al., 2012), and thus the effects of DNA
methyltransferase inhibition on reprogramming efficiency may act through similar
mechanisms as SUV39H1 knockdown, although this has not been definitively
investigated.
Other components of repressive chromatin that oppose iPS reprogramming
appear to act at sites outside of DBRs. Demethylation of H3K27me3 by Utx is required for
reprogramming (Mansour et al., 2012), while the repressive histone variant macroH2A
inhibits it (Gaspar-Maia et al., 2013; Pasque et al., 2012), but both observations are linked
to a common class of pluripotency genes that activate in early reprogramming (GasparMaia et al., 2013; Mansour et al., 2012), in contrast to most DBR genes (Buganim et al.,
2012; Soufi et al., 2012).

In further contrast to H3K9me3, the H3K27me3

methyltransferase EZH2 is required for iPS reprogramming, consistent with its role in
maintaining pluripotency (Buganim et al., 2012; Onder et al., 2012; Pereira et al., 2010).
Thus, iPS reprogramming depends upon continued deposition of H3K27me3 at certain
loci, simultaneous with H3K27me3 removal by Utx at other loci. Finally, reduction of
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another mediator of gene silencing, MBD3 (a component of the NuRD histone remodeling
and deacetylase complex), can allow a high fraction of cells to reprogram to the iPS state
and to do so in a more synchronous manner (Rais et al., 2013; Luo et al., 2013). However,
this co-repressor thwarts reprogramming factor activity at sites they already bind (Rais et
al., 2013), and its role in regulating H3K9me3 domains or preventing factor binding to
heterochromatic genes has not been explored.

Paucity of heterochromatin defines the pluripotent state
A reduction in inaccessible H3K9me3-marked heterochromatin not only speeds
conversion to pluripotency by enhancing transcription factor binding, but it also appears
to be a fundamental hallmark of the pluripotent state. Using electron spectroscopy imaging
(ESI), Bazett-Jones and colleagues identified remarkable differences in chromatin
compaction between embryonic epiblast cells and subsequent lineage-restricted stages
of development (primitive endoderm and trophectoderm), with the former characterized by
a highly dispersed network of 10-nm fibers and the latter showing blocks of highly
compacted chromatin (Ahmed et al., 2010). Studies of mouse ES cells in culture revealed
similar findings by ESI (Hiratani et al., 2010) and a reduction in the number and intensity
of nuclear foci that stain positively for H3K9me3 (Meshorer and Misteli, 2006).
Furthermore, the chromatin of pluripotent cells shows a higher rate of exchange of
chromosomal proteins such as linker histone and HP1, indicative of a more dynamic and
accessible chromatin state (Meshorer and Misteli, 2006). Consistent with such
accessibility, ES cells have elevated levels of global transcriptional activity, including
expression of repetitive sequences and mobile elements, which are repressed in
differentiated cells (Efroni et al., 2008). Importantly, depletion of proteins involved in
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maintaining chromatin accessibility (Efroni et al., 2008) or introduction of elements that
promote heterochromatin formation (Savić et al., 2014) results in impaired ES cell selfrenewal and altered differentiation capacity. Thus, the developmental plasticity of early
embryonic cells, much like the ability of differentiated cells to complete reprogramming, is
tightly linked to the accessibility of chromatin.
The necessity of heterochromatin erasure for the pluripotent state is further
illustrated by studies of ‘partially reprogrammed’ cells that appear during iPS conversion.
These cells lack induction of the pluripotency gene network and have limited
developmental potential, but express the reprogramming factors and have downregulated
their somatic program (Mikkelsen et al., 2008; Sridharan et al., 2009). Nuclear imaging
with ESI revealed that partially reprogrammed cells, but not iPS cells, have highly
compartmentalized heterochromatin structures containing dense chromatin fibers, similar
to differentiated cells (Fussner et al., 2011). This is consistent with the persistence of DNA
methylation and H3K9me3 over specific pluripotency loci, including Oct4 and Nanog, in
these cells (Mikkelsen et al., 2008; Fussner et al., 2011; Chen et al., 2013). Meanwhile,
erasure of H3K9me3, via depletion of Setdb1 or Suv39h1 or overexpression of the Kdm4b
demethylase, is sufficient to allow partially reprogrammed cells to progress to full iPS cells
(Chen et al., 2013). These findings suggest that H3K9me3 is not only a barrier to
pluripotency factor binding in the earliest stages of reprogramming (Soufi et al., 2012), but
also opposes late maturation steps necessary for pluripotency.

Heterochromatin opposes reprogramming by somatic cell nuclear transfer
In contrast to the reliance of iPS reprogramming on defined factors, somatic cell nuclear
transfer (SCNT, see Box 1) utilizes the diverse factors of the egg cytoplasm, acting en
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masse, to restore pluripotency, and the resulting process proceeds more rapidly (Jullien
et al., 2011). Yet, recent evidence suggests that H3K9me3 heterochromatin presents a
barrier to even this form of reprogramming. Zhang and colleagues performed detailed
transcriptomic analysis of two-cell mouse embryos derived by normal fertilization and
SCNT, and they identified ‘reprogramming resistant regions’ (RRRs) containing transcripts
that were silenced only in the SCNT condition (Matoba et al., 2014). The authors found
that the RRRs had features of heterochromatin including selective marking by H3K9me3
and enrichment for LINE and LTR-type repeat elements in the genome. Injection of mRNA
for the H3K9 demethylase Kdm4d into the embryo or knockdown of Suv39h1/h2 in donor
nuclei improved the expression of genes within the RRRs. Importantly, either approach
for reducing H3K9me3 caused dramatic improvements in the developmental potential of
the SCNT-derived embryos, with as much as 80% of the embryos reaching the blastocyst
stage, compared with less than 20% in controls (Matoba et al., 2014). Similarly, dramatic
increases in the number of cleavage stage SCNT-derived embryos were observed for
donor nuclei lacking G9a (Epsztejn-Litman et al., 2008). Other methods to reduce
heterochromatin integrity – including inhibition of histone deacetylases (Bui et al., 2011;
Iager et al., 2008), reduction in DNA methylation (Blelloch et al., 2006), or depletion of
macroH2A (Pasque et al., 2011b) – all improved embryo derivation by SCNT.
Taken together, the current evidence suggests that heterochromatin, and in
particular H3K9me3-marked domains, presents a barrier to reprogramming to
pluripotency.

The H3K9me3 heterochromatic barrier applies regardless of the cell

conversion methodology (SCNT versus defined factors) and impairs both the efficiency of
reprogramming and the quality of the cells produced (Figure 2-2).
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2.3 H3K9me3 as a regulator of cell fate in vivo
The crucial function of H3K9me3 in impeding cell reprogramming (Soufi et al., 2012; Chen
et al., 2013; Matoba et al., 2014) and in silencing lineage-specific genes (Hawkins et al.,
2010; Zhu et al., 2013) suggests that heterochromatin helps maintain cellular identity.
Thus, patterns of H3K9me3 must be reorganized during cell fate transitions in
development, both in the early embryo (see (Fadloun et al., 2013a; Burton and TorresPadilla, 2014) for review) and in terminal lineage maturation.

Maintaining and exiting pluripotency: H3K9me3 and transcription factor crosstalk
In pluripotent stem cells, transcription factor networks ensure that H3K9me2/me3 is
deposited over genes for cell differentiation and removed from essential pluripotency
regulators. In murine ES cells, Setdb1 has been shown to occupy and repress genes
encoding developmental regulators (Bilodeau et al., 2009) and to act as a co-repressor of
Oct4, thereby suppressing trophoblast genes (Lohmann et al., 2010; Yeap et al., 2009;
Yuan et al., 2009). Similarly, Loh et al. elegantly demonstrated that in murine ES cells
Oct3/4 positively regulates the expression of the demethylases Kdm3a and Kdm4c to
remove H3K9me2 and H3K9me3, respectively, from Tcl1 and Nanog, guaranteeing the
maintenance of cell renewal in ES cells (Loh et al., 2007).
Upon implantation of embryos in vivo or differentiation of ES cells in vitro, there is
a progressive and irreversible silencing of Oct3/4 and other pluripotency-associated
genes, including Nanog, Stella, and Rex-1. Deposition of H3K9me2 at these sites, and in
turn DNA methylation, is dependent on the methyltransferases GLP and G9a (EpsztejnLitman et al., 2008; Feldman et al., 2006; Liu et al., 2015b). G9a prevents Oct3/4
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reactivation when differentiated ES cells are returned to pluripotency culture conditions
(Feldman et al., 2006) (Figure 2-2, dashed line). Meanwhile, mutations in GLP that disrupt
its H3K9me1-recognition domain result in decreased H3K9me2, a delay in silencing of
pluripotent genes during ES differentiation, and abnormal embryonic development in vivo
(Liu et al., 2015b). The reverse H3K9me2 dynamics are seen at the master germ-line
regulator genes Ddx4 and DazI, which show high levels of H3K9me2 in ES cells and lose
the modification in in vitro-generated mature primordial germ cell-like cells (Kurimoto et
al., 2015). A reduction in H3K9me2 occurs at lamina-associated domains (LADs), which
normally associate with the nuclear periphery, and is coupled to a relative depletion in
H3K27me3 (Kurimoto et al., 2015), a mark enriched at the borders of LADs (Harr et al.,
2015). The overall picture highlights crosstalk between H3K9me2 and H3K27me3 and a
direct role for H3K9me2/me3 in the developmental control of gene expression.

Requirement of H3K9me2/me3 deposition for normal embryonic development
The importance of H3K9me2/me3 establishment in completing developmental transitions
is illustrated by genetic loss-of-function studies in mouse embryos. G9a- and GLP-null
embryos show early lethality, characterized by dramatic morphological abnormalities
associated with alteration in gene expression and chromatin organization (Tachibana et
al., 2002, 2005). Homozygous inactivation of SETDB1 also leads to embryonic lethality
around the time of implantation, an even earlier stage compared with G9a and GLP
mutants, as well as defects in inner cell mass growth (Dodge et al., 2004). Although single
knockouts of either SUV39H1 or SUV39H2 in mice show no developmental defects,
double-null mice are born at sub-Mendelian ratios and show prenatal lethality linked to
genome instability (Peters et al., 2001).

Furthermore, knockout of HP1b results in
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dramatic genomic instability and leads to perinatal lethality, likely caused by defects in the
development of neuromuscular junctions and cerebral cortex (Aucott et al., 2008).
The distinct lethal phenotypes seen for the different classes of H3K9me-related
methyltransferases and associated factors reflect their diverse contributions during
development. G9a, GLP, and SETDB1 regulate early lineage commitment (Bilodeau et
al., 2009; Lohmann et al., 2010; Yeap et al., 2009; Yuan et al., 2009; Feldman et al., 2006;
Epsztejn-Litman et al., 2008; Tachibana et al., 2005), while SUV39H1/H2 are involved in
genome stability (Peters et al., 2001) and maintenance of fully differentiated cell identity
(Soufi et al., 2012; Onder et al., 2012; Matoba et al., 2014).

H3K9me3 contributes to lineage restriction in mature cell types
The role of H3K9me3-decorated heterochromatin in controlling terminal differentiation and
ensuring the stability of cell identity emerges in two recent studies. Amigorena and coworkers, studying the molecular mechanisms underlying naive T cell differentiation into
distinct T helper (Th) cells subtypes, revealed an interplay between SUV39H1 and HP1α
to maintain a high ratio of H3K9me3 over H3K9ac at key Th1 genes, the latter of which
must be silenced in Th2 cells (Allan et al., 2012). Applying both genetic and
pharmacological loss-of-function approaches, the authors showed that in SUV39H1- and
HP1α-deficient conditions, Th2 cell lineage stability is compromised and cellular plasticity
towards the Th1 fate is increased. This phenotype is also seen in disease-related
conditions: a Th2-mediated allergic lung inflammation is reduced upon depletion of
H3K9me3 (Allan et al., 2012). In a genome-wide approach, Casaccia and collaborators
analyzed differentiation processes in the brain and showed that silencing of H3K9-related,
but not H3K27-related, methyltransferases impairs oligodendrocyte differentiation, altering
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their response to electric stimulation (Liu et al., 2015a). Taken together, these studies
indicate that H3K9me3 and H3K27me3 have different roles in developmental gene
silencing and cell identity maintenance, depending on the cell lineage.

2.4 Molecular control of H3K9me3 deposition
Since H3K9 methyltransferases are broadly expressed (Aagaard et al., 1999; Tachibana
et al., 2001) and are not known to make specific base contacts with DNA (Marmorstein,
2003), additional factors are required to explain the site-selectivity of H3K9me3 deposition
and the developmental dynamics of H3K9me3 domains. In this section, we consider
protein and RNA-based mechanisms by which H3K9me3-based heterochromatic domains
are established.

Transcription factor-based recruitment of heterochromatin
A growing number of sequence-specific transcription factors have been found to recruit
the heterochromatin machinery to particular gene promoters. The retinoblastoma (Rb)
protein interacts with both SUV39H1 and HP1, and it is required for cell cycle-regulated
H3K9me3 at the cyclin E promoter (Nielsen et al., 2001). Also important for
heterochromatin establishment is a large, tetrapod-specific family of zinc finger (ZNF)
transcription factors containing Krüppel-associated (KRAB) domains. Krüppel-associated
box zinc finger proteins (KRAB-ZNFs), which mostly have lineage-specific expression,
repress transcription of target genes by binding the co-repressor KAP1 (also known as
TRIM28 and TIF1b), which in turn interacts with HP1, SETDB1, and histone deacetylases
(Friedman et al., 1996; Ryan et al., 1999; Schultz et al., 2002). Experimental tethering of
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a KRAB domain to a genomic site results in spreading of H3K9me3 and silencing of gene
promoters as far as 15 kb away (Groner et al., 2010). Yet mutant forms of KAP1 that
cannot bind KRAB-ZNFs nonetheless retain many of their genomic binding sites (Iyengar
et al., 2011), suggesting that there is still much to learn about KAP1 recruitment.
Murine satellite repeats contain reiterated binding sequences for transcription
factors, such as Gfi1b, Sall1, Zeb1, and select Pax family members (Vassen et al., 2006;
Yamashita et al., 2007; Bulut-Karslioglu et al., 2012).

Specifically, Pax3 and Pax9

contribute to H3K9me3 deposition and transcriptional repression at major satellites and
are required for the integrity of pericentric heterochromatin (Bulut-Karslioglu et al., 2012),
a startling finding given that these factors are expressed only in select cell types. The
alternative factors that sustain constitutive heterochromatin in Pax3/9-negative cell types,
and the role of these factors in recruiting H3K9me3 to domains containing genes, are not
presently understood.

Contribution of RNA to heterochromatin formation
In addition to the role of transcription factors, noncoding RNA (ncRNA) can function as a
binding platform to establish heterochromatin at specific genomic positions. In the fission
yeast S. pombe, heterochromatin formation at pericentromeres (Volpe et al., 2002) and
other sites (Hall et al., 2002) depends upon the components of the RNA interference
(RNAi) pathway and, paradoxically, requires transcription of the locus to be silenced
(Djupedal et al., 2005; Kato et al., 2005). Double-stranded RNAs (dsRNAs) transcribed
from these regions are processed into small interfering RNAs (siRNAs) by Dicer, which in
turn guide the silencing machinery, including an H3K9 methyltransferase, to the site of
nascent heterochromatin transcription by RNA-RNA base pairing (Bühler et al., 2006;
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Zhang et al., 2008; Bayne et al., 2010). (For review of the role of RNAi in heterochromatin,
see (Grewal and Elgin, 2007; Bühler and Moazed, 2007)).

In S. pombe, there are

additional mechanisms by which ncRNA can establish heterochromatin, independent of
RNAi, involving a growing number of RNA processing factors and components of the RNA
exosome (Bühler et al., 2007; Reyes-Turcu et al., 2011). Meanwhile, in mammals, despite
initial reports that Dicer was required for silencing of pericentric heterochromatin
(Fukagawa et al., 2004; Kanellopoulou et al., 2005), heterochromatin-derived dsRNA has
not been consistently detected across cell systems (Saksouk et al., 2015).
While the mechanisms by which ncRNA may establish heterochromatin in
mammals remain poorly understood, emerging evidence suggests its contribution is
significant. Transcription of mammalian heterochromatin has been observed despite the
presence of H3K9me3 over the same regions (Martens et al., 2005; Terranova et al., 2005;
Lu and Gilbert, 2007). The localization of HP1a at pericentromeric heterochromatin is
dependent on its interaction with RNA, specifically its binding via its hinge domains to
sense-oriented repeat transcripts (Maison et al., 2002; Muchardt et al., 2002; Maison et
al., 2011). Strikingly, injection of pericentromere-derived dsRNA in the early mouse
embryo is sufficient to rescue the phenotype of a mutant with defects in constitutive
heterochromatin (Santenard et al., 2010). During normal development, an early burst of
major satellite transcription precedes and is required for H3K9me3 deposition (Probst et
al., 2010; Casanova et al., 2013). Also, dynamics in major satellite transcription, which in
turn modulate pericentromeric binding of HP1, are important for the cell fate transition of
epithelial-to-mesenchymal transition (Millanes-Romero et al., 2013).

Along the

chromosome arms, LINE-1 repeats undergo a wave of transcription early in development
(Fadloun et al., 2013b), and transcripts derived from these elements may contribute to the
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silencing of nearby genes on the inactive X chromosome (Chow et al., 2010). Finally, in
human ES cells, addition of another ncRNA derived from rDNA arrays is sufficient to
induce widespread H3K9me3 deposition outside the nucleolus and to promote exit from
pluripotency (Savić et al., 2014). These findings suggest an intimate relationship between
RNA and H3K9me3 establishment, although the nature of the interactions and the RNAbinding proteins involved are in need of further elucidation.

2.5 Concluding Remarks
Recent work suggests that large domains of H3K9me2/3 form in a cell type-specific
manner (Hawkins et al., 2010; Soufi et al., 2012), but the protein machinery responsible
for such precise developmental dynamics remain largely mysterious (see Box 2 Outstanding Questions). First, the mechanisms and relative contributions of RNAdependent versus transcription factor-dependent H3K9me3 recruitment must be defined
for these regions, and it is not presently understood how either process can nucleate
H3K9me3 deposition over a domain as large as multiple megabases (Hawkins et al., 2010;
Zhu et al., 2013). In addition, simple inspection of the large H3K9me3 patches on a
genomic level shows that they can terminate precisely over a local domain, suggesting a
type of boundary. Elucidating these mechanisms for the initiation and delimitation of
H3K9me2/3 domains will enable more targeted strategies to perturb H3K9me3-dependent
heterochromatin at specific sites, possibly to enhance reprogramming in a manner tailored
to the starting and desired cell types.
As RNAi-based knockdown of all five H3K9 methyltransferases has been found to
promote reprogramming to pluripotency (Chen et al., 2013; Onder et al., 2012; Soufi et

43

al., 2012; Sridharan et al., 2013), it will be important to carefully dissect the unique and
redundant roles of each enzyme in the establishment of specific H3K9me2/3 domains in
diverse cellular contexts, and the relative contributions of the dimethyl and trimethyl forms.
This would be facilitated by the creation of conditional knockouts of these genes, alone
and in combination. Mapping of H3K9me2/3 domains in specific lineages and
developmental stages, coupled with conditional deletion of methyltransferases, will reveal
the enzymes responsible for tissue-specific domains and their contribution to
developmental gene regulation.
Finally, studies of lineage-specific H3K9me2/3 domains should investigate if they
similarly impede direct conversion or transdifferentiation between two differentiated fates
(see Box 1). Whether perturbation of heterochromatin components can universally
improve the fidelity of these direct conversions, or whether the role of H3K9 methylation
in reprogramming is pluripotency- or tissue-specific, will be an exciting avenue for further
investigation.
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2.6 Supporting text boxes
Box 1. Methods of Cellular Reprogramming

Reprogramming refers to the erasure of the identity of a cell to convert it to a different type
of cell, most commonly the conversion of a specialized fate to an earlier, undifferentiated
state. Multiple techniques (see (Yamanaka and Blau, 2010)) now exist to transform
differentiated cells into cells that are pluripotent, which means that they can give rise to
any cell type in the embryo.

Somatic cell nuclear transfer (SCNT)
Seminal work in the 1950s established that transfer of a nucleus from a differentiated cell
into an enucleated egg induces a restoration of developmental potential and the
production of viable embryos (Gurdon et al., 1958). SCNT has been used to successfully
clone mammals, such as sheep (Wilmut et al., 1997) and mice (Wakayama et al., 1998).
Nonetheless, the frequency at which SCNT gives rise to viable organisms is low, with most
resulting embryos exhibiting phenotypic and gene expression abnormalities (Matoba et
al., 2014; Pasque et al., 2011a). Elegant studies have revealed specific molecular events
required to complete reprogramming after SCNT (Jullien et al., 2011, 2014), but given the
complexity of the egg cytoplasm that is mediating the process, the underlying mechanism
is likely to involve myriad factors acting in concert.

Generating induced pluripotent stem (iPS) cells
Takahashi and Yamanaka made a critical breakthrough by defining a specific set of four
transcription factors that, when ectopically overexpressed, are sufficient to convert a
45

differentiated cell into an iPS cell (Takahashi and Yamanaka, 2006). The factors originally
identified – Oct4, Sox2, Klf4, and cMyc – are central regulators of the pluripotency gene
network in ES cells (Boyer et al., 2005), and additional combinations of factors capable of
generating iPS cells have since been reported (Buganim et al., 2012; Shu et al., 2013). In
all cases, the resulting iPS cells meet stringent criteria for pluripotency, such as ability to
rescue tetraploid blastocysts and contribute to the germline, and on the transcriptional
level most iPS lines are highly similar to ES cells derived from the pluripotent inner cell
mass (Buganim et al., 2012; Shu et al., 2013; Wernig et al., 2007). However, iPS
reprogramming is a highly inefficient process, as it proceeds to completion only in a small
fraction of cells (generally <0.1%) and at long latency (weeks to months) (Vierbuchen and
Wernig, 2012; Papp and Plath, 2013).

Direct cell fate conversion
The strategy of ectopically expressing defined cocktails of lineage-specific transcription
factors has been used to convert or transdifferentiate differentiated cells to other
developmental lineages, without going through a pluripotent intermediate (Davis et al.,
1987; Graf and Enver, 2009; Ladewig et al., 2013). Despite the promise of these
techniques, the reprogrammed cells generally exhibit substantial gene expression
differences from their native counterparts, limiting their in vivo functionality and therapeutic
utility (Cahan et al., 2014; Morris et al., 2014).
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Box 2. Outstanding questions

What are the proteins and ncRNAs that control the cell type-specific locations and
boundaries of large H3K9me3 domains across the mammalian genome?

To what extent do Suv39h and Setdb1 have specific, non-redundant roles in repressing
cell identity genes, and how does this relate to the distinct embryonic phenotypes upon
deletion of these H3K9me3-related methyltransferases?

How do H3K9me2- and H3K9me3- arked chromatin domains differ in their exclusion of
transcription factors and resistance to gene activation?

What are the relative contributions of H3K27me3 and H3K9me3 to developmental gene
regulation in different lineages, and to what extent do they cooperate in cell fate
establishment?

Does

H3K9me3-dependent

heterochromatin

impede

direct

conversion

between

differentiated cell types, similar to its role in limiting reprogramming to pluripotency?
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2.7 Tables and Figures

domain properties

H3K9me3 domains

H3K27me3 domains

Genomic distribution

Constitutive heterochromatin
1-3
and tissue-specific sites

Tissue-specific sites

Chromatin accessibility

Prevent binding by diverse TFs

2

1,4-8

Allow binding by general TFs and
9-10
paused RNA polymerase

Presence at ‘poised’ genes, Downstream of some
11
competent for activation
H3K4me3-marked promoters

Overlapping with H3K4me3 at
12-13
many promoters

Timing of gene reactivation
during iPS reprogramming

Latest stages of
2,14-15
reprogramming

Early-to-mid stages of
16
reprogramming

Major methyltransferases
and role in reprogramming

SETDB1, SUV39H1/H2:
2,15,17
impede iPS conversion

PRC2 complex (EZH2 or EZH1):
14,17-18
required for generating iPS

Table 2-1. Differences between H3K9me3 and H3K27me3 Heterochromatin
Domains
TFs = transcription factors. References: 1(Hawkins et al., 2010), 2(Soufi et al., 2012), 3(Liu
et al., 2015a), 4(Boyer et al., 2006), 5(Lee et al., 2006), 6(Ezhkova et al., 2009), 7(Zhu et
al., 2013), 8(Xu et al., 2014a), 9(Breiling et al., 2001), 10(Dellino et al., 2004), 11(Matsumura
et al., 2015),
15

12

(Bernstein et al., 2006),

(Chen et al., 2013),

16

13

(Voigt et al., 2012),

(Mansour et al., 2012),

2010).
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17

14

(Buganim et al., 2012),

(Onder et al., 2012),

18

(Pereira et al.,

Figure 2-1. Megabase-scale domains of H3K9me3 vary by cell type and match
regions resistant to reprogramming factor binding.
Shown is a 25-Mb segment of human chromosome 16, visualized in the UCSC Genome
Browser. The purple tracks show H3K9me3 signals by chromatin immunoprecipitation and
sequencing (ChIP-seq), normalized by input-subtraction, for the selected cell/tissue types.
All ChIP-seq data come from the Roadmap Epigenomics Mapping Consortium
(GSE16368). Note the close correspondence between the H3K9me3-enriched domains
in foreskin fibroblasts (red arrows) and the fibroblast Differentially Bound Regions (DBRs,
black bars), which are regions that fail to be targeted by pluripotency reprogramming
factors in fibroblasts but are bound in ES cells (Soufi et al., 2012). Each of these regions
lack H3K9me3 enrichment in ES cells, as well as in select other tissues (blue asterisks).
Green arrows indicate representative H3K9me3 domains in other tissues that are absent
in fibroblasts.
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Figure 2-2. H3K9me2/3 heterochromatin domains impede diverse forms of cellular
reprogramming.
The diagram shows major cell fate transitions (black arrows) that occur during
differentiation and reprogramming and the role of H3K9me2/3 in these transitions. The
leftmost black arrow indicates conversion of differentiated cells to pluripotency, which can
be carried out by nuclear transfer to an enucleated egg or by overexpression of
pluripotency transcription factors. In both cases, pluripotency genes inside H3K9me3
domains are more resistant to activation, and the success rate of reprogramming is
improved when H3K9me3 levels are reduced (Chen et al., 2013; Matoba et al., 2014;
Onder et al., 2012; Soufi et al., 2012). Thus, H3K9me3 domains impede reprogramming
to pluripotency (red inhibitory arrows). When embryonic stem (ES) cell-derived
differentiated cells are returned into ES culture conditions, thereby encouraging dedifferentiation (dashed black arrow), the loss of an H3K9me2 methyltransferase increases
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the appearance of undifferentiated colonies and the expression of pluripotency genes
(Feldman et al., 2006). In contrast to reprogramming, the differentiation of pluripotent cells
in culture (upper black arrow) is promoted by increases in H3K9me2/3 (Loh et al., 2007;
Savić et al., 2014). Although H3K9me2/3 domains form in a tissue-specific manner over
the course of development (rightmost black arrows), the role of these domains in the
directed conversion of cells across developmental lineages (bottom black arrow) remains
to be investigated. Abbreviations: iPS, induced pluripotent stem cell reprogramming;
SCNT, somatic cell nuclear transfer.
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CHAPTER 3. METHODS
3.1 Experimental methods
Cell Culture
Human BJ foreskin fibroblasts were obtained from Stemgent (08-0027) at passage 6 and
cultured in Eagle’s Minimum Essential Medium (EMEM) (Sigma-Aldrich M2279)
supplemented with 10% fetal bovine serum (FBS, Hyclone SH30071) and 2mM Lglutamine (Gibco) at 37°C and 5% CO2.

Preparation of crosslinked chromatin lysates
BJ fibroblast cells were grown to ~80% confluence in 150-mm dishes (5 - 20 plates per
chromatin batch, ~4 x 106 cells per plate). Cells were crosslinked directly in the culture
dishes, at room temperature, by addition of 2 ml formaldehyde solution (50 mM HEPESKOH, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 11% formaldehyde) to 20 ml
media, for 1% final formaldehyde concentration. After 10 min, crosslinking was quenched
by addition of glycine to a final concentration of 125 mM, followed by incubation for 5 min
at room temperature. Cells were harvested from the plate with a plastic cell lifter, pelleted
at 200 g for 4 min (4°C), and washed three times with ice-cold PBS. All subsequent steps
were performed on ice or in centrifuges cooled to 4°C. To enrich for nuclei, cells were
allowed to swell for 10 minutes in 4 ml Hypotonic Lysis Buffer (20 mM HEPES-KOH pH
7.5, 20 mM KCl, 1 mM EDTA, 10% glycerol, 1% IGEPAL CA-630, 0.25% Triton-X, 1 mM
DTT, 0.2 mM PMSF, Protease Inhibitor Cocktail - Roche #11873580001) and were
mechanically dounced for 50 strokes. Nuclei were pelleted at 1,350 g for 4 min, washed
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with hypotonic buffer, and pelleted again at the same speed. Pellets were resuspended in
10 ml Nuclear Wash Buffer (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 1 mM DTT, 0.2 mM PMSF, Protease Inhibitor Cocktail) and incubated for 10 min,
rocking. Nuclei were pelleted at 1,350 g for 4 min and resuspended in 0.5 - 1 ml Sonication
Lysis Buffer (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.5%
N-lauroylsarcosine, 0.1% sodium deoxycholate, 1 mM DTT, 0.2 mM PMSF, Protease
Inhibitor Cocktail) and transferred to 15-ml polystyrene tubes. Sonication was performed
in polystyrene tubes using a Diagenode Bioruptor UCD-200 (power HI, cycles of 30s on /
30s off) for at least 25 cycles. After sonication, lysates were transferred to microcentrifuge
tubes, supplemented with Triton-X to 1% final concentration (to promote chromatin
solubility), and centrifuged at 20,000 g to pellet debris. Supernatants were transferred to
new tubes, snap-frozen in liquid nitrogen, and stored at -80°C while chromatin shearing
was assessed by agarose gel electrophoresis of purified DNA (as described for chromatin
immunoprecipitation, below). Sonication was repeated as necessary until the majority of
DNA was 200-400bp, with only a faint trail of larger material.

Chromatin immunoprecipitation
Immunoprecipitation was performed using Dynabead Protein G magnetic beads (Thermo
Fisher, 10004D) saturated with the antibody of interest, such as anti-H3K9me3 (Abcam
ab8898) or anti-mouse IgG control (Abcam ab46540). 5 μg of antibody and 25 ul of
Dynabead slurry were used per 25 μg of chromatin (according to mass of purified DNA
measured by nanodrop), with scaling as necessary. Dynabeads were first washed twice
with 800 μl PBS, using a magnetic rack, and then resuspended in a volume of PBS that
is 4X the original slurry volume. This suspension was supplemented with the desired
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amount of antibody, mixed, and incubated on a rotating rack at 4°C for 2 - 6 hours, to allow
antibody conjugation. Sonicated, crosslinked chromatin lysates (see above) were thawed
on ice, and the desired mass of chromatin (25 μg or more) was aliquoted a low-retention
1.5-ml tube (Axygen MCT-150-L-C) tubes. Chromatin was diluted to 1 ml final volume with
ice-cold Chromatin IP Buffer (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 0.1% N-lauroylsarcosine, 1% Triton 1 mM DTT, 0.2 mM PMSF, Protease Inhibitor
Cocktail). A separate aliquot of chromatin (one-fifth the mass) was reserved as the input
sample. Antibody-conjugated beads were washed twice with Chromatin IP buffer and then
resuspended in the 1-ml sample of chromatin. Immunoprecipitations were incubated for
16 hours at 4°C on a rotating rack. Using a magnetic rack, the unbound lysate was
aspirated, and the beads were washed 5 times with 900 μl ice-cold ChIP RIPA Buffer (50
mM HEPES, pH 7.5, 500 mM LiCl, 1 mM EDTA, 1% IGEPAL CA-630, 0.7% sodium
deoxycholate, Protease Inhibitor Cocktail) and once with 900 μl ice-cold TE buffer (10 mM
Tris-HCl, pH 8.0, 1 mM EDTA). Chromatin was eluted in 200 μl ChIP Elution Buffer (50
mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS) at 65°C for 30 min, shaking, and the eluate
was transferred to a new tube. Reserved input sample was similarly diluted at least 3-fold
in Chromatin IP Buffer, to 200 μl final volume. To purify DNA from ChIP eluate and Input,
samples were decrosslinked by heating at 65°C for 18 hours. Chromatin was diluted with
200 μl TE and treated with 8 μl RNase A (10 mg/ml stock, Roche #10109169001), followed
by incubation for 2 hours at 37°C. Protein was degraded by addition of 4 μl Proteinase K
(20 mg/ml stock, Roche #03115828001) and incubation for 2 hours at 55°C. DNA was
purified by two rounds of extraction with 400 μl phenol-chloroform-isoamyl alcohol. The
extracted aqueous phase was supplemented with 16 μl of 5 M NaCl and 1.5 μl glycogen
(20 mg/ml stock, Roche #10901393001). DNA was precipitated by addition of 2 volumes
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(800 μl) 100% EtOH and overnight incubation at -20°C. DNA was pelleted at 20,000 g for
10 min (4°C), washed with 500 μl 80% EtOH, and pelleted again. The DNA pellet was airdried and dissolved in 200 μl TE buffer. DNA yield was quantified by Quant-iT PicoGreen
dsDNA Assay (Thermo Fisher P7589). Five-fold serial dilutions of the input DNA were
prepared in DNA and were used as a standard curve when analyzing ChIP eluates by
qPCR, in order to quantify sequence recovery as percent input.

Sucrose gradient sedimentation of chromatin
For preparative gradients used for proteomic and sequencing studies, crosslinked and
sonicated chromatin was purified (see above) from near-confluent BJ fibroblasts in 20 150mm plates (at least 8 x 107 cells, 0.5 mg DNA) per gradient. Chromatin lysates were
prepared in 0.5 mL Sonication Lysis Buffer (see above) to allow the majority of the sample
to be loaded on a single gradient. Prior to running gradients, chromatin shearing efficiency
was verified by purifying DNA from a 5 μl chromatin aliquot (as described above for ChIP
input DNA), while the remaining lysate was snap-frozen in liquid nitrogen and stored at 80°C. Empirically, we found that achieving sufficient levels of DNA shearing, comparable
to standard ChIP, was important to achieve robust heterochromatin enrichment via
sucrose gradient sedimentation.
6-40% linear sucrose gradients in Chromatin IP buffer were poured into 12-mL
Ultra-Clear centrifuge tubes (Beckman #344059, 14 x 89 mm), using a Hoefer SG-15
gradient maker fitted with a two-way stopcock (Bio-Rad #7328102). Gradients were
prepared by loading the chambers of the gradient maker with two solutions of
approximately equal weight: 5.7 mL of 40% Sucrose Solution (40% sucrose, 10 mM TrisHCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton-X, 0.1% N55

lauroylsarcosine, 1 mM DTT, 0.2 mM PMSF, Protease Inhibitor Cocktail) and 6.4 mL of
6% Sucrose Solution (6 mL of 40% Sucrose Solution, plus 34 mL of: 10 mM Tris-HCl, pH
8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton-X, 0.1% N-lauroylsarcosine,
1 mM DTT, 0.2 mM PMSF, Protease Inhibitor Cocktail), which are gradually mixed as the
solutions exit the gradient maker. Gradients were filled bottom-up, beginning with the
heavier 40% Sucrose Solution. To load the gradients, 455 μl of thawed chromatin lysate
was mixed with 65 μl of the 40% Sucrose Solution, for a 5% final concentration of sucrose,
and then the resulting sample was layered gently on the 6-40% gradients with a 1-mL
pipet. Gradients were spun on a Beckman SW 41 Ti rotor at 41,000rpm for 3 hours (4°C),
using conditions similar to those developed by Bickmore and colleages (Gilbert et al,
2004). Slow acceleration and deceleration settings were used. After sedimentation,
gradients were fractionated top-down using a micropipet, generating 24 fractions of
500µL. 30µL of each fraction used for DNA purification (performed as for ChIP samples,
see above) to allow fraction-specific qPCR studies; the remaining samples were snapfrozen and stored at -80°C.
The fractions found by qPCR to have the strongest enrichment for heterochromatic
regions (fractions #10-17) were pooled as the “structural heterochromatin (strucHC)
fraction”, while fraction #2 (second fraction from the top) was used as the “euchromatin
fraction.” Both samples were dialyzed to Chromatin IP buffer (10 mM Tris-HCl pH 8.0, 100
mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% N-lauroylsarcosine, 1% Triton 1 mM DTT,
0.2 mM PMSF, Protease Inhibitor Cocktail) to remove sucrose. Dialysis was performed
for two rounds of five hours each using Slide-A-Lyzer G2 Casettes 7K MWCO (Thermo
Fisher). 5% of the dialyzed chromatin samples (approximately 250 ng DNA for strucHC
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fraction) were used for DNA purification, using the same procedure as for ChIP eluates
above, to enable subsequent qPCR and sequencing studies. For purification of proteins
from gradient fractions, equal DNA equivalents were used for both the euchromatin and
strucHC fractions, based on Quant-iT PicoGreen dsDNA Assay (Thermo Fisher P7589).
Prior to protein precipitation, the dialyzed fractions were buffered by adding Tris-HCl pH
8.0 (to 100 mM final concentration) and then decrosslinked by heating at 65°C overnight
followed by 99°C for 30 min. The proteins were precipitated in 6 volumes acetone
(overnight at -20°C), pelleted at 3,600 g, washed once with ice-cold acetone, resuspended
in 8M urea, and quantified by Bradford Assay (Bio-Rad #500-0006). Alternatively, the
dialyzed strucHC and euchromatin fractions were used for chromatin IP against H3K9me3
or IgG control (using above ChIP protocol). For these IP eluates in ChIP Elution Buffer,
one-twelfth of the sample was used for DNA purification, as above. For protein analysis,
the remaining eluate was run in a cetrifugal evaporator to reduce the volume to ~25 μl,
mixed with 4X NuPAGE LDS Sample Buffer (Thermo Fisher NP0007) and β-mercaptoethanol (2.5% final concentration), and decrosslinked by heating at 99°C for 30 min.

Proteomics analysis of chromatin samples
Proteins were prepared for mass-spectrometry by in-gel digestion. Samples were mixed
with 4X NuPAGE LDS Sample Buffer (Thermo Fisher NP0007) and β-mercaptoethanol
(2.5% final concentration) and loaded into NuPAGE Novex 4-12% Bis-Tris Protein Gels
(Thermo Fisher NP0335). Gels were run at 100V in NuPAGE MOPS SDS Running Buffer
(Thermo Fisher NP0001) and washed three times with dH2O for five minutes each. Gels
were stained with SimplyBlue SafeStain (Thermo Fisher LC6060) for 1 hour at room
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temperature, photographed, and destained in dH2O overnight. Gels were then incubated
in 40% ethanol, 10% acetic acid for 1-2 hours to fix and further destain. Lanes were
excised and cut into five pieces that were digested in separate tubes (but pooled prior to
nLC-MS/MS). Each piece was further diced into ~1 mm3 cubes and transferred to clean
microcentrifuge tubes.
Gel slices were reduced with 10 mM DTT for 1 hour at 56°C, alkylated using 55
mM iodoacetamide for 45 minutes (room temperature in dark) and digested overnight with
trypsin at room temperature at a concentration of 12.5 ng/μl. Digestion was interrupted
adding 1% formic acid. Samples were then desalted using in-house prepared C18
microcolumns, and the five peptide samples from the same gel lane were combined. Nano
liquid chromatography was performed using a Thermo Scientific Easy nLC 1000 equipped
with a 75 µm x 18 cm in-house packed column using Reprosil-Pur C18-AQ (3 µm, Dr.
Maisch GmbH). Buffer A was 0.1% formic acid and Buffer B was 0.1% formic acid in
acetonitrile. Peptides were resolved using a 165 min gradient from 2 to 28% B at a flow
rate of 300 nL/min. The HPLC was coupled online to an Orbitrap Elite mass spectrometer
(Thermo Scientific) for the first replicate and a Q-Exactive (Thermo Scientific) for the
second and the third replicate operating in positive mode. Spectra were acquired using a
data dependent acquisition (DDA) method, performing the full MS scan in the orbitrap at
60,000 (Elite) and 70,000 (Q-Exactive) resolution. The MS/MS was performed for both
instruments at 17,500 resolution in the orbitrap mass analyzer. Loop count was set to 15
(Elite) and 12 (Q-Exactive) and collision energy was set to 20. Database searching was
performed using MaxQuant v1.5.2.8 (Cox and Mann, 2008), using all standard settings
unless otherwise stated. Database used was Human UniProt (v July 2015). For protein
quantification the iBAQ option (Schwanhäusser et al., 2011) was enabled and adopted.
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qPCR analysis of gradient fractions
Purified DNA samples from gradient fractions were quantified with Quant-iT PicoGreen
dsDNA Assay (Thermo Fisher P7589) and diluted with TE buffer to 0.1 ng/μl, to allow
loading of equal DNA mass per qPCR reaction. DNA concentrations were verified after
dilution by repeat PicoGreen assay and were adjusted as needed. 10 μl qPCR reactions
were prepared in 384-well optical plates with 2 μl DNA sample, 0.1 μl primer mix (10μM
each primer), and 5μL Power SYBR Green PCR Master Mix (Thermo Fisher #4367659).
Plates were in a 7900HT Real-Time PCR machine (Thermo Fisher #4329001), using the
following thermal cycler protocol: 50°C for 4 min, 95°C for 10 min, followed by 40 cycles
of 95°C for 15 s then 54°C for 15 s then 72°C for 45 s, with a dissociation curve generated
to verify that a single PCR product was generated. qPCR results for each fraction were
normalized to the input sample. Primer sequences for detecting sites inside and outside
DBRs were from (Soufi et al., 2012) and are listed in the table below. All PCR amplicons
correspond to Oct4/Sox2 binding sites: bound in fibroblasts and ES cells for non-DBR
sites, and bound only in ES cells for DBR sites (Soufi et al., 2012).

Table 3-1. Primers used for qPCR analysis of Gradient Fractions and H3K9me3
ChIP.
primer name

forward primer (5' - 3')

reverse primer (5' - 3')

location

Ch3_DBR_3

TGGTCTTGAATTCCTGGCTG

GCTTAAGAATCGTCCGGAGG

DBR site

Ch3_DBR_4

ACCGCCATACCCAACTTG

GATGGCCCTAGGTCTTTAATGG

DBR site

Ch20_DBR_2

ATCAAGTGCCAGGAATGGAG

ATGGAGCCCGAATTTCTCAG

DBR site

Ch20_DBR_5

AATTTCAAGCGGAGCCCTAG

TCAGAAACCCTATTGAAGCCTC

DBR site

Ch22_DBR_2

GCCATTCGTGTGCAGAAAAG

CTGTCCATAGTCAGCGTTCC

DBR site

Ch22_DBR_5

CCTCAAGGGATTGGAAGATCTC

GGTGCCCAGATTAAATGTTCC

DBR site

GTATTAGTAATTCAACCCAGACAA

DBR site

DPPA4

TCCACCTCACCTCTTCTT
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NANOG

TGTTGAACCATATTCCTGAT

Ch3_nonDBR_1

CATGGAGCAATTGTGAATAAATGTG ATTAGGCTGGGGCTTTCTG

intergenic

Ch3_nonDBR_2

CCTCCAGTATCAACCGAAGAG

TCCGAAGACTCCTACTCACAC

promoter

Ch3_nonDBR_3

AAATGCTAAGAGGGTGTGGG

GAGAGTTGCCAGGAACAGAG

gene body

Ch20_nonDBR_1

CCCCGCAGACAATGACTATTAG

AGGTGTGAGCGTTCGATATG

intergenic

Ch20_nonDBR_3

GGACCACAGCACGGAAAC

CCTTCTCACTCCTCTTCTCCG

promoter

Ch22_nonDBR_2

GGGCTTGCATAGTGAAAACATG

ACGGTAGAGGACAGGGAAG

gene body

Ch22_nonDBR_3

CAGATTAATGTTTGCCAGGGC

AATATTTCCATTGCTCCAAAATTTCC

gene body

Ch22_nonDBR_4

CCCCTATCATTGTGAGAGTGTG

CAATTTACCCGCCACATCAC

promoter

TCTACCAGTCTCACCAAG

DBR site

Preparation of Gradient-seq and ChIP-seq libraries
Approximately 50 ng of purified DNA was used for each library, and two biological
replicates (independent gradients) were sequenced per sample type. For samples
containing large DNA fragments (including the structural heterochromatin fraction, IPs off
of this fraction, and the input to the gradient), the pure DNA was first sheared in a Covaris
S220 sonicator using snap-cap microTUBEs (Covaris #520045) for 5 min (settings: 175W
peak power, 10% duty factor, 200 cycles/burst) to produce 150-350 bp fragments.
Libraries were then prepared using the NEBNext Ultra DNA Library Prep Kit for Illumina
(New England Biolabs E7370S), and amplified using 8 - 9 cycles of PCR using NEBNext
Multiplex Oligos for Illumina (New England Biolabs E7335S and E7500S). For H3K9me3
ChIP-seq and ChIP Input libraries, the adapter-ligated DNA was size-selected using
Agencourt Ampure XP beads (Beckman Coulter A63881), following the protocol in the
NEBNext Ultra kit for a 200-bp average insert size. The libraries for Gradient-seq were not
size-selected. Library yield and fragment size distribution was assessed on a Bioanalyzer
2100 instrument (Agilent Technologies), using the DNA 1000 kit (Agilent Technologies
5067-1504).
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Western blotting
Whole-cell protein extracts were prepared by resuspending cells in RIPA extraction buffer
(25 mM Tris, pH 7.5, 150 mM NaCl, 1% Na-deoxycholate, 1% IGEPAL CA-630, 0.1%
SDS)

supplemented

with

Protease

Inhibitor

Cocktail

(Roche

#11873580001).

Suspensions were incubated on ice for 10 minutes and sonicated for 15 s on HI using a
Diagenode Bioruptor UCD-200. Samples were centrifuged at 20,000 g for 10 min (4°C) to
pellet debris, and the supernatant was transferred to new tubes. Protein content was
quantified by BCA assay (Thermo Fisher Scientific #23227). Protein samples were mixed
with 4X NuPAGE LDS Sample Buffer (Thermo Fisher Scientific NP0007) and 10X
NuPAGE Sample Reducing Agent (Thermo Fisher Scientific NP0009), and were
denatured at 70°C for 10 min. Samples were loaded in NuPAGE Novex 4-12% Bis-Tris
Protein Gels (NP0335), and run using NuPAGE Running Buffers (NP0001; NP0002). Wet
transfer to PVDF membranes (100V for 1.5 hr) was performed using NuPAGE Transfer
Buffer (NP0006) containing 20% methanol, and membranes were blocked overnight in 5%
nonfat dairy milk in TBS-T (20 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween-20). Primary
antibodies were diluted in 1% milk/TBS-T at the following concentrations: anti-GAPDH
(1:1000, Santa Cruz Biotechnology sc-365062), anti-SUV39H1 (1:1000, Bethyl
Laboratories A302-127A), anti-RBMX (1:1000, Cell Signaling Technology #14794), antiH3K9me3 (1:1000, Abcam ab8898), and anti-Histone H3 (1:3000, Abcam ab1791). HRPconjugated secondary antibodies (Santa Cruz Biotechnology sc-2004, sc-2005) were
diluted 1:5,000 in 1% milk/TBS-T. Blots were developed using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Fisher Scientific #34080) and visualized with an
Amersham Imager 600 (GE Healthcare Life Sciences).

61

Immunostaining
Cells were grown on plates coated with collagen I (Corning #354236), washed twice briefly
with PBS, and fixed in 4% paraformaldehyde in PBS for 20 minutes at room temperature.
Fixed cells were washed 3 times with PBS (all washes 5-10 minutes at room temperature,
rocking), permeablized with ice-cold 0.1% Triton-X in PBS for 10 minutes, and washed
twice TBS-T (20 mM Tris-HCl pH 7.4, 150mM NaCl, 0.05% Tween-20). Samples were
blocked with 4% donkey serum (Sigma-Aldrich D9663) in PBS for 1-2 hours at room
temperature or overnight at 4°C. Primary antibodies added in blocking solution and
incubated overnight at 4°C, using the following concentrations: anti-human-albumin
(1:100, Bethyl Laboratories A80-229A), anti-alpha-1-antitrypsin (1:200, Thermo Fisher
Scientific RB-367), anti-FOXA3 (1:300, Santa Cruz Biotechnology sc-5361), anti-HNF1A
(1:150, Santa Cruz Biotechnology sc-6547), and anti-HNF4A (1:150, Santa Cruz
Biotechnology sc-8987). Cells were washed 3 times with TBS-T and then incubated with
AlexaFluor 488- or 594-conjugated secondary antibodies raised in donkey (Thermo Fisher
Scientific) at a 1:500 dilution in PBS, for 45 minutes at room temperature, protected from
light. Samples were then washed 3 times with PBS, counterstained with 1μg/mL DAPI
(Thermo Fisher, D1306) in PBS for 10 minutes, and washed with PBS once. Fluorescence
images were taken using a Nikon eclipse TE2000-U microscope controlled by Nikon
elements software and equipped with the appropriate filters.

Lentivirus production
Lentiviral plasmids pWPI.1-FOXA3, pWPI.1-HNF1A, and pWPI-HNF4A were kindly
provided by the laboratory of Lijian Hui (Huang et al., 2014). Plasmid DNA was purified
from bacteria using the EndoFree Plasmid Maxi Kit (Qiagen #12362). 293T cells were
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grown in DMEM High Glucose (Thermo Fisher Scientific #11995) supplemented with 10%
FBS (Hyclone SH30071) and seeded in 10-cm dishes at a density of 8 x 105 cells/plate.
After 24 hours, transfection mixtures were prepared by mixing 2.5 μg lentiviral vector, 1.7
μg packaging plasmid psPAX2 (Addgene #12260), 0.8 μg envelope plasmid pMD2.G
(Addgene #12259), and 30 μl Fugene 6 Transfection Reagent (Promega E2691) with 570
μl OptiMEM-I Reduced Serum Medium (Thermo Fisher Scientific #31985070), per plate.
Transfection mixtures were vortexed, incubated for 15 min, and added drop-wise to plates
containing 10 mL media. Media was changed 16 hours after transfection. 60 hours later,
media containing viral particles was collected. Debris was pelleted at 800 g for 10 min
(4°C), and the supernatant was passed through a 0.45 μm syringe filter (Millipore
SLHV033RS). Viral particles were concentrated by ultracentrifugation at 25,000 rpm for
1.5 hr (4°C) with an SW-32 swinging bucket rotor (Beckman Coulter), and the viral pellet
was resuspended in pure DMEM for 1/100th the original supernatant volume. Viral titer
was determined immunostaining for FOXA3, HNF1A, and HNF4A in fibroblasts three days
after infection with serial dilutions of concentrated virus. Dilutions of virus that produced
10-35% transgene-expressing cells were used to calculate the multiplicity of infection
(MOI), and in turn the titer, using the relationship MOI = (-1) * ln(1 - [proportion infected]).

hiHep reprogramming
Transdifferentiation of fibroblasts to hiHep cells was carried out as previously described
(Huang et al., 2014). BJ fibroblasts growing in complete EMEM (see above) were plated
on collagen I-coated plates at a density of 3 x 104 cells per well in 12-well format. One day
after plating, cells were infected with a cocktail of three lentiviruses (pWPI.1-FOXA3,
pWPI.1-HNF1A, and pWPI.1-HNF4A), with an MOI of 1.25 per virus, in media containg
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4.5 μg/ml polybrene. One day after infection, virus-containing media was removed, cells
were washed twice with PBS, and fresh complete EMEM was added. On the second day
after infection, medium was switched to Human Maintenance Medium (HMM): DMEM/F12
(Hyclone SH30023.01) supplemented with 0.544 mg/L ZnCl2, 0.75 mg/L ZnSO4·7H2O, 0.2
mg/L CuSO4·5H2O, 0.025 mg/L MnSO4·1H2O, 2 g/L Bovine serum albumin (SigmaAldrich), 2 g/L galactose (Sigma-Aldrich G0750), 0.1 g/L ornithine (Sigma-Aldrich O2375),
0.03 g/L proline (Sigma-Aldrich P5607), 0.61 g/L nicotinamide (N0636), 1X Insulintransferrin-sodium selenite media supplement (Sigma-Aldrich I1884), 40 ng/ml TGF-α
(Peprotech AF-100-16A), 40 ng/ml EGF (Peprotech AF-100-15), 10 μM dexamethasone
(Sigma-Aldrich D4902), and 1% FBS (Hyclone SH30071). Media was changed with fresh
HMM every 48 hours. Cells were analyzed for hepatic markers at 12-14 days after lentiviral
infection.

siRNA transfection experiments
All knockdown experiments were performed with two cycles siRNA transfection, three
days apart. The following Silencer Silect siRNAs from Thermo Fisher Scientific were used:
Negative Control No. 1 siRNA (#4390843), SUV39H1 siRNA (s13660), RBMX siRNA “#1”
(s56033), RBMX siRNA “#2” (s56035), and RBMX siRNA “#3” (s223747). Transfections
were performed using 10 nM final concentration of siRNA and 2.5 μl/ml final concentration
Lipofectamine RNAiMAX (Thermo Fisher Scientific #13778150). 10X transfection
mixtures were prepared by adding 100 nM siRNA and 25 μl/ml Lipofectamine to OptiMEMI Reduced Serum Medium (Thermo Fisher Scientific #31985070) and incubating for 10
min at room temperature. On day 0, cells were reverse transfected by seeding a 0.9X
volume of cells/media into wells containing 0.1X volume of 10X transfection mixture. After
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24 hours, siRNA-containing media was replaced with normal culture media. After 3 days,
forward transfections were performed on adherent cells by adding 0.1X volume of 10X
transfection mixture drop-wise to 0.9X volume of culture media. Media was again replaced
24 hours after transfection. RNA or protein was harvested on day 6, three days after the
second siRNA transfection. For experiments performed with uninfected, proliferating
fibroblasts, cells were passaged over the course of this six-day time-course, as needed to
prevent over-growth.
Knockdown experiments in cells expressing hepatic transcription factors were
performed as follows. First, on day -1, cells were infected as a batch (single well or plate)
with pWPI.1-FOXA3, pWPI.1-HNF1A, and pWPI.1-HNF4A lentiviruses (MOI of 1.25 per
virus), in media containg 4.5 μg/ml polybrene. 24 hours after infection, on day 0, viruscontaining media was removed, cells were washed twice with PBS, and cells were
detached from the plate and split for reverse siRNA transfection. The remainder of the sixday siRNA time-course was performed as described as above, except that, on day 4,
media was changed to HMM (see above under “hiHep reprogramming”) to promote
hepatic induction. By infecting cells with factors prior to splitting for transfection with
specific siRNAs, we ensure similar dosage of factors across the conditions being
compared.

RNA isolation and Reverse Transcription-PCR
Total RNA was isolated using the ZR-96 Quick-RNA kit (Zymo Research, R1052), which
includes an on-column DNase I treatment step, and eluted in 30 μL RNase-free dH2O.
cDNA was prepared using the High Capacity cDNA Reverse Transcription Kit (Thermo
Fisher #4368814). For detection of transcripts from liver genes in fibroblast
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heterochromatin, TaqMan-based quantitative PCR was performed using using the
TaqMan assays listed below and TaqMan Gene Expression Master Mix (Thermo Fisher
#4369016), and data was normalized to an average of GAPDH and 18SRNA endogenous
controls. For detection of transcripts normally expressed in fibroblasts, qPCR was
performed using Power SYBR Green PCR Master Mix (Thermo Fisher #4367659), and
data was normalized using the GAPDH primer as an endogenous control (see primers
listed below). qPCR reactions were run in 384-well format on an 7900HT Real-Time PCR
machine (Thermo Fisher #4329001), using the following thermal cycler protocol: 50°C for
2 min, 95°C for 10 min, followed by 45 cycles of 95°C for 15 s then 60°C for 1 min. For
SYBR-based qPCR reactions, a dissociation curve was generated to verify that a single
PCR product was generated.

Table 3-2. TaqMan Gene Expression Assays used for RT-PCR experiments.
transcript target

Thermo Fisher Scientific TaqMan ID

human GAPDH

Hs02758991_g1

human RNA18S5

Hs03928990_g1

human FOXA2

Hs00232764_m1

human NR1H4

Hs01026590_m1

human DSC2

Hs00951428_m1

human DSG2

Hs00170071_m1

human ONECUT1

Hs00413554_m1

human CYP2C9

Hs04260376_m1

human CYP2C19

Hs00426380_m1

human SERPINA7

Hs02384980_m1

human HNF4G

Hs01071345_m1

human F9

Hs01592597_m1
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Table 3-3. Primers for SYBR-based RT-PCR experiments.
transcript

forward primer (5' - 3')

reverse primer (5' - 3')

hGAPDH

CCAGGTGGTCTCCTCTGACTTC

TCATACCAGGAAATGAGCTTGACA

hSUV39H1

GTCATGGAGTACGTGGGAGAG

CCTGACGGTCGTAGATCTGG

hSUV39H2

TCGATACGGCAATGTGTCTC

ACAATGCTATTCGGGGAAGA

Hrbmx

CAGTTCGCAGTAGCAGTGGA

TCGAGGTGGACCTCCATAA

hRBMXL1

AGCAGCTCACGTGATGGATA

GATCACTTCGGCTGCTTGAG

Preparation of polyA-selected RNA libraries
Two biological replicates were sequenced per experimental condition. Purified total RNA
was diluted to 50 μl in BTE buffer (10 mM Bis-tris, pH 6.7, 1 mM EDTA), denatured by
heating at 65°C for 5 minutes, and place immediately on ice. Oligo(dT)25 Dynabeads
(Thermo Fisher Scientific #61002) were washed three times in 2x Oligo-dT Binding Buffer
(2xOBB: 20 mM Tris, pH 7.5, 1 M LiCl, 2 mM EDTA), resuspended in 50 μl 2xOBB, and
mixed with an equal volume of denatured RNA. RNA and beads were incubated at room
temperature for 10 min, shaking. Beads were washed three times with Oligo-dT Washing
Buffer (10 mM Tris, pH 7.5, 150 mM LiCl, 1mM EDTA), and eluted in 10 μl BTE buffer by
heating at 80°C for 2 min. Strand-specific cDNA libraries were generated using the
NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New England Biolabs,
E7420S). This protocol includes a heat-based mRNA step (15 min at 94°C in first-strand
cDNA synthesis buffer), and actinomycin D (Sigma-Aldrich A1410) is added during firststrand cDNA synthesis to inhibit DNA-dependent DNA polymerase activity and prevent
template switching. Adapter-ligated cDNAs were amplified by 12 cycles of PCR with
NEBNext Multiplex Oligos for Illumina (New England Biolabs E7335S and E7500S).
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Library yield and fragment size distribution was assessed on a Bioanalyzer 2100
instrument (Agilent Technologies), using the DNA 1000 kit (Agilent Technologies 50671504).

Next-generation sequencing
Libraries were quantified by qPCR using the KAPA Library Quantifcation Kit for Illumina
(KAPA Biosystems KK4824). Libraries were diluted to 8 nM concentration and pooled for
multiplexing, and then their diluted concentrations were checked a second time using the
KAPA kit, adjusting as necessary. Diluted libraries were denatured in 0.2 M NaOH, loaded
into the cartridge of the NextSeq 500/550 High Output v2 kit (Illumina FC-404-2005, 75
cycles) at a concentration of 3.2 pM in the kit’s Hybridization Buffer, and sequenced in an
Illumina NextSeq 500 machine.

3.2 Computational and statistical analyses
Tests of statistical significance
Repeated measurements being compared between two samples were analyzed for
significance by two-tailed Student’s T-test. Distributions of unequal sizes, such as gene
expression values for two different sets of genes, were compared by Wilcoxon rank sum
test, implemented in R using the wilcox.test() function (paired=FALSE). Paired
distributions (equal size) were analyzed by Wilcoxon signed rank test, using R’s
wilcox.test() function (paired=TRUE). Correction for multiple comparisons, where noted,
were performed using the Benjamini-Hochberg procedure, implemented via DAVID
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Bioinformatics tools or the p.adjust() function in R, and a 5% FDR cutoff was applied. For
testing the significance of overlaps between two sets drawn from a common pool, the
hypergeometric test was used, implemented with the dhyper() function in R.

Alignment and visualization of Gradient-seq and ChIP-seq data
For new sequencing data generated in these studies, sequencer output was demultiplexed
(bcl2fastq using BaseSpace) to produce FASTQ files for individual samples. Sequenced
reads were aligned to the hg19 assembly of the human genome using bowtie2 v2.1.0
(Langmead and Salzberg, 2012), run with the ‘--very-sensitive’ parameter. Bowtie output
files were converted to .bam files using samtools v1.1, and then to .bed files using bedtools
v2.20.1 ‘bamtobed’ (Quinlan and Hall, 2010). For each sample, reads mapping to the
same genomic position (duplicate reads) were collapsed to a single entry (unique reads).
75bp sequencing reads were extended to 200 bp, to match the average size of DNA prior
to library preparation. Meanwhile, all ChIP-seq data obtained from public consortia (see
Table 3-4 below) were downloaded from GEO as aligned, unique reads with lengths of
200 bp.
To generate input-normalized genome coverage tracks, BED files were converted
to BedGraph files using genomeCoverageBed (bedtools v2.20.1) and normalized to the
number of millions of reads sequenced (rpm), to correct for lane or sample biases. For
each sample’s normalized BedGraph, the normalized BedGraph for the corresponding
input sample was subtracted on a basepair-by-basepair basis. The resulting subtracted
BedGraph was converted to a bigWig file using bedGraphToBigWig (v4).
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Table 3-4. Publicly available ChIP-seq datasets used for genome browser tracks or
domain calling.
Listed below are ChIP-seq datasets from the Roadmap Epigenomics Mapping Consortium
(“Roadmap”) (Bernstein et al., 2010) and the ENCODE project (ENCODE Project
Consortium, 2012) that were used for generation of input-subtracted genome browser
tracks. Asterisks indicate datasets that were also used for calling enriched genomic
domains for a given histone mark.
Human cell type
foreskin fibroblasts
foreskin fibroblasts
foreskin fibroblasts
foreskin fibroblasts
foreskin fibroblasts
liver
liver
IMR90 fibroblasts
IMR90 fibroblasts
skeletal muscle
skeletal muscle
+
cord blood CD3 cells
+
cord blood CD3 cells
+
naïve CD8 T cells
+
naïve CD8 T cells
PBMCs
PBMCs
K562 cells
K562 cells
K562 cells
K562 cells

ChIP type
H3K9me3 *
H3K27me3 *
Input *
H3K4me3
H3K36me3
H3K9me3 *
Input *
H3K9me3
Input
H3K9me3
Input
H3K9me3
Input
H3K9me3
Input
H3K9me3
Input
H3K9me3
H3K27me3
H3K36me3
Input

Source
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
ENCODE
ENCODE
ENCODE
ENCODE

GEO accession #
GSM817236, GSM817239
GSM817237, GSM817240, GSM958154
GSM817246, GSM817247, GSM958168
GSM817235, GSM941718, GSM958158
GSM817238, GSM817241, GSM958149
GSM537695, GSM537710, GSM669986
GSM670008, GSM669910, GSM621629
GSM469974
GSM521926
GSM621632
GSM621641
GSM537637
GSM537619
GSM613812
GSM613816
GSM613878
GSM613893
GSM733776 (2 replicates)
GSM733658 (2 replicates)
GSM733714 (2 replicates)
GSM733780

Calling enriched genomic domains
Genomic domains enriched in ChIP-seq or Gradient-seq datasets were called using a 10kb sliding window algorithm with a 500-bp sliding step, implemented using custom scripts.
For every 10-kb window in the genome, the number of reads for the genomic feature of
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interest (normalized to the number of reads sequenced) was divided by the number of
reads in that window for the corresponding input file (also normalized to the number of
reads sequenced). Divide-by-zero errors were avoided by spiking in a small value into
both numerator and denominator (0.25 reads per million reads sequenced). Enriched
domains were initially formed by taking all 10-kb windows whose signal-over-input value
exceeds a threshold, after averaging all replicates. For human H3K9me3 ChIP-seq
(produced by our lab or the Epigenomics Roadmap), the signal-over-input values form a
bimodal distribution; consequently, we used kmeans clustering (via the kmeans() function
in R) to find the partition between the “unenriched” and “enriched” modes of the
distribution. This led to the selection of 1.23 as the threshold for the BJ fibroblast H3K9me3
ChIP-seq produced in this study and 1.41 as the threshold for the foreskin fibroblast
H3K9me3 ChIP-seq produced by the Epigenomics Roadmap (see Table 3-4) – values
that reflect the different dynamic ranges of the two datasets and yield highly concordant
domain maps (86% overlap). Similarly, kmeans clustering was used to select a threshold
of 1.30 for the human liver H3K9me3 ChIP-seq from the Epigenomics Roadmap (Table 34). For other genomic datasets, fixed enrichment thresholds were applied, instead of
kmeans clustering, to ensure fair comparisons. For example, the strucHC sequencing has
similar dynamic range as our H3K9me3 ChIP-seq data, and thus the same threshold of
1.23 was applied. For H3K27me3 ChIP-seq data from the Epigenomics Roadmap, the
same threshold was used as the Roadmap H3K9me3 data (1.41). Rates of domain
overlap among these datasets were similar across a wide range of chosen threshold
values and were further corroborated by threshold-free correlation analyses.
Once enriched 10-kb windows were chosen, all adjacent enriched 10-kb windows
were merged into contiguous domains. To increase the local resolution of the domain
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calls, an edge-pruning step was applied, whereby 500-bp steps were removed from either
end of each domain until a 500-bp step is encountered with a signal-over-input value of at
least 1.2. (This step serves to eliminate “overhangs” where a local region of strong signal
causes an entire 10kb window to be called as enriched. Empirically, this pruning step
removes 5% or less of the total domain coverage.) Finally, any remaining overlaps among
domains were merged, to produce the final domain calls.
For calling euchromatin domains, a small modification was made because of the
close similarity of the euchromatin fraction (containing the majority of chromatin
fragments) to the gradient input. To increase contrast for domain-calling, the euchromatin
signal was normalized to the strucHC signal (instead of the input). A threshold of 1.2 was
applied, based on the bimodal distribution of euchromatin-over-strucHC values. The
remainder of the domain-calling procedure was as described above.
Intermediate signal domains were defined by taking all regions outside of strucHC
and euchromatin domains that also had sequencing signal in both gradient replicates.
Thus, uninformative regions without sequencing data were not assigned a structural type.
The strucHC subtype of H3K9me3 or H3K27me3 domains are simply regions of overlap
between the strucHC domains and histone mark domains. Among the remaining regions
for each histone mark, the euchromatic subtype was called by selecting regions where the
exact same 10-kb window met enrichment criteria for both euchromatin and the histone
mark. (In other words, it was not sufficient for there merely to be overlap between one
euchromatic 10-kb window and a nearby 10-kb window enriched for the histone mark;
both properties had to co-occur in the same window, ensuring the stringency of the
euchromatic calls.) Finally, remaining regions enriched for the histone mark that were
neither strucHC nor euchromatic were called as intermediate.
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Correlation analysis of Gradient-seq and ChIP-seq datasets
As for domain calling (see above), the genome was divided into 10-kb sliding windows
(500-bp sliding step). For each window, the number of reads for the genomic sample of
interest (normalized to the number of reads sequenced) was divided by the number of
reads in that window for the corresponding input file (also normalized to the number of
reads sequenced). As above, divide-by-zero errors were avoided by spiking in a small
value into both numerator and denominator (0.25 reads per million reads sequenced).
Using the cor() function in R, we computed the pairwise Spearman correlation among the
samples in terms of their signal-over-input values, across all 10-kb windows genome-wide.
Spearman correlation values were used to construct a heatmap using the “pheatmap”
package in R. The dendrogram distances and clustering were set according to
dissimilarity, where dissimilarity = [ 1 - (Spearman correlation) ]. Similar correlations and
identical clustering were obtained by Pearson correlation.

Defining genes sets overlapping chromatin domains
The hg19 Refseq gene table was downloaded from the UCSC Table Browser. Refseq
genes were defined as “inside” a chromatin domain of interest if at least 50% of the gene
body overlapped that domain class. If there were multiple overlaps of the Refseq gene
with different domains in that category, these overlaps were summed together, and the
Refseq gene was said to overlap the domains as long as the sum met the 50% cutoff.
Many Refseq genes have the same gene symbol; for analyses at the gene symbol level
(such as gene expression by mRNA-seq), genes symbols were said to overlap the domain
if any of their associated Refseq genes met the 50% cutoff. Results regarding gene
expression in chromatin domain types were highly invariant to the percentile cutoff chosen.
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Computing histone mark enrichment over domains
A large number of ChIP-seq datasets for human fibroblast histone marks were
downloaded from GEO (see Table 3-5 below for full list). This included all histone marks
profiled in fibroblasts by the Roadmap Epigenomics Mapping Consortium (Bernstein et
al., 2010), as well as data from Narita and colleagues (Chandra et al., 2012) to enable
inclusion of H3K9me2. The Roadmap data was downloaded as aligned reads, while the
Narita lab data was downloaded as raw reads and aligned using bowtie v1.
The following procedure was used to compute histone mark levels within domains
of interest, such as strucHC domains (as in Figure 4-2B) or different types of H3K9me3
domains (as in Supplementary Figure 4-3A). First, each domain in the genome was
divided into 100 equally sized bins. For each histone mark ChIP-seq experiment, the read
pileup per bin was determined. These pileups per bin were then normalized for ChIP-seq
sequencing depth (number of millions of reads) and the length of the bin in kb. For each
bin of each domain, the normalized pileups were averaged across all replicate ChIP-seq
datasets for that mark (from the same cell type and data source). These averages were
then subtracted by the results for the corresponding input samples (from the matching
replicates/batches of chromatin, also normalized for sequencing depth and bin size). This
yielded a topography of histone mark enrichment or depletion across each individual
domain, broken into a vector of 100 values for the 100 bins. An average of these vectors
was then taken across all domains of that type in the genome, weighted by domain length.
For clarity of display, only the 13 most well-studied histone marks are plotted in
Figure 4-2B and Supplementary Figure 4-3A, using the datasets indicated with a
checkmark in Table 3-5 below. When available, datasets from primary foreskin fibroblasts
were prioritized over IMR90 fibroblasts, given the greater similarity of the former to the BJ
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foreskin fibroblasts used in our own experiments. However, we note that results between
IMR90 and foreskin fibroblasts were in agreement in all cases, and all acetylated
modifications not included in these figures were similarly depleted from strucHC and
H3K9me3 domains (data not shown).

Table 3-5. ChIP-seq datasets used for computing histone mark signal over
genomic domains.
Datasets used for results presented in Figure 4-2B and Supplementary Figure 4-3A are
indicated with a check mark in the final column. Remaining datasets below yielded
concordant results (data not shown), as explained above.
ChIP type

Cell type

Source

H3K4me1
H3K4me3
H3K9me3
H3K27ac

foreskin fibroblasts
foreskin fibroblasts
foreskin fibroblasts
foreskin fibroblasts

Roadmap
Roadmap
Roadmap
Roadmap

GEO accession #

GSM817234, GSM941717, GSM958164
GSM817235, GSM941718, GSM958158
GSM817236, GSM817239
GSM1127076, GSM1127060,
GSM958163
H3K27me3 foreskin fibroblasts Roadmap
GSM817237, GSM817240, GSM958154
H3K36me3 foreskin fibroblasts Roadmap
GSM817238, GSM817241, GSM958149
Input
foreskin fibroblasts Roadmap
GSM817246, GSM817247, GSM958168
H3K4me2 IMR90 fibroblasts
Roadmap
GSM521899, GSM521900
H3K9ac
IMR90 fibroblasts
Roadmap
GSM469973, GSM521912
H3K9me1 IMR90 fibroblasts
Roadmap
GSM752986, GSM752987
H3K79me1 IMR90 fibroblasts
Roadmap
GSM521904, GSM521906,
GSM521907, GSM521908
H3K79me2 IMR90 fibroblasts
Roadmap
GSM521909, GSM521911
H4K20me1 IMR90 fibroblasts
Roadmap
GSM521915, GSM521917
Input
IMR90 fibroblasts
Roadmap
GSM521926, GSM521927,
GSM521928, GSM521929,
GSM521930, GSM521931,
GSM521932, GSM521933
H3K9me2 IMR90 fibroblasts
Chandra et GSM942082, GSM942084
al., 2012
Input
IMR90 fibroblasts
Chandra et GSM942119
al., 2012
H3K9me3 IMR90 fibroblasts
Chandra et GSM942075
al., 2012
H2AK5ac
IMR90 fibroblasts
Roadmap
GSM521866, GSM521868
H2AK9ac
IMR90 fibroblasts
Roadmap
GSM818012, GSM818013
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H3K56ac
H4K5ac
H4K8ac

IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts
IMR90 fibroblasts

Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap
Roadmap

H4K91ac

IMR90 fibroblasts

Roadmap

GSM818017, GSM832837, GSM832838
GSM521871, GSM521873, GSM521874
GSM521875, GSM521877, GSM521878
GSM521879, GSM521880
GSM521869, GSM521870
GSM521893, GSM521894
GSM521895, GSM521897, GSM521898
GSM469970, GSM521901
GSM469974, GSM521913, GSM521914
GSM521881, GSM521883
GSM469965, GSM521884
GSM521885, GSM521886
GSM469966, GSM469967, GSM521887
GSM469968, GSM521889
GSM521890, GSM521892
GSM521902, GSM521903
GSM469975, GSM521918
GSM521919, GSM521921,
GSM521922, GSM521923
GSM521924, GSM521925

Analysis of repetitive elements enriched in chromatin domains
The Repeat Masker table for hg19 was downloaded from the UCSC table browser and
was intersected with BED files listing non-overlapping domains, using Bedtools. For each
type of repeat, the total number of base pairs falling within domains was computed as a
percentage of the total genomic coverage of that repeat. This analysis was performed for
each repeat class, repeat family, and individual repeat name listed in the Repeat Masker
table. P-values were determined by permutation test, using 1000 simulations of domains
randomly shuffled across the genome by Bedtools (preserving domain number and size).
For each repeat, the P-value was the proportion of domain simulations that produced an
equal or greater overlap with that repeat. To correct for multiple hypothesis testing, P
values were used to calculate the FDR using the Benjamini-Hochberg procedure.
Enriched repeats with an FDR < 0.05 were treated as statistically significant.
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Analysis of DNA methylation in chromatin domains
Processed whole-genome bisulfite sequencing (WGBS) data for human foreskin
fibroblasts was downloaded from GSM1127120 (Roadmap Epigenomics Consortium et
al., 2015). This data file reports the percent methylation per CpG. CpGs were then divided
into two categories based on whether they fell in annotated CpG islands (UCSC Table
Browser). Both categories of CpG sites (inside and outside of CpG islands) were
intersected with chromatin domains of interest, and the distribution of percent-methylation
values was plotted.

Analysis of datasets for Lamin B1 ChIP-seq, DNase-seq, and MNase sensitivity
Lamin B1 ChIP-seq reads and input reads for IMR90 fibroblasts (Dou et al., 2015) were
downloaded from GSE63440, aligned using bowtie2 v2.1.0 (parameters: --very-sensitive),
and extended to 200 bp. PCR duplicates were collapsed to unique reads. The enrichment
of Lamin B1 ChIP reads to input reads (after normalizing for sequencing depth) was
computed over 10-kb genomic windows, with a 500-bp sliding step, using custom scripts.
Lamin-B1 enrichment values over input were averaged across the two replicates and were
plotted for all 10-kb windows falling entirely inside a chromatin domain type of interest.
ENCODE DNase-seq data for BJ fibroblasts (two replicates) were downloaded as
aligned reads GSM736518 and GSM736596 (Thurman et al., 2012). The aligned reads
were binned into 10-kb windows, with a 500-bp sliding step, and normalized based on the
number of millions of reads sequenced. These normalized pileups were plotted for all 10kb windows falling entirely inside a chromatin domain type of interest.
MACC scores, which represent sensitivity to MNase from an enzymatic titration,
were downloaded for human K562 cells from GSE78984 (Mieczkowski et al., 2016).
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MACC scores were provided at 500-bp resolution, and these scores were converted to
10-kb sliding window scores (500-bp slide) by averaging the component 500-bp values
within each 10-kb window. During this averaging, missing values were ignored (rather than
counting them as zero), and data was not reported for the 10-kb window if fewer than five
of the constituent 500-bp bins contained data. The 10-kb MACC scores were then plotted
for chromatin domains, similarly to the Lamin B1 and DNase I data.

Analysis of DNA replication timing data
ENCODE Repli-seq data for BJ fibroblasts (Pope et al., 2014) were downloaded as
aligned reads from ENCSR894LZX. These files contain sequencing of newly replicated
DNA in six cytometry-fractionated cell populations, with two replicates per timepoint. The
downloaded alignments were intersected with each domain BED file using bedtools, and
the number of intersecting reads was divided by the number of millions of reads in the
sequencing file. These normalized intersection scores were then averaged between the
two sequencing replicates per timepoint, and then they were expressed as a fraction of
the sum of the intersection scores across the six timepoints. Thus, the final values for each
domain type sum to 1.0 across the six cell cycle fractions.

Analysis of RNA microarray data for hiHep reprogramming
Microarray data for human fibroblasts, cultured human hepatocytes, hiHep cells, and
immortalized hiHeps were downloaded from GSE42643 (Huang et al., 2014). The
microarray data was quantile-normalized with median polish using the Partek Genomics
Suite. For Refseq genes with multiple probes, only the probe with the highest variance
across all samples was used. The full microarray was filtered down to genes expressed
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significantly higher in normal hepatocytes compared to fibroblasts (P < 0.05, at least 2fold). For analyses specifically related to silent genes in fibroblasts (eg, Extended Data
Figure 1A), the list was further reduced to genes expressed in the bottom 40% among in
fibroblasts, which corresponded to the lower mode of a biomodal distribution. Log2normalized gene expression for hiHep cells was calculated on a relative scale, with 0%
representing the log2-normalized fibroblast expression, and 100% representing the log2normalized hepatocyte expression. Negative values (hepatic genes expressed lower in
hiHeps than fibroblasts) were rounded up to 0%. Expression values on this scale were
plotted as violin plots in R using the vioplot package, modified to display multiple colors.

Analysis of RNA microarray data for patient-derived fibroblasts
Exon microarray data were downloaded from GSE33855 (Highley et al., 2014) and
quantile-normalized with median polish using the Partek Genomics Suite. This dataset
includes fibroblasts from patients with Amyotrophic Lateral Sclerosis (ALS), some with
germline mutations and some with sporadic disease, in addition to healthy controls. To
extract whole gene-level expression from exon-directed probes (multiple per gene), we
analyzed the microarray as described in the original publication (Highley et al., 2014):
exon-specific probes were removed from consideration if their log2-normalized signal
(averaged across all biological samples) was 3 standard deviations above or 1 standard
deviation below the average signal for all the probes for that gene. This served to remove
probes with nonspecific hybridization or affected by alternative splicing, respectively. An
average was then taken of the remaining probes for each gene, for each patient sample.
These log2-transformed values were then converted back to a linear scale and averaged
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across the patients for a given genotype – TARDBP-mutated (n=3), sporadic ALS (n=6),
or control (n=6) – in order to calculate, for each gene, the fold-change versus control.

Alignment and visualization of mRNA-seq data
Sequencer output was demultiplexed (bcl2fastq using BaseSpace) to produce FASTQ
files for individual samples. Sequenced reads were aligned to the hg19 Refseq gene
model, in a strand-specific manner, using TopHat v2.0.11 (parameters: --b2-very-sensitive
--library-type fr-firststrand) (Kim et al., 2013). To generate genome coverage tracks, BED
files were first pooled between biological replicates. Reads aligning to genomic regions
longer than the sequencing length (75 bp), due to spanning of splice junctions, were
discarded for genomic visualization purposes. Pooled BED files were then converted to
BedGraph files using genomeCoverageBed (bedtools v2.20.1) and normalized to the
number of millions of reads sequenced (rpm), to correct for lane or sample biases. The
resulting subtracted BedGraph was converted to a bigWig file using bedGraphToBigWig
(v4).

Gene expression analysis for mRNA-seq data
Sequenced reads were assigned in a strand-specific manner to genes from the hg19
Refseq table using HTSeq v0.6.1 (parameters: --stranded=reverse --mode=intersectionnonempty --type=exon -i gene_id) (Anders et al., 2015), such that all exons for all Refseq
genes with the same official gene symbol were considered to belong to the same feature.
The unnormalized HTSeq tables, after removal of lines for unassigned reads, were
analyzed by the DESeq2 v1.11.45 (Love et al., 2014) package in R to produce normalized
count tables. All samples for both the “hepatic-TF” and “no-TF” RNA-seq studies were
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normalized in DESeq2 at the same time. For quantification of fibroblast gene expression
across chromatin categories, the DESeq2-normalized counts for the control siRNAtransfected fibroblasts in the no-TF condition were used, after dividing each value by the
length of that gene’s exon model in kb and averaging the two biological replicates.
Differentially expressed genes were determined in a pairwise manner using DESeq2, with
a significance cutoff of p.adjust < 0.05. For analysis of genes upregulated by siRNAs
compared to control siRNA in the “hepatic TF” condition, genes significantly
downregulated by hepatic TFs alone (hepatic-TF control siRNA compared to no-TF control
siRNA) were removed from consideration – 3,487 out of 26,839 total genes. This was to
ensure that upregulated genes could be interpreted as being truly upregulated by the
siRNA, rather than the siRNA treatment inhibiting the downregulation of the gene by the
hepatic TFs. For mRNA-seq sample correlation analyses, a regularized log2transformation was performed on the normalized counts using DESeq2, and Euclidean
distances were calculated using the dist() function in R and visualized as a
heatmap/dendrogram using the “pheatmap” package.

Defining protein sets enriched in heterochromatin and gradient top
Intensity-based absolute quantification (iBAQ) values were ranked in order of their iBAQ
score for each of three biological replicates of each sample, to facilitate comparison
among samples with very different numbers of identified proteins. Technical replicate MS
runs were averaged. Proteins with only a single detected peptide were removed from
consideration, and common contaminants (immunoglobulin chains, skin keratins) were
filtered out. Protein ranks were compared between samples by two-tailed Student’s T test.
Proteins with a significantly higher rank (P < 0.05) in the strucHC+H3K9me3 sample
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(H3K9me3-directed IP using strucHC fraction chromatin) compared to the Gradient Top
fraction were used to define the “heterochromatin proteins.” Proteins detected in
strucHC+H3K9me3, but without significant enrichment or depletion compared to the
Gradient Top sample, were used to define the “shared” proteins. Meanwhile, for the
strucHC whole fraction sample, proteins with significantly higher rank in the strucHC
fraction compared to the Gradient Top fraction were defined as “strucHC enriched.”
Finally, remaining proteins were classified as “Gradient Top” proteins if they were either
significantly enriched in the Gradient Top fraction over strucHC+H3K9me3, significantly
enriched in Gradient Top over strucHC, or unique to the Gradient Top fraction. Note that
proteins not detected in the Gradient Top fraction were assigned a rank equal to the total
number of proteins detected for that replicate; thus, proteins detected uniquely in
strucHC+H3K9me3 or the strucHC fraction could still be quantified as significantly
enriched. Note also that the significance by T-test requires at least two values per sample
being compared, and thus the “heterochromatin” and “strucHC-enriched” proteins by
definition had to have been detected in at least two out of three replicates of the
strucHC+H3K9me3 and strucHC samples, respectively.

3.3 Genomic and proteomic dataset availability
All next-generation sequencing data generated by this study (FASTQ files of sequenced
reads and bigwig files for browser visualization) were uploaded to GEO accession number
GSE87041, and they will be made available upon publication. Proteomic raw data files are
available on the Chorus database under Project ID 1172, Experiment ID 2585.
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4.1 RESPECTIVE CONTRIBUTIONS
The majority of the experiments and analyses in this chapter were performed by me alone,
with guidance from Kenneth S. Zaret. Simone Sidoli and Shu Lin, with guidance from
Benjamin A. Garcia, performed the mass spectrometry experiments and the quantitative
proteomics analysis on peptide samples that I provided. Kelsey Kaeding prepared and
sequenced the mRNA-seq libraries for the transcriptome analysis after siRNA treatment,
using RNA samples that I prepared, and she also validated the efficiency of the
knockdowns by RT-PCR. Zhiying He assisted with some of the hiHep reprogramming
experiments.

Greg Donahue provided custom scripts and advice for computational

analyses, worked directly with me for alignment of next-generation sequencing data, and
performed the analysis of whole-genome bisfulfite sequencing data.

Computational

analyses performed by primarily by me included the mapping and analysis of chromatin
domains enriched for various features, the differential gene expression analysis for
mRNA-seq, and the analysis of available microarray data for studying hiHep
reprogramming or the consequences of TARDBP mutation. The manuscript was written
by me and Dr. Zaret.
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4.2 ABSTRACT
Heterochromatic

regions

in

mammalian

cells

suppress

recombination,

silence

transcription, and are crucial for maintaining cell differentiation. Genomic and biochemical
characterization of heterochromatin has relied on the associated histone modifications
H3K9me3 and H3K27me3, yet these marks are also found in euchromatic regions that
permit transcription. We employed a biophysical method to isolate structurally compact
heterochromatin from human somatic cells, mapped its genomic organization compared
to histone modifications, and used proteomics to reveal an extensive number of
heterochromatin-bound

proteins.

We

discriminate

subtypes

of

H3K9me3-

and

H3K27me3-marked domains, in structural heterochromatin versus euchromatin, and we
present a resource of hundreds of proteins that preferentially bind heterochromatin,
revealing an enrichment for RNA-binding proteins and proteins that oppose iPS
reprogramming. The structural heterochromatin landscape includes repressed genes for
alternative lineages that are resistant to activation by introduced transcription factors.
Depletion of identified heterochromatin-associated proteins reduces this barrier, rendering
alternative-lineage genes more competent for transcriptional activation.
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4.3 INTRODUCTION
Cell differentiation is achieved, in part, through the selective repression of transcription of
a large fraction of the genome. Among such silent domains, regions of heterochromatin
are distinguished by their high levels of physical compaction, causing intense staining with
DNA dyes or by electron microscopy (Heitz, 1928; Underwood et al., 2016). The
condensed structure of heterochromatin restricts the accessibility of DNA to binding by
transcription factors (Soufi et al., 2012) and allows persistent gene silencing, despite the
presence of transcriptional activators (Ayyanathan et al., 2003; Hathaway et al., 2012).
The packaging of DNA into dense chromatin structures also suppresses recombination at
repeat-rich sequences, promoting genome stability (Peters et al., 2001). But lacking has
been a direct method to identify genomic domains with high physical compaction while
allowing recovery and analysis of constituent proteins.
A hallmark of repeat-rich heterochromatic regions, conserved from fission yeast to
humans, is the dimethylation and trimethylation of histone 3 lysine 9 (H3K9me2 and
H3K9me3). In mammals, the methyltransferases SUV39H1/SUV39H2 and SETDB1 are
responsible for H3K9me2 and H3K9me3 (Peters et al., 2001; Schultz et al., 2002), while
G9a and GLP catalyze only H3K9me2 (Tachibana et al., 2005). The direct binding of
H3K9me2/3 by heterochromatin protein 1 (HP1) recruits additional repressive complexes
(Eissenberg and Elgin, 2014). Human fibroblasts contain broad, megabase-scale domains
of H3K9me3 that include repressed genes for neural function and adhesion, as well as
developmental transcription factors (Hawkins et al., 2010; Soufi et al., 2012). H3K9me3
and HP1 are also deposited over zinc finger (ZNF) genes that contain Krüppel-associated
box (KRAB) domains, which is dependent on the recruitment of SETDB1 by the KRAB-
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ZNFs themselves and their co-repressor KAP1 (Schultz et al., 2002; Vogel et al., 2006;
O’Geen et al., 2007). The global pattern of H3K9me3 domains shows partial
rearrangement across different cell lineages (Soufi et al., 2012; Becker et al., 2016), but
the protein machinery that mediates the developmental dynamics of large-scale H3K9me3
domains is largely unknown..
Repressed genes also can be associated with H3 lysine 27 trimethylation
(H3K27me3), catalyzed by the Polycomb Repressive Complex 2 (PRC2) (Margueron and
Reinberg, 2011). This mark is prominent on the inactive X chromosome and at promoters
for developmental transcription factors (Ezhkova et al., 2009; Hawkins et al., 2010; Xu et
al., 2014a). However, H3K27me3-marked sites can be accessible to general transcription
factors and RNA polymerase (Breiling et al., 2001; Dellino et al., 2004) and the literature
is conflicted on whether the term “heterochromatin” includes H3K27me3-marked regions
(Trojer and Reinberg, 2007; Beisel and Paro, 2011).
We previously described megabase-scale, H3K9me3-enriched domains that are
resistant to binding by the pluripotency transcription factors Oct4, Sox2, Klf4, and cMyc
(OSKM) in human fibroblasts, but where the factors bind in human embryonic stem (ES)
cells (Soufi et al., 2012). These Differentially Bound Regions (DBRs) contain pluripotency
genes whose activation during iPS reprogramming is restricted to rare cells late in the
reprogramming process (Buganim et al., 2012). Reducing H3K9me3 levels, by depleting
SUV39H1/H2 methyltransferases, improves the efficiency of iPS reprogramming (Onder
et al., 2012; Soufi et al., 2012) as well as reprogramming by somatic cell nuclear transfer
(Matoba et al., 2014). However, the chromatin components that mediate the resistance of
H3K9me3 heterochromatin to gene activation during reprogramming are poorly
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understood, and whether H3K9me3 heterochromatin impedes reprogramming between
differentiated lineages is not clear.
To discover proteins embedded in heterochromatin, mass spectrometry (MS) has
been performed after H3K9me3-directed chromatin immunoprecipitation (ChIP) (Soldi and
Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015) or pulldown with a H3K9me3 bait
(Vermeulen et al., 2010; Eberl et al., 2013), but the relationship between H3K9me3associated proteins and heterochromatin per se is unclear. In two cases, proteomic
analysis was performed in mouse pluripotent ES cells (Engelen et al., 2015; Ji et al., 2015),
a cell type found to lack compacted blocks of heterochromatin by high-resolution imaging
techniques (Fussner et al., 2011; Underwood et al., 2016). More importantly, H3K9me3
and HP1 are found outside of heterochromatin, including in the gene bodies of expressed
genes, and can promote transcriptional elongation (Piacentini et al., 2003; Vakoc et al.,
2005; Riddle et al., 2012). Gene clusters on Drosophila chromosome 4q and human ZNF
clusters on chromosome 19 contain H3K9me3 and HP1, despite simultaneous
transcription (Riddle et al., 2012; Vogel et al., 2006; Blahnik et al., 2011). A definitive
accounting of transcriptionally permissive H3K9me3 domains is currently lacking.
Although RNA-binding proteins appear abundant after H3K9me3 ChIP (Soldi and Bonaldi,
2013) or among readers of the H3K9me3 mark (Vermeulen et al., 2010), it is unclear of
these proteins are specifically associated with the transcriptionally repressed,
heterochromatic form of H3K9me3-marked chromatin.
In this study, we find that H3K9me3 domains, more than H3K27me3 domains,
impede the activation of liver genes during reprogramming of fibroblasts to hepatocytes.
In our investigation of H3K9me3 domains, we found that such regions are resistant to
sonication, which causes their underrepresentation in ChIP-seq, and which allowed us to
88

physically isolate heterochromatic domains on sucrose gradients. We performed
quantitative genomics and proteomics on the isolated heterochromatin, as well as
functional analysis of selected heterochromatin proteins. The results provide resource
maps of subsets of H3K9me3 and H3K27me3 domains that are in euchromatin versus
heterochromatin, and they reveal unexpected complexity in the proteins that are enriched
in what we define as “structural heterochromatin.” We show that structural
heterochromatin

proteins identified

by our approach

inhibit the

activation

of

developmentally silenced genes, establishing the proteins as functional regulators of
heterochromatin.

4.4 RESULTS
Silent genes in H3K9me3 domains are more resistant to reprogramming than silent
genes in H3K27me3 domains
Human fibroblasts can be reprogrammed to a hepatocyte-like fate by the ectopic
expression of liver transcription factors (Huang et al., 2014; Du et al., 2014). The resulting
human induced hepatocytes (hiHeps) express hepatic markers and recapitulate some
features of liver metabolism, but expression profiling reveals a failure to fully express all
hepatocyte genes (Huang et al., 2014; Du et al., 2014). We analyzed a published
microarray comparing hiHep cells to fibroblasts and cultured human hepatocytes (Huang
et al., 2014), focusing on genes that are silent in fibroblasts and upregulated in
hepatocytes. We found that genes marked by H3K9me3 in the starting fibroblasts have a
profound failure to activate during cell conversion to hiHeps (Supp. Fig. 4-1A), with the
median barely above 0% induction. By contrast, genes marked by H3K27me3, another
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mark associated with transcriptional silence (Margueron and Reinberg, 2011), show no
greater defect in activation than genes lacking either mark (Supp. Fig. 4-1A). The
H3K9me3-marked genes in fibroblasts that fail to activate include genes that crucial for
terminal hepatocyte differentiation, including NHR1H4 (encoding the bile acid receptor
FXR), FOXA2, metabolic enzymes, cytochrome P450 subunits, secreted plasma proteins,
and epithelial adhesion proteins. We conclude that H3K9me3-marked chromatin is the
most refractory to gene activation by hepatic factors, similar to that seen at DBRs for
reprogramming to pluripotency (Soufi et al., 2012; Matoba et al., 2014), leading us to
further investigate the nature H3K9me3 domains in the human fibroblasts.

Heterochromatic Differentially Bound Regions are resistant to sonication
Using data from the NIH Epigenomics Roadmap (Bernstein et al., 2010), we find that
genome mapping tracks for input-subtracted H3K9me3 show pronounced enrichment
over DBRs (Figure 4-1A, purple track), but raw H3K9me3 signals are only modestly
elevated in these regions (Figure 4-1A, yellow track). Surprisingly, the input signals alone
show depletion over most H3K9me3 domains, including DBRs (Figure 4-1A, blue track,
red arrows). Sequencing of both input and ChIP is typically performed after size-selecting
short DNA fragments, thereby depleting regions that are more resistant to sonication. A
study reported that megabase-scale H3K9me3 domains are largely dependent on culture
conditions, but the ChIP data was analyzed without normalizing to input from the same
sample (Zhu et al., 2013). Our own input-normalized analysis of the same ChIP-seq
datasets showed that megabase-scale H3K9me3 domains are present at shared and
different sites across diverse human cell types (Supp. Fig. 4-1B) (Becker et al., 2016).
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Sites of high sonication susceptibility map to active promoters (Auerbach et al., 2009), but
resistance to sonication has not been used to identify heterochromatic regions.
We prepared crosslinked, sonicated chromatin from human BJ foreskin fibroblasts,
in which the DBRs were mapped (Soufi et al., 2012) and used sucrose gradient
ultracentrifugation under conditions that separate chromatin fragments by size (Gilbert et
al., 2004) (Figure 4-1B). By qPCR, we compared the migration sites previously shown to
be functionally euchromatic versus heterochromatic in fibroblasts: euchromatic sites
outside DBRs that are bound by Oct4/Sox2 in fibroblasts and ES cells, versus
heterochromatic sites inside DBRs that are bound in ES cells but lack binding in fibroblasts
(Soufi et al., 2012). DBR sites (Figure 4-1C, red) are significantly depleted from the
fractions at the top of the gradient, which contain the most highly sheared DNA.
Meanwhile, fractions from the middle of the gradient, containing longer DNA fragments
normally excluded from ChIP-seq (Figure 4-1B), were selectively enriched for DBR sites
(Figure 4-1C). The magnitude of DBR enrichment in middle gradient fractions is
comparable to that achieved by conventional H3K9me3 ChIP-qPCR (Supp. Fig. 4-1C).
Thus, gradient-mediated separation of sonication-resistant chromatin provides a
biophysical readout of chromatin regions of heterochromatic domains.
We pooled the fractions of the gradient showing the greatest enrichment of DBR
sites (fractions #10-17, red box in Figure 4-1B). This material was termed the “structural
heterochromatin (strucHC) fraction” and was compared to a “euchromatin fraction” from
the top of the gradient (fraction #2) in all subsequent analyses. Secondary H3K9me3
ChIP, performed from the strucHC fraction, resulted in additive enrichment of DBR sites
(Supp. Fig. 4-1C). The chromatin recovery by H3K9me3 IP, as a fraction of input, was
much greater for the strucHC fraction compared to bulk chromatin or the euchromatin
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fraction (Supp. Fig. 4-1D), confirming that the gradient step enriches for H3K9me3-marked
chromatin.

Genomic mapping of the structural heterochromatin landscape
We sequenced DNA from the strucHC and euchromatin fractions of the gradient
(“Gradient-seq”) (Figure 4-1D). For samples containing larger DNA fragments, including
strucHC fractions, IPs off of this fraction, and input to the gradient, the purified DNA was
sonicated further (Supp. Fig. 4-2A,B). In parallel, we performed conventional inputnormalized H3K9me3 ChIP-seq and mRNA-seq of BJ fibroblast cells.
We found that of the 258 DBRs (Soufi et al., 2012), 256 are positively enriched in
strucHC over input chromatin, in contrast to similarly sized regions that flank DBRs (Figure
4-1E). Browser views show that the strucHC sequencing signals form megabase-scale
domains that correspond closely to H3K9me3 ChIP-seq domains, including DBRs, while
the euchromatin fraction exhibits an inverse pattern (Figure 4-1F). Meanwhile, many
H3K27me3-marked sites overlap with regions of euchromatin signal, while others show
strong strucHC enrichment even in the absence of H3K9me3 (Figure 4-1F, green arrows).
To quantitatively compare these samples without imposing numerical thresholds, we
computed the pair-wise Spearman correlation coefficients among the samples after
binning the input-normalized data into 10 kb windows. Genome-wide, the strucHC signal
has a strong correlation with H3K9me3 ChIP-seq from either this study or the Epigenomics
Roadmap (Figure 4-2A). Meanwhile, strucHC has weaker (but still positive) correlation
with H3K27me3. Finally, the strucHC fraction and H3K9me3/H3K27me3 ChIP samples all
anti-correlate with the euchromatin fraction (Figure 4-2A).
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To identify genomic domains that were enriched in each sample (horizontal colored
bars above each track in Figure 4-1F), we used a sliding window algorithm to select 10 kb
intervals that exceeded a threshold for signal divided by input, followed by edge-pruning
of enriched regions in 500-bp steps (see Chapter 2). The identified domains for strucHC
cover 997 MB of the hg19 genome assembly and have weighted average length 135 kb.
Euchromatin domains, which total 1240 MB, were identified using the same procedure,
except the euchromatin sequencing was compared directly to strucHC, which provided
greater contrast than input. Finally, mappable regions not in strucHC or euchromatin
domains, meaning that they had comparable abundance in the two gradient fractions,
were classified as intermediate domains.
To assess histone mark levels in strucHC domains, we downloaded ChIP-seq data
for 27 marks profiled in human fibroblasts by the Roadmap Epigenomics consortium
(Bernstein et al., 2010) as well as ChIP-seq for H3K9me2 (Chandra et al., 2012). We
computed the enrichment or depletion of each mark, relative to input, over the width of
each strucHC domain and plotted the average across all domains (Figure 4-2B).
H3K9me3 is most strongly enriched in strucHC, while H3K27me3 and H3K9me2 have
modest levels of enrichment. All other marks tested, including those associated with active
promoters/enhancers or transcriptional elongation, are strongly depleted (Figure 4-2B).
Consistent with these associations, 607 MB of the strucHC domains (60.8%) are also
called as H3K9me3 domains, while 327 MB (32.8%) are H3K27me3 domains (Figure 42C). Interestingly, these two molecular forms of strucHC domains are largely distinct, with
only 70 MB of overlap (7.0%), reminiscent of ChIP-Seq data (Hawkins et al., 2010;
Chandra et al., 2012).
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Genes within strucHC domains are transcriptionally repressed, in comparison to
genes falling inside euchromatic domains, with the intermediate domains nearly as
repressed as strucHC (Figure 4-2D). StrucHC is enriched for genes important for nonfibroblast lineages, including genes for cell surface (neuronal ion channels, G-proteincoupled receptors, and epithelial adhesion proteins), immune defense proteins, factors for
endodermal and ectodermal development, keratins, muscle components, and enzymes
for digestion and hepatic metabolism (Figure 4-2E). As expected, strucHC domains
contain the majority of satellite repeat sequences and are significantly enriched for LINE
elements and endogenous retroviruses. Using whole-genome bisulfite sequencing
(WGBS) data from the Roadmap Epigenomics consortium (Bernstein et al., 2010), we find
that DNA methylation rates at CpGs islands are highly divergent between the structural
classes (Figure 4-2F, left). Domains of strucHC have the highest rate of methylation at
CpG islands (median CpG is methylated at ~75% of copies), while at euchromatic CpG
islands three-quarters of CpGs have no detectable methylation (Figure 4-2F, left).
Meanwhile, outside of CpG islands, rates of DNA methylation are high in all three
categories (Figure 4-2F, right), consistent with methylation being widespread outside of
islands (Jones, 2012). Non-CpG-island methylation is actually highest in euchromatin
(Figure 4-2F, right), perhaps because of the DNA methylation associated with transcribed
gene bodies (Jones, 2012).

Gradient-seq reveals euchromatic subtypes of repressive histone mark domains
We observed that ZNF gene clusters on chromosome 19 have high levels of H3K9me3,
despite expression of the genes (Figure 4-3A), as reported previously (Vogel et al., 2006;
Blahnik et al., 2011). Notably, the expressed ZNF gene clusters are depleted from the
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strucHC fraction and enriched in the euchromatin fraction (Figure 4-3A). These regions
are further enriched by H3K9me3 IP off of the euchromatin fraction (Figure 4-3A),
confirming that a sonication-sensitive chromatin structure can coexist with the H3K9me3
mark on the same chromatin fragment.
To identify similar regions on a genome-wide basis, we selected all 10-kb intervals
that were enriched in the euchromatin fraction over strucHC fraction and for domains of
H3K9me3 or H3K27me3. These euchromatic subtypes of these histone mark domains
occupied 31 MB of sequence for H3K9me3 (3.2% of the total H3K9me3) and 193 MB
(28.7%) for H3K27me3 (Figure 4-2C). Most of the genes in euchromatic H3K9me3 or
H3K27me3 domains were expressed, although at lower levels than the euchromatin as a
whole (Figure 4-3B). Consistent with this, euchromatic H3K9me3 domains, but not other
H3K9me3 domains, were enriched for H3K36me3 (Supp. Fig. 4-3A), a mark associated
with transcriptional elongation (Vakoc et al., 2006). At transcribed ZNF genes, H3K9me3
and H3K36me3 are both observed in the gene bodies, but the H3K9me3 signal is reduced
or absent over the promoters (Supp. Fig. 4-3B).
The euchromatic H3K9me3 domains had robust selectivity for gene family clusters,
with more than half of the genes inside these domains belonging to the KRAB-ZNF family
(n=150 of 230 InterPro database matches), in addition to the protocadherin gamma cluster
and certain homeobox (HOX) genes (Figure 4-3C). Genes in Euchromatic H3K9me3 are
listed in Table 4-1. The 3% of fibroblast H3K9me3 domains that are euchromatic contain
a majority of sites regulated by the HUSH complex (Tchasovnikarova et al., 2015), an
enrichment of 39-fold compared to the strucHC subtype (Figure 4-3D). Indeed, the sites
reported to have the greatest dependence on HUSH/SETDB1 for H3K9me3 levels fall in
euchromatin (Supp. Fig. 4-3C), consistent with the complex localizing to genes that are
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“dimmed” but nonetheless expressed (Tchasovnikarova et al., 2015).

Euchromatic

H3K27me3 domains include all four human HOX gene clusters (Figure 4-3E) and keratin
type I and protocadherin gamma clusters, in addition to non-clustered genes for basichelix-loop-helix and forkhead transcription factors (Figure 4-3C).
While as expected, the majority of satellite repeats fall in strucHC, the specific
repeat type HSATII, which due to its constitutive silence might otherwise be classified as
heterochromatic, is consistently found in euchromatic H3K9me3 domains (Figure 4-3F).
That HSATII has an accessible structure is corroborated by its enrichment in available
tracks of DNase-I sensitivity (Supp. Fig. 4-3D). A unique feature of HSATII is its massive
overexpression in diverse human cancers (Ting et al., 2011) and cellular senescence (De
Cecco et al., 2013). Heterochromatic regions have been found to have an elevated rate
of mutation accumulation across human cancers (Lawrence et al., 2013), and we find that
this effect is more pronounced in the strucHC and intermediate H3K9me3 subtypes,
compared to euchromatic H3K9me3 or H3K27me3-marked regions (Supp. Fig. 4-3E).
Thus, Gradient-seq provides structural insight into different repressed domains associated
with human disease.

Relationship between strucHC and other markers of heterochromatin
Our finding that chromatin regions with the same repressive histone marks could be
partitioned into structural subtypes with markedly different sonication sensitivity as
measured by Gradient-seq (Figure 4-4A) led us to investigate to what extend to those
differences are reflected in other properties associated with heterochromatin. The
structural categories were indeed highly predictive of the levels of CpG methylation at CpG
islands, as quantified by WGBS (Bernstein et al., 2010) (Figure 4-4B). Both inside and
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outside H3K9me3 domains, methylation rates were consistently high at strucHC islands
and low at euchromatic islands, with moderate levels in the intermediate category (Figure
4-4B), correlating with the levels of gene silencing for these subtypes (Figure 4-3B).
Interestingly, methylation rates are highest in the 133 MB of strucHC that lack enrichment
for H3K9me3 or H3K27me3 (Figure 4-4B, far right), confirming that the strucHC domains
have heterochromatic features even where they diverge from traditional histone markbased approaches. By contrast, outside of CpG islands, methylation rates are high in all
categories (Supp. Fig. 4-4A), and highest in the euchromatin subtypes, similar to that
observed for the total strucHC and euchromatin domains (Figure 4-2F).
We find that association of chromatin with the nuclear lamina, meanwhile, is
related to both structural classification and the type of histone mark. Levels of Lamin B1
binding by ChIP-seq (Dou et al., 2015) are generally higher in H3K9me3 domains
compared to H3K27me3 domains (Figure 4-4C), consistent with previous reports (Guelen
et al., 2008). However, within H3K9me3 domains, the strucHC and intermediate subtypes
are much more consistently enriched for Lamin B1 binding (Figure 4-4C) and overlap at a
higher rate with previously mapped Lamina Associated Domains (Guelen et al., 2008)
(Supp. Fig. 4-4D), compared to the euchromatic subtype of H3K9me3. Similarly, within
H3K27me3 domains and regions without enrichment for H3K9me3 or H3K27me3,
strucHC subtypes have higher levels of lamina association (Figure 4-4C, Supp. Fig. 44D).
Sensitivity to nucleases like DNase I or micrococcal nuclease is a classic measure
of chromatin accessibility. We next compared our chromatin subtypes using ENCODE
data for sequencing after DNase I digestion (DNase-seq) in BJ fibroblasts (Thurman et
al., 2012). As expected, 10-kb windows within euchromatin domains are consistently more
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DNase-sensitive than windows in strucHC or intermediate domains (Figure 4-4D, far left),
further corroborating that Gradient-seq detects differences in the structural accessibility of
chromatin. Meanwhile, DNase-seq does not clearly distinguish strucHC from intermediate
domains, two forms of chromatin that are mostly transcriptional silent (Figure 4-2D) and
yet are quantifiably different according to Gradient-seq (Figure 4-4A, far left), consistent
with the specificity of DNase I for open chromatin regions (Thurman et al., 2012).
Euchromatin domains are highly DNase-sensitive even where they overlapped with
H3K27me3 (Figure 4-4D, middle right), but interestingly not when they overlap with
H3K9me3 (Figure 4-4D, middle left), even though both types of regions are
transcriptionally active (Figure 4-3B).
One recent study (Mieczkowski et al., 2016) performed MNase titrations to define
the MNase accessibility (MACC) of chromatin regions, with a higher MACC score
indicating sensitivity at lower concentrations of MNase. Similar to the results with DNaseseq, the MACC signal for human K562 cells (Mieczkowski et al., 2016) is elevated in
euchromatin domains, both as a whole and in H3K27me3 domains, but not in euchromatin
overlapping H3K9me3 (Supp. Fig. 4-4B). Although the MACC and Gradient-seq
experiments were performed in different in different cell types, we confirmed these findings
at regions with similar H3K9me3 or H3K27me3 patterns in both K562 cells and foreskin
fibroblasts (Supp. Fig. 4-4C). Indeed, in such regions, the pattern of MNase resistance
closely mirrors the pattern of strucHC versus euchromatin domains (Supp. Fig. 4-4C, left),
indicating that there is widespread similarity of sonication-resistance and MNaseresistance. However, a clear exception occurs at regions bearing both H3K9me3 and
H3K36me3 in both cell types (Supp. Fig. 4-4C, right), which are classified as euchromatic
according to Gradient-seq but have negative MACC signals. Thus, in contrast to Gradient98

seq, nuclease-based methods are unable to distinguish transcriptionally active H3K9me3
domains from transcriptionally inactive ones, perhaps reflecting an intrinsic property of
H3K9me3-marked chromatin to resist enzymatic cleavage reactions.
Finally, we analyzed replication timing within each chromatin subtype using Repliseq data (Pope et al., 2014), in which newly replicated is sequenced in six cytometryfractionated cell cycle phases. All forms of H3K9me3 domains, including both strucHC
and euchromatin, replicate late, while H3K27me3 domains replicate in early-to-mid S
phase (Figure 4-4E), consistent with previous observations (Chandra et al., 2012). Thus,
in contrast to gene expression and methylation at CpG islands, late replication is a
property more closely associated with the H3K9me3 histone mark than chromatin
structure, and can co-occur with gene transcription.
In summary, we have used gradient-sedimentation of sonication-resistant
chromatin to purify a set of transcriptional silent chromatin domains (strucHC), which
includes the majority of H3K9me3 domains as well as a subset of DNase-resistant
H3K27me3 or unmarked regions, but notably excludes the H3K9me3/H3K27me3 regions
with transcribed genes and hypomethylated CpG islands.

The proteome of H3K9me3-marked structural heterochromatin
To identify proteins embedded in structural heterochromatin, as distinct from
transcriptionally active H3K9me3 domains, we performed label-free quantitative proteomic
studies on three biological replicates of the strucHC fraction, along with H3K9me3 IPs
performed off of each strucHC fraction (Figure 4-5A). Results were compared to the
euchromatin-containing fraction, which contains both euchromatic fragments as well as
soluble proteins from the lysate, and thus for accuracy will be referred to as the “gradient
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top” fraction. Proteins were decrosslinked, digested with trypsin, and analyzed by nano
liquid chromatography coupled to tandem mass spectrometry (MS/MS). Protein
abundance in each sample was determined using intensity-based absolute quantification
(iBAQ) (Cox and Mann, 2008; Schwanhäusser et al., 2011), and protein ranks were
compared between samples. In total, across the different samples, we identified 3,097
proteins with at least two peptides. Of the 1,864 proteins detected in the strucHC fraction,
217 proteins had a significantly higher rank in strucHC compared to the gradient top
fraction (T-test, P < 0.05), and these were termed “strucHC-enriched proteins” (red dots
in Figure 4-5B, left). The strucHC-enriched proteins are listed in Table 4-2. However, we
cannot exclude the possibility that some non-chromatin-bound proteins may sediment to
the strucHC fraction and be included among the proteins enriched in this fraction.
To

specifically

identify

proteins

that

crosslink

to

H3K9me3-marked

heterochromatin, we focused our proteomic analysis on the H3K9me3-directed IPs
performed using strucHC chromatin (Figure 4-5A, henceforth “strucHC+H3K9me3”).
Analysis of the DNA isolated from the same samples reveal a high enrichment for
heterochromatic regions (Figure 4-1F, Supp. Fig. 4-1C). The strucHC+H3K9me3
chromatin was eluted after stringent high-salt washes, and thus has comparable specificity
for chromatin-bound proteins as traditional ChIP-mass spec approaches, but inclusion of
the gradient sedimentation step allows depletion of transcriptionally active H3K9me3
domains. Out of 716 proteins detected in the strucHC+H3K9me3 sample, we identified
172 “heterochromatin proteins” (Table 4-3) that were significantly enriched in
strucHC+H3K9me3 compared to the gradient top fraction (Figure 4-5B, right, orange
dots). As expected, there was substantial overlap between the heterochromatin proteins
and strucHC-enriched proteins (Figure 4-5C). An additional 429 proteins detected in both
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strucHC+H3K9me3 and the gradient top fraction, but without significantly different ranks
between the two samples, and hence were classified as “shared” (Figure 4-5B, right, grey
dots). Finally, among the remaining proteins, 1,474 proteins were classified as belonging
the gradient top, meaning they were uniquely detected in that sample or were significantly
enriched by rank in comparison to the strucHC or strucHC+H3K9me3 samples.
The 172 identified heterochromatin proteins include several proteins known to
compose or associate with compacted chromatin (Figure 4-5D), including the linker
histone (H1.1, H1x, and H1.0), histone variant macroH2A, and lamin B1, as well as the
repressive histone modifier histone deacetylase 2. Also included among the
heterochromatin proteins are NONO and SFPQ, proteins that form a co-repressor
complex (Mathur et al., 2001; Dong et al., 2009) and are known to interact with the
H3K9me3 mark (Vermeulen et al., 2010), and we find strongly enriched in
strucHC+H3K9me3 (Figure 4-5D, bottom). Strong enrichment was also observed
HNRNPK, which is required for silencing and H3K9me3 deposition at genes and repetitive
elements (Bao et al., 2015; Thompson et al., 2015). Furthermore, the identified
heterochromatin proteins include proteins that interact directly with HP1 and have been
linked to gene repression, such as HP1BP3 , THRAP3, and BCLAF1 (Vermeulen et al.,
2010). Meanwhile, HPγ itself was in the category shared between heterochromatin and
euchromatin, consistent with our genomic data showing that HP1-associated ZNF
domains (Vogel et al., 2006) are enriched in euchromatin.
To our knowledge, only one previous study used proteomics to comprehensively
identify proteins present in H3K9me3 chromatin in differentiated mammalian cells (Soldi
and Bonaldi, 2013). The results of this study, using H3K9me3-directed ChIP-MS in HeLa
cells, agree strongly with our own: 60 (37%) of the 172 heterochromatin proteins identified
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by our approach were previously found to be enriched by H3K9me3 ChIP (Soldi and
Bonaldi, 2013) (Figure 4-5E, left orange bar), an enrichment of 27-fold compared to the
gradient top proteins (Figure 4-5E, blue). Moreover, 124 out of the 208 (60%) proteins
discovered by H3K9me3 ChIP-MS (Soldi and Bonaldi, 2013) fall into the heterochromatin
or shared categories from our study. Meanwhile, other studies have used proteomics to
characterize specific subsets of H3K9me3-related proteins, such as “readers” that interact
with a H3K9me3 bait (Vermeulen et al., 2010) or proteins associated with pericentromeric
satellites in mouse ES cells (Saksouk et al., 2014). The heterochromatin protein group
also has a significantly higher rate of overlap with both of these studies compared to
gradient top proteins (Figure 4-5E, middle panels), though as expected fewer proteins fall
into these specific categories. The strucHC-enriched proteins similarly have an elevated
rate of overlap with all three studies (Figure 4-5E, red bars). Similar to previous studies of
constitutive heterochromatin (Saksouk et al., 2014), we find nucleolar proteins among the
heterochromatin proteins, including nucleolin (NCL), BRIX1, NOP2/NOP56/NOP58,
Pescadillo homolog (PES1), and GTPBP4. This is consistent with role of H3K9me2/3 in
repressing rDNA arrays (Santoro et al., 2002) and the physical association of
heterochromatin at the nucleolar periphery (Politz et al., 2013).
Remarkably, despite the low levels of gene transcription within strucHC domains
(Figure 4-2D), 119 of the 172 heterochromatin proteins have RNA-binding activity
according to a published database (Gerstberger et al., 2014), including known corepressors HNRNPK, NONO, and SFPQ (Mathur et al., 2001; Dong et al., 2009;
Thompson et al., 2015). RNA binding by HP1 has long been known to be important for its
localization to heterochromatin (Muchardt et al., 2002), but RNA binding has not been
appreciated as a common feature among mammalian heterochromatin proteins. Yet the
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RNA-binding proteins we find in heterochromatin, compared to the total heterochromatin
proteins, have an even higher rate of agreement of previously published sets of H3K9me3
ChIP-MS proteins or H3K9me3 readers (Figure 4-5F). Thus, the association of such
proteins with H3K9me3-marked chromatin has been demonstrated through multiple
independent approaches, and our use of gradient sedimentation ensures that such
proteins are indeed associated with the heterochromatic, transcriptionally repressed
portion of H3K9me3 domains.
A major functional property of the H3K9me3 form of heterochromatin is impeding
reprogramming to pluripotency (Onder et al., 2012; Soufi et al., 2012; Matoba et al., 2014).
Using data from a genome-wide screen (Toh et al., 2016), we find that heterochromatin
proteins are enriched for factors that are repressors of iPS reprogramming (siRNAs that
increase iPS conversion) and depleted for factors that enhance reprogramming (Supp.
Fig. 4-5A). To our knowledge, across several studies, 22 of the 172 heterochromatin
proteins have been shown to impede iPS reprogramming (Supp. Fig. 4-5B), several of
which are RNA binding proteins, including HNRNPK (Thompson et al., 2015) and
muscleblind-like protein 1 (MNBL1) (Han et al., 2013).
Surprisingly, we noted that the heterochromatin proteins included six proteins
implicated in the neurodegenerative disease amyotrophic lateral sclerosis (ALS), with
strong quantitative enrichment in strucHC+H3K9me3 (Figure 4-5G). Based on the total
number of proteins known to be recurrently mutated in ALS (Cirulli et al., 2015), this rate
of overlap with heterochromatin and strucHC-enriched proteins is significantly higher than
expected (Figure 4-5E, far right). Among such proteins, TARDBP (also called TDP-43)
has been well-studied as a biochemical component of the pathological inclusions found in
ALS neurons and a genetic cause of certain forms of familial ALS (Lee et al., 2012).
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TARDBP has been shown to oppose iPS reprogramming in two independent genomewide screens (Qin et al., 2014; Toh et al., 2016) (Supp. Fig. 4-5B), suggesting that it might
be important for heterochromatic silencing. Using transcriptome data from fibroblasts
isolated from ALS patients (Highley et al., 2014), we find that germline mutation of TDP43 is associated with a modest but widespread upregulation of genes in strucHC,
compared to healthy controls (Supp. Fig. 4-5C,D,E). Such upregulation is absent in
sporadic ALS cases, where the fibroblast copies of TDP-43 are normal. These findings
help explain overexpression of heterochromatic repeat elements and the altered
organization of compacted chromatin in ALS disease models (Li et al., 2012; Amlie-Wolf
et al., 2015). Thus, identification of proteins crosslinked to chromatin in the strucHC
fraction has revealed new proteins with functional roles in human heterochromatin.

Activation of liver-specific genes is impeded by H3K9me3-marked strucHC and
associated proteins RBMX/RBMXL1
We next investigated whether strucHC and its bound proteins, in addition to impeding
reprogramming to pluripotency, oppose conversion to the hepatic lineage. Indeed, in
human fibroblasts, liver genes in H3K9me3 domains in strucHC or intermediate forms, but
not liver genes in H3K9me3 domains in euchromatin, have a profound failure to activate
during cell conversion to hiHep cells (Figure 4-6A, median indicated by white circles).
These include genes for important for hepatic cell fate, metabolism, epithelialization, and
secretion into the blood plasma (Figure 4-6B; genes listed in Table 4-4). Compared to
fibroblasts, these genes show a diminution of H3K9me3 in human liver (Figure 4-6C).
While genes in H3K27me3 in fibroblasts allowed greater levels of hepatic gene induction,
the strucHC form of H3K27me3 was slightly more refractory than the intermediate or
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euchromatic forms of this mark (Figure 4-6A). We conclude that H3K9me3-marked
chromatin, of either the strucHC or intermediate form, is most refractory to gene activation
by hepatic factors.
We reasoned that disruption of heterochromatin might render this class of
H3K9me3-marked genes more competent for activation by hepatic transcription factors
(TFs). We used a cocktail of three factors previously shown to produce hiHep cells
(FOXA3, HNF1A, and HNF4A) (Huang et al., 2014) and confirmed that expression of
these factors was sufficient to convert foreskin fibroblasts to hepatocyte-like cells
expressing liver markers (Supp. Fig. 4-6A). We found that two cycles of siRNA against
SUV39H1, which reduced H3K9me3 levels (Supp. Fig. 4-6B), greatly enhanced the
activation of a panel of hepatic genes marked by H3K9me3 in fibroblasts (Figure 4-6D).
SUV39H1 knockdown alone, in the absence of hepatic TFs, did not result in detectable
expression by RT-qPCR (Figure 4-6D).
The protein RNA Binding Motif Protein, X-linked (RBMX) had the second highest
enrichment in strucHC+H3K9me3 among heterochromatin proteins (Figure 4-5D, bottom,
red dot), and the related protein RBMXL1 was enriched in the strucHC fraction and
detected in one strucHC+H3K9me3 replicate. RBMX is known to bind chromatin
independent of its RNA recognition motif (Matsunaga et al., 2012), and its depletion
causes defects in pericentromeric cohesion (Matsunaga et al., 2012), a phenotype
reminiscent of SUV39H1 mutants (Peters et al., 2001). However, RBMX is not known to
function in gene silencing or heterochromatin. We find that siRNAs co-targeting RBMX
and RBMXL1 (RBMX/L1) (Supp. Fig. 4-6C,D) enable the activation of liver-specific genes
in strucHC by hepatic TFs, comparable to SUV39H1 knockdown (Figure 4-6D). The
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enhanced expression persisted in hiHep cells 14 days after induction (Supp. Fig. 4-6E),
demonstrating gene expression stability substantially later than the RBMX knockdown.

Regulation of diverse genes in strucHC by RBMX/L1
To understand the role of RBMX/L1 in impeding hepatic TF activity genome-wide, we
performed mRNA-seq in fibroblasts treated with RBMX/L1 siRNA, compared to control
siRNA and siRNA against SUV39H1, after 7 days of hepatic TF expression (Figure 4-7A).
Unsupervised clustering of the mRNA-seq data by Euclidean distance confirmed the
similarity of biological replicates and showed that the RBMX/L1 siRNA treatment clustered
with the SUV39H1 knockdown (Supp. Fig. 4-7A, green box). Out of 1333 genes
upregulated by RBMX/L1 knockdown (compared to non-targeting siRNA) in the presence
of hepatic TFs, 65% were also upregulated by SUV39H1 (P < 10-200) (Figure 4-7B).
Within strucHC, the SUV39H1 knockdown condition revealed 281 genes that are
responsive to heterochromatin disruption and can be activated by either endogenous
factors or the hepatic TF cocktail. Among these 281 genes, the effect of SUV39H1 siRNA
was well correlated with the effect of RBMX/L1 siRNA (Figure 4-7C, left), with upregulation
by RBMX/L1 siRNA reaching statistical significance for 102 of these genes. Genes
upregulated by both SUV39H1 and RBMX/L1 siRNA include the liver-specific genes
encoding C-Reactive Protein (CRP) and the nuclear receptor NR1H4/FXR (Figure 4-7D).
We note that certain strucHC genes are uniquely regulated by either SUV39H1 or
RBMX/L1 (Figure 4-7C). A list of strucHC genes upregulated by each siRNA is provided
in Table 4-5.
We also performed mRNA-seq in cells treated with SUV39H1, RBMX/L1, and
control siRNA in the absence of ectopic transcription factors (Figure 4-7A, Supp. Fig. 4106

7). Fewer genes in strucHC were upregulated in this condition (109 after SUV39H1
knockdown and 67 for RBMX/L1 knockdown, Supp. Fig. 4-7C), consistent with our qPCR
studies (Figure 4-6D) and prior studies on SUV39H1 (Bulut-Karslioglu et al., 2014).
Importantly, in the absence of ectopic TFs, knockdown of RBMX/L1 was sufficient for the
activation of genes within strucHC and H3K9me3 domains, such as the TMEM178 (Figure
4-7E) and the imprinted gene Paternally Expressed 3 (PEG3). Thus, the role of RBMX/L1
in impeding gene activation is not dependent upon ectopic TF expression. Taken together,
our studies with RBMX/L1 validate the proteomic study of the strucHC gradient fraction as
a resource for discovering novel regulators of genes within heterochromatin.

4.5 DISCUSSION
It is becoming clear that silent chromatin adopts diverse structural and functional forms,
and that understanding the mechanisms of gene silencing provides insight that is crucial
for being able to reprogram cells by modifying silent chromatin. Genome mapping of
histone modifications such as H3K9me3 and H3K27me3 has been integral to the study of
lineage-specific gene repression (Ezhkova et al., 2009; Hawkins et al., 2010; Xu et al.,
2014a), but these marks are also found in transcriptionally active or accessible chromatin
(Vakoc et al., 2005; Blahnik et al., 2011; Riddle et al., 2012; Breiling et al., 2001). Here we
show that the recovery of sonication-resistance chromatin fragments using sucrose
gradients is an effective method of heterochromatin purification, with efficiency
comparable of conventional ChIP. This approach allows us, for the first time, to distinguish
heterochromatic forms of H3K9me3 and H3K27me3 domains from those that are
competent for transcription, and to comprehensively identify proteins that are associated
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with definitive regions of heterochromatin. Using this dataset, we show that particular
heterochromatin proteins are required to prevent activation of cell type-inappropriate
genes, either under homeostatic conditions or in the presence of ectopic transcription
factors. We also provide diverse resources for future studies on heterochromatin subtypes
and the genes and repeat elements they contain.
Our use of sucrose gradients was inspired by previous studies applying gradient
sedimentation to MNase I-digested or sonicated chromatin (Gilbert et al., 2004; Ishihara
et al., 2010), but these approaches focused on fragments that changed buoyancy without
changing size or resistance to fragmentation. Our method, in addition to its enrichment of
heterochromatic regions, has the advantage of avoiding an electrophoresis-based sizeselection step, thereby enabling subsequent IP or analysis of protein content.
The literature has been conflicted on whether heterochromatin includes
H3K27me3-marked regions or applies solely to H3K9me3-marked and HP1-bound
regions (Trojer and Reinberg, 2007; Beisel and Paro, 2011). We find that many
H3K27me3 domains are enriched in the sonication-resistant strucHC fraction comparable
to heterochromatic DBRs (Figure 4-1F, green arrows versus purple arrows), with 49% of
the H3K27me3 domains overlapping with strucHC. Meanwhile, 29% of H3K27me3
domains are enriched in the euchromatic gradient fraction, correlating with enhanced
permissiveness to transcription. Thus, H3K27me3-marked chromatin spans a wide range
of physical states, suggesting that this histone mark alone is insufficient to predict or
exclude heterochromatin status. This also highlights a potential danger of generalizing
from model loci to all sites bearing the same histone mark, as we find that all four HOX
clusters, which have been pivotal to the study of Polycomb biology (Margueron and
Reinberg, 2011), reside in euchromatin domains.
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Compared to H3K27me3, H3K9me3 domains have a much stronger tendency to
be heterochromatic, with only 3.2% being significantly enriched in the euchromatic
fraction. Although the euchromatic subtype represents a small fraction of the total
H3K9me3 domains, it contains genes that have been used to normalize H3K9me3 ChIPseq data (Zhu et al., 2013) or to study the HUSH complex, KAP1, and SETDB1
(Tchasovnikarova et al., 2015; Groner et al., 2010), without recognition that these sites
are euchromatic and atypical for H3K9me3. Although most genes in euchromatic
H3K9me3 domains are expressed (Figure 4-3B) and are more readily activated by ectopic
transcription factors (Figure 4-6B), H3K9me3 has a repressive role at these sites in
dimming gene expression (Tchasovnikarova et al., 2015; Groner et al., 2010). As active
genes marked by H3K9me3 are still bound by multiple isoforms of HP1 (Vogel et al.,
2006), our data allow new studies on which chromatin components distinguish the
heterochromatic and euchromatic forms of H3K9me3 domains.
We find that genes marked by H3K9me3, if in strucHC or intermediate domains,
are markedly deficient in activation by hepatic transcription factors during hiHep
reprogramming, with the majority of hepatocyte genes persisting at near-fibroblast levels
(Figure 4-6A). A comparable defect was not observed for the heterochromatic form of
H3K27me3 domains, demonstrating a significant distinction between H3K9me3- and
H3K27me3-marked chromatin. This finding shows, for the first time, that H3K9me3marked chromatin impedes direct conversion between two mature lineages. This agrees
with prior work showing that such chromatin impedes binding by iPS reprogramming
factors and reprogramming itself (Soufi et al., 2012; Onder et al., 2012), and it suggests
that diverse other forms of cell reprogramming might similarly be limited by the extent to
which strucHC domains can be accessed.
109

The ability to purify heterochromatin physically provided the opportunity to uncover
the protein composition of repressed chromatin domains, without contaminating
euchromatin or bias for particular histone modifications. The proteins we find to be
enriched in H3K9me3-marked heterochromatin include many proteins known to be
involved in gene repression or associated with H3K9me3 (Figure 4-5D). Beyond specific
examples corroborated by the literature, we show that this set of heterochromatin proteins
as a whole is enriched for functional features of heterochromatin, such as impeding
reprogramming to pluripotency (Supp. Fig. 4-5A,B). Using this dataset, we were able to
discover that two related proteins, RBMX and RBMX/L1, although not previously
implicated in transcriptional repression, impede gene activation, with knockdown
phenotypes comparable in magnitude to a classic heterochromatin regulator (Figure 46D). We find that RBMX/L1 and SUV39H1 inhibit TF-mediated gene induction at many
sites where they are otherwise dispensable for silencing, suggesting that gene induction
assays using alternative-lineage TFs may be important to test the functionality of
heterochromatin proteins.
Heterochromatin regulation is instrumental to cell fate control in development and
iPS reprogramming. Our findings support a role for heterochromatin in impeding
conversion between mature lineages, they define subtypes of heterochromatin that
contribute differentially to this barrier, and they reveal a large resource of proteins that can
be investigated in order to overcome it. Understanding the general and specific aspects
of heterochromatin, starting with the datasets provided here, could lead to the selective
opening of silent chromatin domains and more efficient cellular reprogramming to new,
fully differentiated types of cells.
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Figure 4-1. Heterochromatic regions can be enriched and mapped genomically by
isolating sonication-resistant chromatin.
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(A) The positions of DBRs (black bars; Soufi et al., 2012) compared to H3K9m3 ChIPseq for IMR90 fibroblasts (Roadmap Epigenomics consortium, GSE16256) with and
without normalization to input. Red arrows indicate regions of depletion in the input track
alone.
(B) Crosslinked, sonicated chromatin from human BJ fibroblasts was separated on a
sucrose gradient. Agarose gel shows the size ranges of DNA purified from each fraction.
Boxes indicate the fractions used as the euchromatin and structural heterochromatin
(strucHC) samples in subsequent analyses.
(C) qPCR on DNA isolated from sucrose gradient fractions from BJ fibroblasts. Based on
prior work (Soufi et al., 2012), all qPCR sites (red and blue) contain binding sites for
OCT4/SOX2 in ES cells, but red sites fall inside DBR domains and lack OCT4/SOX2
binding in fibroblasts. An equal DNA mass was loaded per fraction, and results were
averaged from two biological replicates. Error bars show SEM among tested qPCR sites.
(D) Plan for ChIP and gradient-purified samples used for DNA sequencing.
(E) Sequencing signal per domain in strucHC gradient fraction minus input. For each point,
signal is averaged over an entire domain, which is either a DBR (red) or the flanking 2 MB
on both sides of a DBR (blue). Black lines show the median and interquartile ranges. P
value by Wilcoxon rank sum test.
(F) Browser view of 18 MB segment of chr12 showing physical mapping of chromatin
structure by Gradient-seq in foreskin fibroblasts compared to ChIP-seq signals for
repressive histone marks. Horizontal, colored bars above sequencing tracks indicate
enriched domains called by a sliding window algorithm. The pattern in the strucHC fraction
has broad similarity to H3K9me3 domains, which include DBRs (purple arrows), and anticorrelates with the signal in the Euchromatin fraction and gene expression by mRNA-seq.
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However, some strucHC domains contain chromatin co-marked by H3K9me3 and
H3K27me3 (red arrows), or H3K27me3 alone (green arrows). “strucHC + K9 IP” indicates
the H3K9me3 IP performed using the strucHC fraction chromatin. H3K27me3 ChIP data
was obtained from the Epigenomics Roadmap consortium.
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Figure 4-2. The genomic landscape of structural heterochromatin contains distinct
histone modification signatures and cell type-inappropriate genes.
(A) Spearman correlation analysis and unsupervised clustering of ChIP- and Gradient-seq
datasets. Samples were compared using their input-normalized tag density binned into 10
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kb sliding windows. Data from the Epigenomics Roadmap is labeled with “(R)”; all other
samples were sequenced in this study.
(B) Histone mark levels, normalized for input, over the width of strucHC domains, using
Roadmap Epigenomics data. The plots show an average of all 28,807 strucHC domains,
weighted by domain length. An additional 14 acetyl marks depleted in strucHC are not
shown.
(C) Schematic showing the distribution of H3K9me3 and H3K27me3 domains across the
three structural categories defined by Gradient-seq. In the strucHC category, domains are
drawn to scale, to indicate the number of megabases (MB) of overlap.
(D) Expression levels of genes within the three structural categories of chromatin defined
by Gradient-seq. Boxplots show mRNA-seq tag counts per gene, normalized by DESeq2
and divided by gene length (whiskers: 5th and 95th percentiles). P values by Wilcoxon rank
sum test.
(E) Gene Ontology (GO) analysis of Refseq genes inside strucHC domains. GO terms
were manually filtered to remove redundant categories. FDR was computed by BenjaminiHochberg. Shown are the top 15 most significant terms, sorted by gene count.
(F) Rates of methylation per CpG were determined by whole-genome bisulfite sequencing
(Roadmap Epigenomics consortium data for foreskin fibroblasts, GSM1127120). The
distribution of methylation rates was plotted for each category (whiskers: 10th and 90th
percentiles). P values by Wilcoxon rank sum test.
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Figure 4-3. A subset of H3K9me3 and H3K27me3 domains are structurally
euchromatic and permissive to transcription.
(A) Browser view of euchromatic H3K9me3 domains over ZNF gene family cluster, which
is depleted from strucHC. Note the mRNA-seq signal indicating transcription of these
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genes. The “euchr. + K9 IP” track shows the H3K9me3 ChIP performed off of the
euchromatic (“Euchr.”) fraction of the gradient.
(B) Genes in euchromatic H3K9me3 and H3K27me3 domains are largely expressed, in
contrast to the strucHC or intermediate (“int.”) subtypes, which contain mostly silent genes.
Boxplots show mRNA-seq tag counts per gene, normalized by DESeq2 and divided by
gene length (whiskers: 5th and 95th percentiles). The number of genes per category is
shown in parentheses. P values by Wilcoxon rank sum test.
(C) Gene annotation for euchromatic subtypes of H3K9me3 and H3K27me3 domains,
using the InterPro database of protein families. FDR was computed by BenjaminiHochberg. Redundant terms were omitted.
(D) Analysis of genomic sites reported to lose H3K9me3 after depletion of the HUSH
complex/SETDB1 (Tchasovnikarova et al., 2015). Shown are the number of such sites
(left) and the frequency of sites per MB (right) per chromatin category.
(E) Browser view of euchromatic H3K27me3 (“K27”) domain over HOX-A gene cluster.
(F) Fraction of satellite repeat types overlapping with strucHC versus euchromatic
H3K9me3 domains. Asterisks indicate significantly enrichment (FDR < 0.05) in strucHC
(red) or euchromatic H3K9me3 (blue) based on 1000 simulations of randomly shuffled
domains.
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Figure 4-4. Relationship between structural subtypes of histone mark domains
and hallmark properties of heterochromatin.
(A) Genomic windows (10-kb size, 500-bp sliding step) were classified by their association
with strucHC, intermediate (“int”), or euchromatin (“euchr”) domains, and also by their
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presence inside or outside H3K9me3 and H3K27me3 domains. Windows were then
scored for their sequencing signal in the strucHC fraction divided by the euchromatin
fraction, and the distribution of scores per category is plotted (whiskers: 5th and 95th
percentiles).
(B) The frequency of methylation per CpG was determined by whole-genome bisulfite
sequencing (Roadmap consortium data for foreskin fibroblasts, GSM1127120). For CpGs
falling within CpG islands, the distribution of methylation frequencies was plotted for each
chromatin category (whiskers: 10th and 90th percentiles).
(C) As in Panel A, except that 10-kb windows are scored based on the IMR90 lamin B1
ChIP-seq signal (reads per million sequenced) divided by the corresponding input signal
(Dou et al., 2015).
(D) As in Panel A, except that 10-kb windows are scored based the number of DNase-seq
reads per million reads mapped, averaged across two replicates, using ENCODE data for
BJ fibroblasts (Thurman et al., 2012).
(E) BJ fibroblast Repli-seq reads (Pope et al., 2014) for each cell cycle phase were
intersected with each domain type, and the number of intersecting reads were normalized
for sequencing depth and expressed as a fraction of the total signal for that domain type,
so that each column sums to 1.
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Figure 4-5. Proteomic analysis of purified H3K9me3-marked heterochromatin.
(A) Summary of quantitative proteomics study of 3 purified fractions.
(B) Proteins were scored by their relative rank between samples (x axis) and the
significance of the difference between samples (T-test, y-axis). Proteins significantly
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enriched in the strucHC + H3K9me3 IP compared to gradient top (orange dots) were
defined as heterochromatin proteins. Proteins detected in strucHC + H3K9me3 IP, but
without significant difference from gradient top (grey dots) were defined as shared
proteins.
(C) Overlap of strucHC-enriched proteins with two groups of proteins (heterochromatin
and shared) that were detected in the strucHC + H3K9me3 IP.
(D) Top: List of a selection of heterochromatin proteins that were previously shown to
contribute to heterochromatin and/or gene repression. Bottom: the 172 heterochromatin
proteins were sorted and plotted by their fold-enrichment in the strucHC + H3K9me3
(relative to gradient top), with the selected proteins above indicated by orange dots.
RBMX, a focus of subsequent studies, is indicated in red. References: 1Thompson et al.,
2015; 2Dong et al., 2009; 3Mathur et al., 2001; 4van Dijk et al., 2010; 5Hayashihara et al.,
2010; 6Vermeulen et al., 2010.
(E) Percentage of each proteomic category (eg, heterochromatin proteins) that is found in
each published dataset. The raw number of proteins found in common is listed below the
bars. Significance were computed relative to the background overlap for the total set of
3,097 MS-detected proteins: *p<0.05, **p<0.001.
(F) Percentage of proteins that overlap with each dataset, as in Panel E, plotted for the
total set of 172 heterochromatins and for the heterochromatin proteins that have RNAbinding activity according to (Gerstberger et al., 2014).
(G) As in Panel D (bottom), but proteins recurrently mutated in ALS (Cirulli et al., 2015)
are indicated in green.
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Figure 4-6. H3K9me3 domains and heterochromatin proteins impede the activation
of hepatic genes in fibroblasts.
(A) Violin plots showing the levels of gene activation during hiHep reprogramming.
Microarray data (Huang et al., 2014) was curated for genes expressed in cultured
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hepatocytes over fibroblasts. Expression of these genes in hiHep cells was plotted on a
relative scale ranging from fibroblast levels (0%) to hepatocyte levels (100%), using log2transformed values. Median values indicated by white circles. P values calculated versus
all hepatic genes by Wilcoxon rank sum test.
(B) Examples of hepatic genes in fibroblast H3K9me3 domains (strucHC or intermediate
subtypes) that were analyzed in part (A), grouped according to protein function.
(C) Browser views comparing fibroblast (“fib.”) and liver chromatin state and expression
levels at hepatic genes. For both tissues, ChIP-seq data for H3K9me3 and H3K27me3
and mRNA-seq data were obtained from the Epigenomics Roadmap (Bernstein et al.,
2010). Red arrows indicate liver-specific mRNA-seq signal for the labeled genes.
(D) RT-PCR for hepatic genes marked by H3K9me3 in fibroblasts, after two cycles of
siRNA transfection. Knockdowns were performed in fibroblasts expressing the hepatic TFs
FOXA3, HNF1A, and HNF4A (left) and in fibroblasts without ectopic TF expression (right).
Error bars show the SEM of two biological replicates. P values by Student’s T test.
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Figure 4-7. RBMX is required to suppress transcriptional activation at diverse
genes in strucHC domains.
(A) Diagram of mRNA-seq experiment, performed under two conditions: with and without
expression of the hepatic factors FOXA3, HNF1A, and HNF4A for hiHep reprogramming.
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(B) Genes significantly upregulated by SUV39H1 and RBMX/L1 siRNA, compared to
control siRNA, in the presence of hiHep factors. Genes downregulated by the hiHep
factors in the control siRNA condition were removed from consideration. P-value indicates
the significance of the overlap between gene sets.
(C) Comparison of fold-changes induced by SUV39H1 siRNA versus RBMX/L1 siRNA, in
the presence of hihep factors, at genes inside strucHC domains. Genes are color-coded
based on whether they were upregulated with statistical significance (Padj < 0.05) in one
sample, the other, or both. The extent of overlap of statistically upregulated strucHC genes
is shown in the Venn diagram.
(D) Browser views of genes in strucHC that are upregulated by si-SUV39H1 and siRBMX/L1 in the presence of hepatic factors. Note the mRNA-seq signal when either
siRNA is added in the presence of factors (red arrows), but not in control siRNA samples
or in the absence of factors. H3K27me3 data was obtained from the Epigenomics
Roadmap; all other samples were sequenced in this study.
(E) Browser view of gene in strucHC that is upregulated by si-RBMX/L1 both in the
presence and absence of hepatic factors.
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Supplementary Figure 4-1. H3K9me3-marked heterochromatin impedes hiHep
reprogramming, resists sonication, and is enriched by gradient sedimentation.
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(A) Violin plots showing the levels of gene activation during hiHep reprogramming.
Microarray data (Huang et al., 2014) was curated for genes silent in fibroblasts and
expressed in cultured hepatocytes. Genes were then classified by histone mark in
fibroblasts (starting cell type) using Roadmap Epigenomics ChIP-seq data. Expression of
these genes in hiHep cells was plotted on a relative scale ranging from fibroblast levels
(0%) to hepatocyte levels (100%), using log2-transformed values. Median values indicated
by white circles. P values calculated by Wilcoxon rank sum test.
(B) H3K9me3 ChIP-seq profiles for various human cell and tissue types, comparing inputnormalized signal (purple) to unnormalized signal (yellow). Data obtained from the
Epigenomics Roadmap consortium (Bernstein et al, 2010). Some domains of H3K9me3
enrichment over input are present constitutively across differentiated tissues (black box),
whereas others are present in non-fibroblast tissues (blue box) or are specific to fibroblasts
and similar tissue types (green box).
(C) qPCR for DBR and non-DBR sites, plotted relative to the average of the non-DBR
sites. Fraction #14 was the gradient fraction showing greatest DBR enrichment. Error bars
show SEM of qPCR sites tested.
(D) Rate of chromatin recovery by H3K9me3-directed IP, comparing IP from gradient
fractions versus IP from input chromatin (conventional ChIP). DNA yield measured by
PicoGreen assay.
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Supplemental Figure 2
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Supplementary Figure 4-2. Preparation of sequencing libraries for Gradient-seq.
(A) Agarose gel showing sonication of purified DNA for Gradient-seq experiment, to shear
large fragments down to a ~200 bp size for library preparation and sequencing.
(B) Number of reads for each DNA sequencing sample, showing the proportion of reads
that aligned to the genome and passed filtering to remove duplicate reads. “+K9 IP”
indicates the H3K9me3 IPs performed from the strucHC and euchromatin (“euchr.”)
fractions.
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Supplemental Figure 3
histone mark levels over domain subtypes

A

strucHC + int. subtypes
of H3K9me3 domains
(96.8%)

euchromatic subtype
of H3K9me3 domains
(3.2%)
H3K36me3

ChIP signal
over input
(reads per kb
per million
mapped)

n=15,957

B

n=2,428

D

chr19: 36,968,000 – 37,218,000

euchromatic
K9 domains

*

chr7

50 kb

euchromatic
K9 domains

100 kb

H3K9me3

0.25

H3K9me3

0.25

strucHC

0.25

strucHC

0.25

0.25
0.5

H3K27me3

1

mRNA-seq
DNAse I

0.5

mRNA-seq

1

H3K36me3

1

H3K4me3

0.5

H3K27me3

1

H3K36me3

0.25

euchromatin

euchromatin

genes

HSATII

repeats

promoters of transcribed genes

C

H3K9me3 sites that
require HUSH complex

E
10

fold-change
in H3K9me3

noncoding
mutations
per MB
per gene

upon
HUSH/SETDB1
deletion

noncoding mutation rate per gene
in human cancers

*
8

*

*

(Lawrence et al, 2013)

* p < 2E-14

6
4
2

strucHC int.
# of HUSH sites: (126) (95)

euchr.
(250)

# genes:

H3K9me3
subtypes

strucHC int. euchr.
(1,188) (292) (209)

strucHC int. euchr.
(2,869) (684) (1,628)

H3K9me3
subtypes

H3K27me3
subtypes

all genes
(17,667)

Supplementary Figure 4-3. Characterization of euchromatic subtype of H3K9me3
domains.
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(A) Histone mark levels in human fibroblasts, normalized for input, plotted over subtypes
of H3K9me3 domains: the strucHC/intermediate subtypes (left), and the euchromatic
subtype (right). All ChIP-seq data was obtained from the Roadmap Epigenomics
consortium (Bernstein et al, 2010), except for H3K9me2 ChIP-seq data (Chandra et al,
2012).
(B) Browser view showing enrichment of H3K36me3 (green arrow) in euchromatic
H3K9me3 domains containing with transcribed genes. Note that the gaps in H3K9me3
domains (diminution of H3K9me3 signal) coincide with H3K4me3-marked active gene
promoters.
(C) Among genomic sites that depend upon the HUSH complex and SETDB1 for
H3K9me3 levels, we plotted the fold-change in H3K9me3 upon deletion of HUSH
components and SETDB1, using data from (Tchasovnikarova et al, 2015). The 12 most
HUSH-dependent sites (points in blue circle) all fell inside the euchromatic subtype of
H3K9me3.
(D) Brower view showing overlap of euchromatic H3K9me3 domains over HSATII repeats,
which are also Dnase I-hypersensitive (Roadmap Epigenomics track for IMR90
fibroblasts). View is proximal to the chr7 centromere (coordinates 61,721,00061,871,000).
(E) Structural subtypes of H3K9me3 and H3K27me3 domains were compared for rates of
noncoding mutations per gene, averaged across all human cancers, using data from
(Lawrence et al, 2013). P values calculated by Wilcoxon rank sum test. Whiskers: 5th - 95th
percentiles.
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Supplementary Figure 4-4. Relationship of chromatin subtypes from Gradient-seq
to DNA methylation, MNase sensitivity, and lamina association.
(A) This plot considers only CpG dinucleotides that are not part of CpG islands. Using
Gradient-seq data, chromatin was classified into strucHC, intermediate (“int”), and
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euchromatin (“euchr”) categories, for the total mappable genome (“total”), within H3K9me3
and H3K27me3 domains, or outside of those domains (“neither mark enriched”). Wholegenome bisulfite sequencing (Roadmap consortium data for foreskin fibroblasts,
GSM1127120) was used to determine the frequency of methylation per CpG dinucleotide.
The distribution of methylation frequencies is plotted for non-CpG-island CpGs falling
within each chromatin subtype (whiskers: 10th and 90th percentiles).
(B) MACC scores, where higher MACC indicate that chromatin is more sensitive to
MNase, were determined on a 500-bin basis for K562 cells by Mieczkowski et al., 2016.
MACC scores were averaged across 10-kb sliding windows, and the distribution of MACC
scores is plotted for all 10-kb windows falling inside a given chromatin subtype (whiskers:
5th and 95th percentiles).
(C) Browser views comparing MACC signal in K562 cells (Mieczkowski et al., 2016) and
Gradient-seq signal in foreskin fibroblasts, using regions with similar patterns of
H3K9me3, H3K27me3, and H3K36me3 histone marks between the two cell types.
Gradient-seq signal is plotted as the euchromatin signal minus the strucHC signal (“euchr
- strucHC"). Left: Note that the pattern of euchr/strucHC domains is highly similar to the
pattern of positive/negative MACC signal, in regions where both cell types have similar
H3K9me3 (without H3K36me3) domains or H3K27me3 domains. Right: Sites bearing
H3K9me3 and H3K36me3 in both cell types are classified as euchromatin according to
Gradient-seq, but have negative MACC scores, indicating MNase resistance. All histone
mark tracks are replicate-pooled and input-subtracted. Foreskin fibroblast H3K27me3 and
H3K36me3 ChIP-seq data was obtained from the Epigenomics Roadmap (GSE16368);
H3K9me3 ChIP-seq was from this study. K562 ChIP-seq data was downloaded from
ENCODE (GSE29611).
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(D) Rate of overlap between each chromatin subtype and Lamina Associated Domains
(LADs) mapped in IMR90 fibroblasts (Guelen et al., 2008). The number of megabases of
overlap divided by the number of megabases total in the chromatin subtype was used to
calculate the percentage.
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Supplemental Figure 5
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Supplementary Figure 4-5. Heterochromatin proteins such as TARDBP impede iPS
reprogramming and contribute to heterochromatic silencing in human cells.
(A) Proteomic categories were compared to lists of iPS repressors (proteins whose
knockdown

increases

reprogramming)

and
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iPS

effectors

(knockdown

inhibits

repreogramming) from a genome-wide RNAi screen (Toh et al., 2016). The ratio of
repressors to effectors is plotted for each category, and the numbers of repressors and
effectors are listed above the bar. Asterisk indicates P < 0.05 by simulation test.
(B) Listed are heterochromatin proteins whose knockdown has previously been shown to
enhance iPS reprogramming efficiency, along with the corresponding reference. Note that
TARDBP knockdown was found to enhance reprogramming in two genome-wide screens.
1

Han et al., 2013; 2Bao et al., 2015.

(C) Both scatterplots compare gene expression in fibroblasts from ALS patients to
fibroblasts from healthy controls, using published microarray data (Highley et al, 2014).
Left plot: in fibroblasts from TARDBP-mutant ALS patients, there is upregulation of genes
in strucHC (red dots) compared to controls. Right plot: no upregulation of strucHC genes
is observed in fibroblasts from sporadic ALS patients, which lack germline TARDBP
mutation.
(D) Analysis of microarray data for ALS patient-derived fibroblasts (Highley et al, 2014),
with expression plotted for genes in the 3 structural chromatin categories defined by
Gradient-seq. Gene expression is normalized relative to the average of healthy patients
(n=6). Sporadic ALS cases (no germline TARDBP mutation) serve as a control for
TARDBP-mutant fibroblasts. P values calculated using Wilcoxon signed rank test (paired),
comparing TARDBP-mutant samples to sporadic ALS samples for the same chromatin
category. Whiskers: 5th - 95th percentiles.
(E) Same as Panel D, but showing gene expression for the subtypes of H3K9me3 and
H3K27me3 domains. Boxplots are shown for TARDBP mutant fibroblasts (T) and
fibroblasts from patients with sporadic ALS (S).
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Supplemental Figure 6
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Supplementary Figure 4-6. Knockdown of SUV39H1 and RBMX/L1 enhances
hepatic gene activation during hiHep reprogramming.
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(A) Immunofluorescence imaging confirming induction of hepatic markers after 14 days of
hiHep reprogramming with FOXA3, HNF1A, and HNF4A, compared to uninfected
fibroblasts cultured under the same conditions. Scale bars, 50μM.
(B) Western blots in fibroblasts after two cycles of SUV39H1 siRNA, compared to nontargeting control siRNA.
(C) RT-PCR showing that RBMX/L1 siRNAs deplete transcripts for both RBMX and
RBMXL1, after two cycles of siRNA transfection. Error bars show the SEM of three
biological replicates. P values by Student’s T test.
(D) Western blots for RBMX protein in fibroblasts after two cycles of siRNA transfection.
(E) RT-PCR analysis of fibroblasts treated with two cycles of siRNA, followed by hiHep
reprogramming for 14 days. Three independent siRNAs were tested for the RBMX/L1
knockdown condition; all other samples have two biological replicates shown.
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Supplemental Figure 7
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Supplementary Figure 4-7. RBMX represses select strucHC genes in the absence
of ectopic transcription factors.
(A) Comparison of mRNA-seq samples by Euclidean distance, using the normalized gene
expression scores for each sample. Each sample type has two biological replicates that
cluster together. The two experimental conditions, “hiHep condition” and “no TF condition”,
refer to siRNA knockdowns performed in the presence and absence of hiHep transcription
factors, respectively. The green box highlights the clustering of SUV39H1 siRNA and
RBMX/L1 siRNA in the hiHep condition.
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(B) Venn diagram of genes significantly upregulated by SUV39H1 and RBMX/L1 siRNA,
compared to control siRNA, in the absence of ectopic transcription factors. P-value
indicates the significance of the overlap between gene sets.
(C) Among genes inside strucHC domains, comparison of genes upregulated by
SUV39H1 and RBMX/L1 siRNA in the no TF condition.
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4.8 TABLES

Table 4-1. List of genes in the euchromatic subtype of fibroblast H3K9me3
domains.
Refseq genes with at least 50% overlap with euchromatic H3K9me3 domains were
identified and collapsed down to 308 unique gene symbols. The amount of overlap is
reported in the right-most column, as a fraction of the gene body length. (If there were
multiple Refseq genes for a given symbol, the one with the highest rate of overlap was
chosen.)
RefSeq ID

gene symbol

NR_002451
NM_000677
NM_139058
NM_001098169
NM_144645
NM_001017978
NR_033339
NM_001565
NM_001029865
NM_001037499
NM_001426
NM_001278182
NM_001007253
NM_001080458
NM_022774

ABCA11P
ADORA3
ARX
BSX
C4orf36
CT83
CTBP1-AS2
CXCL10
DBX1
DEFB114
EN1
EOMES
ERV3-1
EVX2
EXO5

NM_012159
NM_005249
NR_026718
NR_102763
NM_001301687
NM_004821
NM_001105574
NR_033205
NM_018952
NM_004502
NM_024016
NM_017410
NR_047507
NR_038435

FBXL21
FOXG1
FOXO3B
GATA6-AS1
GBX2
HAND1
HMX3
HOXB-AS3
HOXB6
HOXB7
HOXB8
HOXC13
HOXC13-AS
HOXD-AS2

name

fraction of gene
in domain

ATP binding cassette subfamily A member 11,
pseudogene
adenosine A3 receptor
aristaless related homeobox
brain specific homeobox
chromosome 4 open reading frame 36
cancer/testis antigen 83
CTBP1 antisense RNA 2 (head to head)
C-X-C motif chemokine ligand 10
developing brain homeobox 1
defensin beta 114
engrailed homeobox 1
eomesodermin
endogenous retrovirus group 3 member 1
even-skipped homeobox 2
exonuclease 5
F-box and leucine rich repeat protein 21
(gene/pseudogene)
forkhead box G1
forkhead box O3B pseudogene
GATA6 antisense RNA 1 (head to head)
gastrulation brain homeobox 2
heart and neural crest derivatives expressed 1
H6 family homeobox 3
HOXB cluster antisense RNA 3
homeobox B6
homeobox B7
homeobox B8
homeobox C13
HOXC13 antisense RNA
HOXD cluster antisense RNA 2
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0.94
0.84
0.98
1
0.52
1
0.5
1
1
1
1
1
0.78
1
0.86
0.88
1
1
1
1
1
1
0.74
0.79
1
0.88
1
1
1

NR_023915
NM_001320334
NM_152349
NM_005568
NR_038400
NR_135279
NR_103734
NR_104059
NR_024383
NR_047483
NR_038914
NR_120618
NR_026732
NR_036508
NR_104179
NR_135129
NR_134920
NR_110091
NR_125869
NR_110544
NR_135110
NM_032517
NM_001308244

IPW
KIAA1143
KRT222
LHX1
LINC00308
LINC00334
LINC00342
LINC00397
LINC00461
LINC00554
LINC01349
LINC01475
LINC01551
LOC100128398
LOC100289333
LOC100505588
LOC101928238
LOC101928597
LOC102723883
LOC102724188
LOC105376633
LYZL1
MAPK9

NM_001190787
NR_036053
NR_036235
NR_039722
NR_030297
NR_030373
NR_106898
NR_030741
NM_145285
NM_030905
NM_032109
NM_001310159
NR_046636
NM_032009
NM_032011
NM_032053
NM_032054
NM_032086
NM_032087
NM_014004
NM_032089
NM_032096
NM_032097
NM_032098
NM_032099
NM_003924
NM_021620
NR_023917
NR_103745
NM_001080521

MCIDAS
MIR1270
MIR4273
MIR4500
MIR571
MIR643
MIR6839
MIR9-2
NKX2-3
OR2J2
OTP
PAX6
PCDH9-AS3
PCDHGA2
PCDHGA3
PCDHGA4
PCDHGA5
PCDHGA6
PCDHGA7
PCDHGA8
PCDHGA9
PCDHGB2
PCDHGB3
PCDHGB4
PCDHGB5
PHOX2B
PRDM13
PTENP1
PTENP1-AS
RASSF10

imprinted in Prader-Willi syndrome (non-protein
coding)
KIAA1143
keratin 222
LIM homeobox 1
long intergenic non-protein coding RNA 308
long intergenic non-protein coding RNA 334
long intergenic non-protein coding RNA 342
long intergenic non-protein coding RNA 397
long intergenic non-protein coding RNA 461
long intergenic non-protein coding RNA 554
long intergenic non-protein coding RNA 1349
long intergenic non-protein coding RNA 1475
long intergenic non-protein coding RNA 1551

lysozyme like 1
mitogen-activated protein kinase 9
multiciliate differentiation and DNA synthesis
associated cell cycle protein
microRNA 1270
microRNA 4273
microRNA 4500
microRNA 571
microRNA 643
microRNA 6839
microRNA 9-2
NK2 homeobox 3
olfactory receptor family 2 subfamily J member 2
orthopedia homeobox
paired box 6
PCDH9 antisense RNA 3
protocadherin gamma subfamily A, 2
protocadherin gamma subfamily A, 3
protocadherin gamma subfamily A, 4
protocadherin gamma subfamily A, 5
protocadherin gamma subfamily A, 6
protocadherin gamma subfamily A, 7
protocadherin gamma subfamily A, 8
protocadherin gamma subfamily A, 9
protocadherin gamma subfamily B, 2
protocadherin gamma subfamily B, 3
protocadherin gamma subfamily B, 4
protocadherin gamma subfamily B, 5
paired like homeobox 2b
PR/SET domain 13
phosphatase and tensin homolog pseudogene 1
PTENP1 antisense RNA
Ras association domain family member 10
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0.78
0.58
0.9
0.87
0.53
0.61
0.84
1
1
0.95
0.55
1
1
1
0.64
1
1
1
0.85
0.79
0.59
0.61
0.61
1
1
1
1
1
1
1
1
1
1
1
0.66
0.7
1
1
1
1
1
0.93
1
1
1
1
1
1
1
1
1
0.81
0.62

NM_021163
NM_001204513
NR_125730
NM_001193307
NR_026830
NM_152679
NM_005642
NM_006593
NM_033208
NM_016170
NR_037893

RBAK
RBAKRBAKDN
RNU6-2
SAMD9
SATB2-AS1
SLC10A4
TAF7
TBR1
TIGD7
TLX2
TMCC1-AS1

NM_020683
NR_003148

TMIGD3
TPM3P9

NR_001524

TTTY3

NR_002176
NM_020633
NM_175619
NM_203303
NM_001318475
NM_001308440
NM_153018
NM_001320666
NM_001282515
NM_001320178
NM_023070
NM_133466
NM_001305203
NM_033132
NM_001010879
NM_173531
NM_033204
NM_001013746
NM_015852
NM_006956
NM_001008727
NM_001297568
NM_003433
NM_003435
NR_023311
NM_021030
NM_001300776
NM_003441
NM_001029976
NM_003450
NM_007147
NM_001172651
NM_001278508
NM_001029997
NM_001007088
NM_001318892
NM_001130519

TTTY3B
VN1R1
ZAR1
ZCCHC13
ZFP1
ZFP28
ZFP3
ZFP30
ZFP37
ZFP69
ZFP69B
ZFP82
ZFP90
ZIC5
ZIK1
ZNF100
ZNF101
ZNF107
ZNF117
ZNF12
ZNF121
ZNF124
ZNF132
ZNF134
ZNF137P
ZNF14
ZNF140
ZNF141
ZNF16
ZNF174
ZNF175
ZNF177
ZNF180
ZNF181
ZNF182
ZNF184
ZNF195

RB associated KRAB zinc finger

0.64

RBAK-RBAKDN readthrough
RNA, U6 small nuclear 2
sterile alpha motif domain containing 9
SATB2 antisense RNA 1
solute carrier family 10 member 4
TATA-box binding protein associated factor 7
T-box, brain 1
tigger transposable element derived 7
T-cell leukemia homeobox 2
TMCC1 antisense RNA 1 (head to head)
transmembrane and immunoglobulin domain
containing 3
tropomyosin 3 pseudogene 9
testis-specific transcript, Y-linked 3 (non-protein
coding)
testis-specific transcript, Y-linked 3B (non-protein
coding)
vomeronasal 1 receptor 1
zygote arrest 1
zinc finger CCHC-type containing 13
ZFP1 zinc finger protein
ZFP28 zinc finger protein
ZFP3 zinc finger protein
ZFP30 zinc finger protein
ZFP37 zinc finger protein
ZFP69 zinc finger protein
ZFP69 zinc finger protein B
ZFP82 zinc finger protein
ZFP90 zinc finger protein
Zic family member 5
zinc finger protein interacting with K protein 1
zinc finger protein 100
zinc finger protein 101
zinc finger protein 107
zinc finger protein 117
zinc finger protein 12
zinc finger protein 121
zinc finger protein 124
zinc finger protein 132
zinc finger protein 134
zinc finger protein 137, pseudogene
zinc finger protein 14
zinc finger protein 140
zinc finger protein 141
zinc finger protein 16
zinc finger protein 174
zinc finger protein 175
zinc finger protein 177
zinc finger protein 180
zinc finger protein 181
zinc finger protein 182
zinc finger protein 184
zinc finger protein 195

0.55
1
0.77
1
0.82
1
0.55
0.56
1
0.55

142

0.53
0.78
1
1
1
0.78
1
0.5
1
0.71
0.81
1
0.68
0.91
0.96
0.84
0.69
0.77
0.61
0.75
0.6
1
0.81
0.78
0.81
1
1
0.59
1
1
0.93
0.63
0.84
0.51
1
0.67
0.64
0.53
0.79
0.84

NM_006991
NM_001203250
NM_001145447
NM_001265597
NM_013359
NM_001129996
NM_001032372
NM_014518
NM_145911
NM_001320952
NM_005674
NR_023392
NM_021047
NM_005773
NM_001256279
NM_001012756
NM_005741
NM_001265588
NM_001165881
NR_024565
NM_021148
NM_001278734
NM_006969
NM_001297752
NM_001130842
NM_001145045
NM_020653
NM_001172831
NR_026867
NM_001012320
NM_001190791
NM_001005368
NR_047557
NR_047558
NM_207333
NM_001242797
NM_024620
NM_001242475
NM_001172674
NM_021632
NR_103847
NM_014594
NM_001007094
NR_026777
NM_001256838
NM_152604
NM_032347
NM_001033719
NM_017879
NM_001297734
NM_144689
NM_001300883
NM_001001415
NM_001256654

ZNF197
ZNF20
ZNF200
ZNF211
ZNF221
ZNF222
ZNF226
ZNF229
ZNF23
ZNF232
ZNF239
ZNF252P
ZNF253
ZNF256
ZNF26
ZNF260
ZNF263
ZNF267
ZNF268
ZNF271P
ZNF273
ZNF274
ZNF28
ZNF283
ZNF286A
ZNF286B
ZNF287
ZNF300
ZNF300P1
ZNF302
ZNF317
ZNF32
ZNF32-AS1
ZNF32-AS2
ZNF320
ZNF322
ZNF329
ZNF345
ZNF347
ZNF350
ZNF350-AS1
ZNF354C
ZNF37A
ZNF37BP
ZNF382
ZNF383
ZNF397
ZNF404
ZNF416
ZNF417
ZNF420
ZNF426
ZNF429
ZNF43

zinc finger protein 197
zinc finger protein 20
zinc finger protein 200
zinc finger protein 211
zinc finger protein 221
zinc finger protein 222
zinc finger protein 226
zinc finger protein 229
zinc finger protein 23
zinc finger protein 232
zinc finger protein 239
zinc finger protein 252, pseudogene
zinc finger protein 253
zinc finger protein 256
zinc finger protein 26
zinc finger protein 260
zinc finger protein 263
zinc finger protein 267
zinc finger protein 268
zinc finger protein 271, pseudogene
zinc finger protein 273
zinc finger protein 274
zinc finger protein 28
zinc finger protein 283
zinc finger protein 286A
zinc finger protein 286B
zinc finger protein 287
zinc finger protein 300
zinc finger protein 300 pseudogene 1
zinc finger protein 302
zinc finger protein 317
zinc finger protein 32
ZNF32 antisense RNA 1
ZNF32 antisense RNA 2
zinc finger protein 320
zinc finger protein 322
zinc finger protein 329
zinc finger protein 345
zinc finger protein 347
zinc finger protein 350
ZNF350 antisense RNA 1
zinc finger protein 354C
zinc finger protein 37A
zinc finger protein 37B, pseudogene
zinc finger protein 382
zinc finger protein 383
zinc finger protein 397
zinc finger protein 404
zinc finger protein 416
zinc finger protein 417
zinc finger protein 420
zinc finger protein 426
zinc finger protein 429
zinc finger protein 43
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0.51
0.75
0.64
0.85
0.54
0.68
0.75
0.93
0.79
0.84
0.51
0.63
0.94
0.55
0.94
0.87
0.56
0.65
1
0.69
0.65
0.77
0.51
0.88
0.78
0.89
0.81
1
1
0.74
0.63
0.66
1
0.53
0.76
0.65
0.72
0.97
0.74
1
0.77
0.95
0.89
0.78
0.84
1
0.88
1
1
0.86
0.74
1
0.97
0.95

NM_014650
NM_001080411
NM_030634
NM_152262
NM_001164276
NM_152357
NM_152355
NM_030824
NM_005815
NM_001297623
NM_001008801
NM_001001668
NM_020813
NM_001297624
NM_133464
NM_152356
NM_001076678
NM_001258280
NM_001134440
NM_001099269
NM_001314059
NM_001318005
NM_145287
NR_003699
NM_032453
NR_125345
NR_027239
NR_110703
NM_152606
NR_003127
NM_001297763
NM_001199295
NM_001277090
NM_001270938
NM_001172775
NM_001044387
NM_001304350
NM_001202406
NM_001172650
NM_152289
NM_001130031
NM_145276
NM_144976
NM_152603
NM_152484
NM_144694
NM_001290314
NR_038249
NM_152412
NR_037159
NM_001159860
NR_110152
NM_152279

ZNF432
ZNF433
ZNF436
ZNF439
ZNF44
ZNF440
ZNF441
ZNF442
ZNF443
ZNF461
ZNF468
ZNF470
ZNF471
ZNF480
ZNF483
ZNF491
ZNF493
ZNF501
ZNF502
ZNF506
ZNF510
ZNF514
ZNF519
ZNF525
ZNF527
ZNF528-AS1
ZNF529
ZNF529-AS1
ZNF540
ZNF542P
ZNF546
ZNF549
ZNF550
ZNF551
ZNF555
ZNF557
ZNF558
ZNF559
ZNF559ZNF177
ZNF561
ZNF562
ZNF563
ZNF564
ZNF567
ZNF569
ZNF570
ZNF571
ZNF571-AS1
ZNF572
ZNF582-AS1
ZNF583
ZNF585A
ZNF585B

zinc finger protein 432
zinc finger protein 433
zinc finger protein 436
zinc finger protein 439
zinc finger protein 44
zinc finger protein 440
zinc finger protein 441
zinc finger protein 442
zinc finger protein 443
zinc finger protein 461
zinc finger protein 468
zinc finger protein 470
zinc finger protein 471
zinc finger protein 480
zinc finger protein 483
zinc finger protein 491
zinc finger protein 493
zinc finger protein 501
zinc finger protein 502
zinc finger protein 506
zinc finger protein 510
zinc finger protein 514
zinc finger protein 519
zinc finger protein 525
zinc finger protein 527
ZNF528 antisense RNA 1
zinc finger protein 529
ZNF529 antisense RNA 1
zinc finger protein 540
zinc finger protein 542, pseudogene
zinc finger protein 546
zinc finger protein 549
zinc finger protein 550
zinc finger protein 551
zinc finger protein 555
zinc finger protein 557
zinc finger protein 558
zinc finger protein 559

0.83
0.93
0.85
1
0.71
0.53
0.81
0.51
0.66
0.94
0.69
1
0.87
0.91
0.61
0.79
0.95
1
1
1
0.79
0.94
0.51
0.54
0.66
1
0.93
0.88
0.61
0.91
0.56
0.9
0.63
1
0.74
0.81
0.62
1

ZNF559-ZNF177 readthrough
zinc finger protein 561
zinc finger protein 562
zinc finger protein 563
zinc finger protein 564
zinc finger protein 567
zinc finger protein 569
zinc finger protein 570
zinc finger protein 571
ZNF571 antisense RNA 1
zinc finger protein 572
ZNF582 antisense RNA 1 (head to head)
zinc finger protein 583
zinc finger protein 585A
zinc finger protein 585B

0.85
0.75
0.91
0.69
0.72
0.96
0.81
0.94
0.93
0.91
1
0.55
1
1
0.57
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NM_001077426
NM_001204817
NM_032530
NM_001286052
NM_001042415
NM_001007248
NM_001164715
NM_025027
NM_001031721
NM_025040
NM_001199324
NM_178523
NM_014789
NM_145233
NR_037802
NM_145297
NM_173658
NR_036521
NM_001142572
NM_001317998
NM_138286
NM_021915
NM_020394
NM_198535
NM_001282796
NM_001271848
NM_001172655
NM_001290210
NM_001289930
NM_001130913
NM_133474
NR_045525
NM_001170905
NM_001159293
NR_027130
NR_126069
NM_001185063
NM_001289952
NM_001012753
NM_001040185
NM_001010851
NM_001024596
NR_130705
NM_173632
NM_001005851
NM_001242802
NR_040027
NM_153358
NM_001080821
NM_001031665
NR_073396
NM_001080493
NM_001171979
NM_001102657

ZNF586
ZNF587
ZNF594
ZNF595
ZNF596
ZNF599
ZNF605
ZNF606
ZNF613
ZNF614
ZNF615
ZNF616
ZNF623
ZNF625
ZNF625-ZNF20
ZNF626
ZNF660
ZNF667-AS1
ZNF669
ZNF677
ZNF681
ZNF69
ZNF695
ZNF699
ZNF7
ZNF700
ZNF701
ZNF717
ZNF718
ZNF720
ZNF721
ZNF724P
ZNF736
ZNF737
ZNF738
ZNF75A
ZNF75D
ZNF761
ZNF763
ZNF765
ZNF766
ZNF772
ZNF773
ZNF776
ZNF780B
ZNF790
ZNF790-AS1
ZNF791
ZNF799
ZNF816
ZNF818P
ZNF823
ZNF829
ZNF836

zinc finger protein 586
zinc finger protein 587
zinc finger protein 594
zinc finger protein 595
zinc finger protein 596
zinc finger protein 599
zinc finger protein 605
zinc finger protein 606
zinc finger protein 613
zinc finger protein 614
zinc finger protein 615
zinc finger protein 616
zinc finger protein 623
zinc finger protein 625
ZNF625-ZNF20 readthrough (NMD candidate)
zinc finger protein 626
zinc finger protein 660
ZNF667 antisense RNA 1 (head to head)
zinc finger protein 669
zinc finger protein 677
zinc finger protein 681
zinc finger protein 69
zinc finger protein 695
zinc finger protein 699
zinc finger protein 7
zinc finger protein 700
zinc finger protein 701
zinc finger protein 717
zinc finger protein 718
zinc finger protein 720
zinc finger protein 721
zinc finger protein 736
zinc finger protein 737
zinc finger protein 738
zinc finger protein 75a
zinc finger protein 75D
zinc finger protein 761
zinc finger protein 763
zinc finger protein 765
zinc finger protein 766
zinc finger protein 772
zinc finger protein 773
zinc finger protein 776
zinc finger protein 780B
zinc finger protein 790
ZNF790 antisense RNA 1
zinc finger protein 791
zinc finger protein 799
zinc finger protein 816
zinc finger protein 818, pseudogene
zinc finger protein 823
zinc finger protein 829
zinc finger protein 836
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0.86
0.65
0.95
0.66
0.73
0.89
0.83
0.9
0.57
0.92
0.91
0.91
0.77
0.74
0.68
1
0.55
0.9
0.51
1
0.79
0.74
0.54
0.82
0.77
0.9
0.7
0.53
0.95
0.57
0.88
0.94
0.8
0.96
0.74
1
1
1
0.53
0.79
0.75
1
0.71
0.93
0.85
0.88
1
0.59
0.59
0.91
0.73
0.59
0.9
0.65

NM_001127372
NM_001136499
NM_001136501
NM_138374
NM_001077624
NM_001193552
NM_001287349
NM_001136116
NM_001145434
NM_001277291
NM_001300951
NM_031218
NM_152455
NM_001112734

ZNF84
ZNF841
ZNF844
ZNF845
ZNF846
ZNF850
ZNF852
ZNF879
ZNF880
ZNF891
ZNF91
ZNF93
ZSCAN29
ZSCAN30

zinc finger protein 84
zinc finger protein 841
zinc finger protein 844
zinc finger protein 845
zinc finger protein 846
zinc finger protein 850
zinc finger protein 852
zinc finger protein 879
zinc finger protein 880
zinc finger protein 891
zinc finger protein 91
zinc finger protein 93
zinc finger and SCAN domain containing 29
zinc finger and SCAN domain containing 30
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1
1
0.92
0.62
0.79
0.94
0.77
0.92
1
0.9
0.94
0.72
0.94
0.56

Table 4-2. List of strucHC-enriched proteins.
Shown are the 217 proteins enriched in the strucHC fraction compared to the euchromatin
fraction. The fold-enrichement column is computed by the relative change in protein rank
between the samples. The right-most column indicates “Y” (yes) if the protein was also
one of the 172 heterochromatin proteins (enriched in the strucHC + H3K9me3 IP sample).
gene symbol

protein

EBNA1BP2
SRSF10
RBMX
SRSF9
HNRNPA2B1

Probable rRNA-processing protein EBP2
Serine/arginine-rich splicing factor 10
RNA-binding motif protein, X chromosome
Serine/arginine-rich splicing factor 9
Heterogeneous nuclear ribonucleoproteins
A2/B1
Ribosome biogenesis protein BRX1 homolog
Ribosome biogenesis regulatory protein homolog
Protein LLP homolog
Heterogeneous nuclear ribonucleoproteins
C1/C2
KH domain-containing, RNA-binding, signal
transduction-associated protein 3
Polymerase delta-interacting protein 3
Heterogeneous nuclear ribonucleoprotein M
Ribosome production factor 2 homolog
Transformer-2 protein homolog beta
Elastin
RNA-binding protein 14
pre-rRNA processing protein FTSJ3
Serine/arginine-rich splicing factor 1
Nuclear receptor coactivator 5
Histone H1.1
Guanine nucleotide-binding protein-like 3
Probable ATP-dependent RNA helicase DDX27
Probable ATP-dependent RNA helicase DDX17
Heterogeneous nuclear ribonucleoprotein K
Nucleolar GTP-binding protein 1
Matrin-3
UAP56-interacting factor
TATA-binding protein-associated factor 2N
DBIRD complex subunit ZNF326
Probable ATP-dependent RNA helicase DDX5
60S ribosomal protein L4
Dermcidin
Heterogeneous nuclear ribonucleoprotein A0
Heterogeneous nuclear ribonucleoprotein U
Probable 28S rRNA (cytosine(4447)-C(5))methyltransferase
Heterogeneous nuclear ribonucleoprotein R

BRIX1
RRS1
LLPH
HNRNPC
KHDRBS3
POLDIP3
HNRNPM
RPF2
TRA2B
ELN
RBM14
FTSJ3
SRSF1
NCOA5
HIST1H1A
GNL3
DDX27
DDX17
HNRNPK
GTPBP4
MATR3
FYTTD1
TAF15
ZNF326
DDX5
RPL4
DCD
HNRNPA0
HNRNPU
NOP2
HNRNPR
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fold-enrichment
in strucHC vs
euchromatin
18.2
17.1
15.8
13.4
13.0

t-test

het
protein?

0.0398
0.0221
0.0047
0.0369
0.0199

Y
Y
Y
Y
Y

12.5
12.2
11.2
10.8

0.0152
0.0401
0.0430
0.0285

Y
Y

10.7

0.0426

Y

10.5
10.4
9.9
8.9
8.4
8.1
8.1
8.0
8.0
8.0
7.8
7.7
7.7
7.5
7.4
7.4
7.1
7.1
7.1
7.0
6.9
6.7
6.7
6.5
6.4

0.0170
0.0004
0.0215
0.0013
0.0450
0.0213
0.0442
0.0039
0.0416
0.0096
0.0137
0.0325
0.0319
0.0057
0.0001
0.0143
0.0438
0.0086
0.0405
0.0383
0.0021
0.0047
0.0017
0.0117
0.0188

Y
Y
Y
Y

6.4

0.0385

Y

Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

HNRNPH3
DDX54
HNRNPF
NOP16
TRA2A
HNRNPH1
WDR46
NSA2
H1F0
CHTOP
SRSF7
PPAN
NOC3L
ALYREF
KHDRBS1
HNRNPL
HNRNPDL
CCDC137
BOP1
EWSR1
MAK16
SLTM
RALY
FUS
DDX56
NONO
FN1
PES1
UTP14A
RBMXL1
CCDC86
RRP15
RNPS1
TRIM4
NIFK
RBFOX2
RBM28
S100A9
SAFB
S100A8
SFPQ
YTHDC1
AKAP8
SRSF4
PWP2
SAFB2
NOL7
GLTSCR2
MYEF2

Heterogeneous nuclear ribonucleoprotein H3
ATP-dependent RNA helicase DDX54
Heterogeneous nuclear ribonucleoprotein F
Nucleolar protein 16
Transformer-2 protein homolog alpha
Heterogeneous nuclear ribonucleoprotein H
WD repeat-containing protein 46
Ribosome biogenesis protein NSA2 homolog
Histone H1.0
Chromatin target of PRMT1 protein
Serine/arginine-rich splicing factor 7
Suppressor of SWI4 1 homolog
Nucleolar complex protein 3 homolog
THO complex subunit 4
KH domain-containing, RNA-binding, signal
transduction-associated protein 1
Heterogeneous nuclear ribonucleoprotein L
Heterogeneous nuclear ribonucleoprotein D-like
Coiled-coil domain-containing protein 137
Ribosome biogenesis protein BOP1
RNA-binding protein EWS
Protein MAK16 homolog
SAFB-like transcription modulator
RNA-binding protein Raly
RNA-binding protein FUS
Probable ATP-dependent RNA helicase DDX56
Non-POU domain-containing octamer-binding
protein
Fibronectin
Pescadillo homolog
U3 small nucleolar RNA-associated protein 14
homolog A
RNA binding motif protein, X-linked-like-1
Coiled-coil domain-containing protein 86
RRP15-like protein
RNA-binding protein with serine-rich domain 1
Tripartite motif-containing protein 4
MKI67 FHA domain-interacting nucleolar
phosphoprotein
RNA binding protein fox-1 homolog 2
RNA-binding protein 28
Protein S100-A9
Scaffold attachment factor B1
Protein S100-A8
Splicing factor, proline- and glutamine-rich
YTH domain-containing protein 1
A-kinase anchor protein 8
Serine/arginine-rich splicing factor 4
Periodic tryptophan protein 2 homolog
Scaffold attachment factor B2
Nucleolar protein 7
Glioma tumor suppressor candidate region gene
2 protein
Myelin expression factor 2
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6.4
6.3
6.3
6.3
6.2
6.2
6.1
6.0
6.0
6.0
6.0
6.0
5.9
5.9
5.7

0.0003
0.0374
0.0044
0.0489
0.0002
0.0005
0.0500
0.0378
0.0048
0.0015
0.0125
0.0472
0.0351
0.0039
0.0076

Y
Y
Y

5.7
5.7
5.6
5.6
5.5
5.3
5.3
5.3
5.2
5.1
5.0

0.0024
0.0129
0.0422
0.0438
0.0008
0.0443
0.0294
0.0009
0.0482
0.0484
0.0079

Y
Y

5.0
4.9
4.9

0.0298
0.0005
0.0500

4.8
4.7
4.6
4.6
4.6
4.5

0.0480
0.0483
0.0254
0.0362
0.0351
0.0168

4.5
4.4
4.4
4.4
4.4
4.2
4.2
4.2
4.2
4.1
4.1
4.1
4.1

0.0083
0.0412
0.0414
0.0203
0.0439
0.0037
0.0401
0.0472
0.0354
0.0385
0.0394
0.0103
0.0401

4.1

0.0496

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Y

Y
Y
Y

Y

Y
Y
Y
Y
Y
Y
Y

Y
Y

HNRNPUL1
FBN1
HNRNPLL
CALML5
RPL17
PUM3
HNRNPUL2
HNRNPAB
DDX50
SRSF6
SRSF5
RRP9
DDX18
DIMT1
HNRNPD
H1FX
ZNF438
RAVER1
YLPM1
RPL14
TBL3
DDX21
SAP18
NAT10
RRP1
KIAA2026
NOC2L
RBM15
FBLN5
DDX47
RSL1D1
LUC7L3
XRN2
WDR43
PSPC1
HSPG2
DES
RPL24
RPS6
RBM4
RPL21
MBNL1
ALKBH5
H2AFY
ZFR
SHROOM3
NOP58
LUC7L2
CPSF7
FBL
U2AF1

Heterogeneous nuclear ribonucleoprotein U-like
protein 1
Fibrillin-1
Heterogeneous nuclear ribonucleoprotein L-like
Calmodulin-like protein 5
60S ribosomal protein L17
Pumilio domain-containing protein KIAA0020
Heterogeneous nuclear ribonucleoprotein U-like
protein 2
Heterogeneous nuclear ribonucleoprotein A/B
ATP-dependent RNA helicase DDX50
Serine/arginine-rich splicing factor 6
Serine/arginine-rich splicing factor 5
U3 small nucleolar RNA-interacting protein 2
ATP-dependent RNA helicase DDX18
Probable dimethyladenosine transferase
Heterogeneous nuclear ribonucleoprotein D0
Histone H1x
Zinc finger protein 438
Ribonucleoprotein PTB-binding 1
YLP motif-containing protein 1
60S ribosomal protein L14
Transducin beta-like protein 3
Nucleolar RNA helicase 2
Histone deacetylase complex subunit SAP18
N-acetyltransferase 10
Ribosomal RNA processing protein 1 homolog A
Uncharacterized protein KIAA2026
Nucleolar complex protein 2 homolog
Putative RNA-binding protein 15
Fibulin-5
Probable ATP-dependent RNA helicase DDX47
Ribosomal L1 domain-containing protein 1
Luc7-like protein 3
5-3 exoribonuclease 2
WD repeat-containing protein 43
Paraspeckle component 1
Basement membrane-specific heparan sulfate
proteoglycan core protein
Desmin
60S ribosomal protein L24
40S ribosomal protein S6
RNA-binding protein 4
60S ribosomal protein L21
Muscleblind-like protein 1
RNA demethylase ALKBH5
Core histone macro-H2A.1
Zinc finger RNA-binding protein
Protein Shroom3
Nucleolar protein 58
Putative RNA-binding protein Luc7-like 2
Cleavage and polyadenylation specificity factor
subunit 7
rRNA 2-O-methyltransferase fibrillarin
Splicing factor U2AF 35 kDa subunit
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4.1

0.0029

4.0
3.9
3.9
3.9
3.8
3.8

0.0459
0.0261
0.0490
0.0066
0.0397
0.0244

3.8
3.7
3.7
3.6
3.6
3.5
3.4
3.4
3.3
3.3
3.3
3.3
3.3
3.3
3.3
3.3
3.2
3.2
3.2
3.2
3.1
3.1
3.1
3.1
3.0
3.0
3.0
3.0
2.9

0.0456
0.0307
0.0211
0.0221
0.0083
0.0203
0.0153
0.0043
0.0381
0.0273
0.0228
0.0500
0.0329
0.0139
0.0151
0.0198
0.0007
0.0391
0.0109
0.0388
0.0496
0.0480
0.0291
0.0027
0.0174
0.0030
0.0192
0.0086
0.0252

2.9
2.9
2.8
2.8
2.8
2.8
2.8
2.8
2.8
2.8
2.7
2.7
2.7

0.0155
0.0074
0.0483
0.0145
0.0141
0.0001
0.0411
0.0050
0.0263
0.0250
0.0009
0.0297
0.0252

2.7
2.7

0.0205
0.0069

Y

Y

Y
Y
Y
Y
Y

Y
Y
Y
Y
Y
Y
Y
Y

Y

Y
Y
Y
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y

INTS7
KHSRP
ELAVL1
IMP3
PTDSS1
FUBP3
RPS4Y1
GAR1
WDR12
CTBP1
FUBP1
AAAS
PRPSAP2
EIF6
NOL11
NLE1
HEATR1
U2AF2
CIRBP
RPL18A
PNO1
CPSF6
LYAR
MYBBP1A
RCC2
CYR61
TARDBP
PWP1
NOP56
EMILIN1
CCAR2
SKIV2L2
LUC7L
NEXN
TIA1
MRTO4
SRRT
NOL9
TSPO
RBM22
PTBP1
EXOSC3
TGFBI
PRPF40A
SRI
RBM12
RCC1
ZNF207
EXOSC9
TRIP6

Integrator complex subunit 7
Far upstream element-binding protein 2
ELAV-like protein 1
U3 small nucleolar ribonucleoprotein protein
IMP3
Phosphatidylserine synthase 1
Far upstream element-binding protein 3
40S ribosomal protein S4, Y isoform 1
H/ACA ribonucleoprotein complex subunit 1
Ribosome biogenesis protein WDR12
C-terminal-binding protein 1
Far upstream element-binding protein 1
Aladin
Phosphoribosyl pyrophosphate synthaseassociated protein 2
Eukaryotic translation initiation factor 6
Nucleolar protein 11
Notchless protein homolog 1
HEAT repeat-containing protein 1
Splicing factor U2AF 65 kDa subunit
Cold-inducible RNA-binding protein
60S ribosomal protein L18a
RNA-binding protein PNO1
Cleavage and polyadenylation specificity factor
subunit 6
Cell growth-regulating nucleolar protein
Myb-binding protein 1A
Protein RCC2
Protein CYR61
TAR DNA-binding protein 43
Periodic tryptophan protein 1 homolog
Nucleolar protein 56
EMILIN-1
Cell cycle and apoptosis regulator protein 2
Superkiller viralicidic activity 2-like 2
Putative RNA-binding protein Luc7-like 1
Nexilin
Nucleolysin TIA-1 isoform p40
mRNA turnover protein 4 homolog
Serrate RNA effector molecule homolog
Polynucleotide 5-hydroxyl-kinase NOL9
Translocator protein
Pre-mRNA-splicing factor RBM22
Polypyrimidine tract-binding protein 1
Exosome complex component RRP40
Transforming growth factor-beta-induced protein
ig-h3
Pre-mRNA-processing factor 40 homolog A
Sorcin
RNA-binding protein 12
Regulator of chromosome condensation
BUB3-interacting and GLEBS motif-containing
protein ZNF207
Exosome complex component RRP45
Thyroid receptor-interacting protein 6

150

2.7
2.6
2.6
2.6

0.0134
0.0075
0.0500
0.0067

2.6
2.6
2.6
2.5
2.5
2.5
2.5
2.4
2.4

0.0126
0.0127
0.0024
0.0021
0.0142
0.0046
0.0183
0.0295
0.0246

2.4
2.4
2.4
2.3
2.3
2.3
2.3
2.3
2.3

0.0234
0.0480
0.0430
0.0468
0.0342
0.0231
0.0346
0.0079
0.0404

2.2
2.2
2.2
2.2
2.2
2.2
2.2
2.1
2.1
2.1
2.0
2.0
2.0
2.0
2.0
1.9
1.9
1.9
1.9
1.9
1.9

0.0350
0.0235
0.0025
0.0109
0.0036
0.0020
0.0347
0.0172
0.0072
0.0156
0.0295
0.0437
0.0147
0.0028
0.0397
0.0465
0.0383
0.0494
0.0283
0.0029
0.0144

1.9
1.9
1.9
1.8
1.8

0.0165
0.0179
0.0232
0.0080
0.0202

1.8
1.7

0.0008
0.0374

Y
Y

Y
Y
Y
Y

Y

Y

Y

Y
Y
Y
Y

Y

Y

Y

Y

DHX15
NUP160
ELOVL5
CTGF
ZC3H18
DNAJC8
NHP2
EDF1
PRMT1
TOP1
WDR18
DDX3Y
DKC1
RRP12
VPS26B
EXOSC6
SPARC
CCDC50
PLRG1
SUPT16H
LIMS1
SPATS2L
DHCR24
EXOSC2
METAP1
GATAD2A
CROCC
CCAR1
SART1
RPA1
DDX1

Putative pre-mRNA-splicing factor ATPdependent RNA helicase DHX15
Nuclear pore complex protein Nup160
Elongation of very long chain fatty acids protein
5
Connective tissue growth factor
Zinc finger CCCH domain-containing protein 18
DnaJ homolog subfamily C member 8
H/ACA ribonucleoprotein complex subunit 2
Endothelial differentiation-related factor 1
Protein arginine N-methyltransferase 1
DNA topoisomerase 1
WD repeat-containing protein 18
ATP-dependent RNA helicase DDX3Y
H/ACA ribonucleoprotein complex subunit 4
RRP12-like protein
Vacuolar protein sorting-associated protein 26B
Exosome complex component MTR3
SPARC
Coiled-coil domain-containing protein 50
Pleiotropic regulator 1
FACT complex subunit SPT16
LIM and senescent cell antigen-like-containing
domain protein 1
SPATS2-like protein
Delta(24)-sterol reductase
Exosome complex component RRP4
Methionine aminopeptidase 1
Transcriptional repressor p66-alpha
Rootletin
Cell division cycle and apoptosis regulator
protein 1
U4/U6.U5 tri-snRNP-associated protein 1
Replication protein A 70 kDa DNA-binding
subunit
ATP-dependent RNA helicase DDX1
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1.7

0.0377

1.7
1.7

0.0318
0.0391

1.7
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.5
1.5
1.5
1.5
1.5
1.5
1.4
1.4

0.0124
0.0077
0.0204
0.0399
0.0398
0.0197
0.0064
0.0394
0.0374
0.0223
0.0448
0.0366
0.0025
0.0113
0.0178
0.0492
0.0171
0.0001

1.4
1.4
1.3
1.3
1.3
1.3
1.3

0.0411
0.0111
0.0238
0.0136
0.0347
0.0206
0.0144

1.3
1.2

0.0168
0.0151

1.2

0.0189

Y

Y
Y

Y

Y

Table 4-3. List of heterochromatin proteins.
Shown are the 172 proteins enriched in the strucHC + H3K9me3 IP sample, compared to
the euchromatin fraction. The fold-enrichement column is computed by the relative change
in protein rank between the samples.

gene symbol
RBM14
RBMX
KHDRBS3
VCAN
KHDRBS1
NONO
DDX5
DCD
SFPQ
S100A9
DDX17
EWSR1
HIST1H1A
SRSF9
FUS
FYTTD1
TAF15
S100A8
SHROOM3
ZNF326
PVRL2
HNRNPM
HNRNPH3
POLDIP3
JUP
DSG1
NCOA5
HNRNPK
BRIX1
EBNA1BP2
RPF2
HNRNPH2
SERPINB12
H1FX
HNRNPH1
ZNF438
KPRP
HNRNPR
PPAN

protein
RNA-binding protein 14
RNA-binding motif protein, X chromosome
KH domain-containing, RNA-binding, signal
transduction-associated protein 3
Versican core protein
KH domain-containing, RNA-binding, signal
transduction-associated protein 1
Non-POU domain-containing octamer-binding protein
Probable ATP-dependent RNA helicase DDX5
Dermcidin
Splicing factor, proline- and glutamine-rich
Protein S100-A9
Probable ATP-dependent RNA helicase DDX17
RNA-binding protein EWS
Histone H1.1
Serine/arginine-rich splicing factor 9
RNA-binding protein FUS
UAP56-interacting factor
TATA-binding protein-associated factor 2N
Protein S100-A8
Protein Shroom3
DBIRD complex subunit ZNF326
Nectin-2
Heterogeneous nuclear ribonucleoprotein M
Heterogeneous nuclear ribonucleoprotein H3
Polymerase delta-interacting protein 3
Junction plakoglobin
Desmoglein-1
Nuclear receptor coactivator 5
Heterogeneous nuclear ribonucleoprotein K
Ribosome biogenesis protein BRX1 homolog
Probable rRNA-processing protein EBP2
Ribosome production factor 2 homolog
Heterogeneous nuclear ribonucleoprotein H2
Serpin B12
Histone H1x
Heterogeneous nuclear ribonucleoprotein H
Zinc finger protein 438
Keratinocyte proline-rich protein
Heterogeneous nuclear ribonucleoprotein R
Suppressor of SWI4 1 homolog
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fold-enrichment in
strucHC + K9me3
vs euchromatin
28.9
19.6

t-test
0.0273
0.0082

19.3
18.7

0.0399
0.0366

18.6
15.8
15.5
15.1
14.8
14.1
14.0
13.6
13.4
13.1
12.8
12.8
12.2
12.1
11.9
11.4
11.3
11.0
10.9
10.8
10.3
10.2
10.0
9.9
9.5
9.5
9.5
9.3
9.2
9.2
9.1
9.0
9.0
9.0
8.3

0.0000
0.0143
0.0347
0.0002
0.0037
0.0406
0.0288
0.0005
0.0060
0.0371
0.0402
0.0420
0.0108
0.0406
0.0113
0.0429
0.0430
0.0013
0.0004
0.0158
0.0475
0.0436
0.0438
0.0108
0.0165
0.0406
0.0213
0.0471
0.0442
0.0370
0.0009
0.0272
0.0447
0.0322
0.0456

NOP2
HNRNPL
HNRNPUL1
H1F0
HNRNPA2B1
SRSF10
RRS1
BLMH
GNL3
MATR3
DDX54
SAFB
PSPC1
RAVER1
GLTSCR2
GTPBP4
WDR46
RB1CC1
SBSN
FTSJ3
CASP14
YLPM1
HNRNPDL
RALY
HNRNPF
TGM3
RBM12B
H2AFY
C3
CMAS
SERPINB6
AKAP8
MYEF2
DDX27
WDR36
HNRNPU
ZC3H14
NOC3L
TRA2A
CPSF7
RBM28
SRSF1
KHSRP
ZNF638
PWP2
PGM5
TRA2B
DST
HNRNPLL
PTDSS1
DDX50

Probable 28S rRNA (cytosine(4447)-C(5))methyltransferase
Heterogeneous nuclear ribonucleoprotein L
Heterogeneous nuclear ribonucleoprotein U-like
protein 1
Histone H1.0
Heterogeneous nuclear ribonucleoproteins A2/B1
Serine/arginine-rich splicing factor 10
Ribosome biogenesis regulatory protein homolog
Bleomycin hydrolase
Guanine nucleotide-binding protein-like 3
Matrin-3
ATP-dependent RNA helicase DDX54
Scaffold attachment factor B1
Paraspeckle component 1
Ribonucleoprotein PTB-binding 1
Glioma tumor suppressor candidate region gene 2
protein
Nucleolar GTP-binding protein 1
WD repeat-containing protein 46
RB1-inducible coiled-coil protein 1
Suprabasin
pre-rRNA processing protein FTSJ3
Caspase-14
YLP motif-containing protein 1
Heterogeneous nuclear ribonucleoprotein D-like
RNA-binding protein Raly
Heterogeneous nuclear ribonucleoprotein F
Protein-glutamine gamma-glutamyltransferase E
RNA-binding protein 12B
Core histone macro-H2A.1
Complement C3
N-acylneuraminate cytidylyltransferase
Serpin B6
A-kinase anchor protein 8
Myelin expression factor 2
Probable ATP-dependent RNA helicase DDX27
WD repeat-containing protein 36
Heterogeneous nuclear ribonucleoprotein U
Zinc finger CCCH domain-containing protein 14
Nucleolar complex protein 3 homolog
Transformer-2 protein homolog alpha
Cleavage and polyadenylation specificity factor
subunit 7
RNA-binding protein 28
Serine/arginine-rich splicing factor 1
Far upstream element-binding protein 2
Zinc finger protein 638
Periodic tryptophan protein 2 homolog
Phosphoglucomutase-like protein 5
Transformer-2 protein homolog beta
Dystonin
Heterogeneous nuclear ribonucleoprotein L-like
Phosphatidylserine synthase 1
ATP-dependent RNA helicase DDX50
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8.3
8.2

0.0200
0.0035

8.2
8.2
7.8
7.6
7.6
7.5
7.5
7.4
7.4
7.4
7.3
7.2

0.0012
0.0031
0.0242
0.0206
0.0390
0.0423
0.0152
0.0130
0.0409
0.0200
0.0089
0.0219

7.2
7.1
7.1
7.1
7.0
7.0
6.9
6.9
6.9
6.9
6.8
6.8
6.6
6.6
6.5
6.5
6.4
6.4
6.4
6.4
6.4
6.2
6.1
6.1
6.1

0.0458
0.0001
0.0479
0.0480
0.0474
0.0478
0.0465
0.0411
0.0106
0.0001
0.0041
0.0484
0.0475
0.0058
0.0489
0.0181
0.0210
0.0490
0.0492
0.0313
0.0489
0.0089
0.0486
0.0366
0.0014

6.1
6.0
6.0
6.0
5.9
5.9
5.8
5.7
5.7
5.5
5.5
5.3

0.0211
0.0429
0.0048
0.0068
0.0500
0.0325
0.0338
0.0008
0.0143
0.0238
0.0139
0.0233

CHTOP
XRN2
SRSF5
SYNE1
PES1
RPL14
HNRNPA0
HNRNPC
HP1BP3
MBNL1
RBM15
WDR43
RCC1
FUBP1
GAR1
HNRNPUL2
TBL3
RBM4
DEK
RCC2
RPS4Y1
SRSF6
SRSF7
CPSF6
SUN1
ELAVL1
ALYREF
TOR1AIP1
DSP
NEMF
DDX21
HNRNPAB
NOP58
TIA1
FUBP3
TOP1
RBM39
SKIV2L2
MAP1A
LMNB1
RSL1D1
ILF3
MYBBP1A
ARG1
STT3B
U2AF2
U2AF1
PARP1
SYNCRIP
NMT1
NOP56
SF1

Chromatin target of PRMT1 protein
5-3 exoribonuclease 2
Serine/arginine-rich splicing factor 5
Nesprin-1
Pescadillo homolog
60S ribosomal protein L14
Heterogeneous nuclear ribonucleoprotein A0
Heterogeneous nuclear ribonucleoproteins C1/C2
Heterochromatin protein 1-binding protein 3
Muscleblind-like protein 1
Putative RNA-binding protein 15
WD repeat-containing protein 43
Regulator of chromosome condensation
Far upstream element-binding protein 1
H/ACA ribonucleoprotein complex subunit 1
Heterogeneous nuclear ribonucleoprotein U-like
protein 2
Transducin beta-like protein 3
RNA-binding protein 4
Protein DEK
Protein RCC2
40S ribosomal protein S4, Y isoform 1
Serine/arginine-rich splicing factor 6
Serine/arginine-rich splicing factor 7
Cleavage and polyadenylation specificity factor
subunit 6
SUN domain-containing protein 1
ELAV-like protein 1
THO complex subunit 4
Torsin-1A-interacting protein 1
Desmoplakin
Nuclear export mediator factor NEMF
Nucleolar RNA helicase 2
Heterogeneous nuclear ribonucleoprotein A/B
Nucleolar protein 58
Nucleolysin TIA-1 isoform p40
Far upstream element-binding protein 3
DNA topoisomerase 1
RNA-binding protein 39
Superkiller viralicidic activity 2-like 2
Microtubule-associated protein 1A
Lamin-B1
Ribosomal L1 domain-containing protein 1
Interleukin enhancer-binding factor 3
Myb-binding protein 1A
Arginase-1
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase subunit STT3B
Splicing factor U2AF 65 kDa subunit
Splicing factor U2AF 35 kDa subunit
Poly [ADP-ribose] polymerase 1
Heterogeneous nuclear ribonucleoprotein Q
Glycylpeptide N-tetradecanoyltransferase 1
Nucleolar protein 56
Splicing factor 1

154

5.2
5.2
5.1
5.1
5.1
5.0
5.0
5.0
5.0
4.8
4.8
4.7
4.6
4.6
4.6

0.0037
0.0291
0.0218
0.0262
0.0005
0.0195
0.0012
0.0262
0.0213
0.0011
0.0478
0.0165
0.0020
0.0181
0.0001

4.5
4.4
4.3
4.3
4.3
4.1
4.0
4.0

0.0279
0.0082
0.0025
0.0292
0.0001
0.0030
0.0228
0.0166

4.0
3.9
3.8
3.8
3.8
3.7
3.7
3.7
3.4
3.3
3.3
3.3
3.1
3.0
3.0
2.9
2.9
2.9
2.9
2.8
2.8

0.0218
0.0187
0.0288
0.0026
0.0062
0.0064
0.0050
0.0094
0.0469
0.0045
0.0007
0.0064
0.0007
0.0333
0.0001
0.0170
0.0193
0.0022
0.0139
0.0258
0.0389

2.8
2.7
2.7
2.7
2.7
2.6
2.6
2.6

0.0033
0.0171
0.0019
0.0009
0.0151
0.0053
0.0212
0.0099

SUPT16H
NUMA1
HNRNPD
DHX15
RPL24
FBL
MYH14
PTBP1
RECQL
TARDBP
PRPF8
ADAR
HACD3
BCLAF1
ABCF1
DKC1
NUDT21
FAM120A
HIST1H4A
HIST1H2BC
THRAP3
PHB2
PRMT1
APEX1
IFI16
FXR1
NCL
RRBP1
RPS13
HDAC2

FACT complex subunit SPT16
Nuclear mitotic apparatus protein 1
Heterogeneous nuclear ribonucleoprotein D0
Putative pre-mRNA-splicing factor ATP-dependent
RNA helicase DHX15
60S ribosomal protein L24
rRNA 2-O-methyltransferase fibrillarin
Myosin-14
Polypyrimidine tract-binding protein 1
ATP-dependent DNA helicase Q1
TAR DNA-binding protein 43
Pre-mRNA-processing-splicing factor 8
Double-stranded RNA-specific adenosine deaminase
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase
3
Bcl-2-associated transcription factor 1
ATP-binding cassette sub-family F member 1
H/ACA ribonucleoprotein complex subunit 4
Cleavage and polyadenylation specificity factor
subunit 5
Constitutive coactivator of PPAR-gamma-like protein 1
Histone H4
Histone H2B type 1-C/E/F/G/I
Thyroid hormone receptor-associated protein 3
Prohibitin-2
Protein arginine N-methyltransferase 1
DNA-(apurinic or apyrimidinic site) lyase
Gamma-interferon-inducible protein 16
Fragile X mental retardation syndrome-related protein
1
Nucleolin
Ribosome-binding protein 1
40S ribosomal protein S13
Histone deacetylase 2
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2.6
2.5
2.5

0.0011
0.0199
0.0224

2.5
2.5
2.5
2.4
2.4
2.4
2.4
2.3
2.3

0.0092
0.0019
0.0408
0.0261
0.0318
0.0025
0.0022
0.0287
0.0175

2.3
2.3
2.2
2.1

0.0094
0.0406
0.0265
0.0157

2.0
2.0
2.0
1.9
1.9
1.8
1.7
1.7
1.7

0.0171
0.0028
0.0474
0.0031
0.0284
0.0028
0.0404
0.0433
0.0108

1.5
1.4
1.4
1.3
1.3

0.0495
0.0265
0.0489
0.0348
0.0200

Table 4-4. Hepatic genes in repressive fibroblast H3K9me3 domains.
List of 221 hg19 Refseq genes in repressive H3K9me3 domains (strucHC or intermediate
subtypes) that are expressed in human hepatocytes over fibroblasts, based on available
microarray data (Huang et al., 2014). The right-most column indicates how much the gene
overlaps with the domains (union of the strucHC and intermediate subtypes of H3K9me3).
Genes with at least 50% overlap qualified for this list. Select genes from this list are shown
in Figure 4-6B.
RefSeq ID

gene symbol

NM_000014
NM_003742
NM_178559
NR_003087

A2M
ABCB11
ABCB5
ABCC13

NM_001097
NM_052956

ACR
ACSM1

NM_182617

ACSM2B

NM_017888

ACSM5

NM_139057

ADAMTS17

NM_207517
NM_153838
NM_005989
NM_000032
NM_001012421
NM_213599
NM_001639
NM_015230

ADAMTSL3
ADGRF4
AKR1D1
ALAS2
ANKRD20A2
ANO5
APCS
ARAP2

NM_001185
NM_054025
NM_000055
NM_001012978
NM_001721
NM_001002760
NM_001104629
NM_000065
NM_002984
NM_033031
NM_001766
NM_001772
NM_001778

AZGP1
B3GAT1
BCHE
BEX5
BMX
BPY2B
C4orf19
C6
CCL4
CCNB3
CD1D
CD33
CD48

name

fraction of gene
in domain
alpha-2-macroglobulin
0.77
ATP binding cassette subfamily B member 11
0.50
ATP binding cassette subfamily B member 5
0.87
ATP binding cassette subfamily C member 13
0.92
(pseudogene)
acrosin
1.00
acyl-CoA synthetase medium-chain family member
0.92
1
acyl-CoA synthetase medium-chain family member
1.00
2B
acyl-CoA synthetase medium-chain family member
1.00
5
ADAM metallopeptidase with thrombospondin type
1.00
1 motif 17
ADAMTS like 3
0.98
adhesion G protein-coupled receptor F4
0.80
aldo-keto reductase family 1 member D1
0.79
5'-aminolevulinate synthase 2
0.77
ankyrin repeat domain 20 family member A2
0.99
anoctamin 5
1.00
amyloid P component, serum
1.00
ArfGAP with RhoGAP domain, ankyrin repeat and
1.00
PH domain 2
alpha-2-glycoprotein 1, zinc-binding
0.92
beta-1,3-glucuronyltransferase 1
0.98
butyrylcholinesterase
1.00
brain expressed X-linked 5
1.00
BMX non-receptor tyrosine kinase
0.56
basic charge, Y-linked, 2B
1.00
chromosome 4 open reading frame 19
0.78
complement component 6
0.93
C-C motif chemokine ligand 4
1.00
cyclin B3
1.00
CD1d molecule
0.57
CD33 molecule
1.00
CD48 molecule
0.56
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NM_003874
NM_001768
NR_003595
NM_145024
NM_000744
NM_031422
NM_001289
NM_024734
NM_152311
NM_014141
NM_006651
NM_153634
NM_000567
NM_172249
NR_024387

CD84
CD8A
CDC14C
CES5A
CHRNA4
CHST9
CLIC2
CLMN
CLRN3
CNTNAP2
CPLX1
CPNE8
CRP
CSF2RA
CXADRP2

NR_024076

CXADRP3

NM_000767
NM_000772
NM_000769
NM_000770
NM_000771
NM_000778
NM_021187
NM_023944
NM_001082
NM_007253
NM_178033
NM_178134
NM_005218
NM_001364
NM_004010
NM_138815
NM_024422
NM_022785
NM_014800
NM_000128
NM_174912
NM_001077710
NM_015381

CYP2B6
CYP2C18
CYP2C19
CYP2C8
CYP2C9
CYP4A11
CYP4F11
CYP4F12
CYP4F2
CYP4F8
CYP4X1
CYP4Z1
DEFB1
DLG2
DMD
DPPA2
DSC2
EFCAB6
ELMO1
F11
FAAH2
FAM110C
FAM19A5

NM_030764
NM_022970
NM_002012
NM_001014986
NM_004476
NM_153696
NM_000814

FCRL2
FGFR2
FHIT
FOLH1
FOLH1
FOLH1B
GABRB3

NM_021123
NM_005256
NM_020973
NM_000583

GAGE7
GAS2
GBA3
GC

CD84 molecule
CD8a molecule
cell division cycle 14C, pseuodgene
carboxylesterase 5A
cholinergic receptor nicotinic alpha 4 subunit
carbohydrate sulfotransferase 9
chloride intracellular channel 2
calmin
clarin 3
contactin associated protein-like 2
complexin 1
copine 8
C-reactive protein, pentraxin-related
colony stimulating factor 2 receptor alpha subunit
coxsackie virus and adenovirus receptor
pseudogene 2
coxsackie virus and adenovirus receptor
pseudogene 3
cytochrome P450 family 2 subfamily B member 6
cytochrome P450 family 2 subfamily C member 18
cytochrome P450 family 2 subfamily C member 19
cytochrome P450 family 2 subfamily C member 8
cytochrome P450 family 2 subfamily C member 9
cytochrome P450 family 4 subfamily A member 11
cytochrome P450 family 4 subfamily F member 11
cytochrome P450 family 4 subfamily F member 12
cytochrome P450 family 4 subfamily F member 2
cytochrome P450 family 4 subfamily F member 8
cytochrome P450 family 4 subfamily X member 1
cytochrome P450 family 4 subfamily Z member 1
defensin beta 1
discs large MAGUK scaffold protein 2
dystrophin
developmental pluripotency associated 2
desmocollin 2
EF-hand calcium binding domain 6
engulfment and cell motility 1
coagulation factor XI
fatty acid amide hydrolase 2
family with sequence similarity 110 member C
family with sequence similarity 19 member A5, C-C
motif chemokine like
Fc receptor like 2
fibroblast growth factor receptor 2
fragile histidine triad
folate hydrolase 1
folate hydrolase 1
folate hydrolase 1B
gamma-aminobutyric acid type A receptor beta3
subunit
G antigen 7
growth arrest specific 2
glucosylceramidase beta 3 (gene/pseudogene)
GC, vitamin D binding protein
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0.97
0.61
1.00
0.52
0.64
1.00
0.91
0.51
0.52
0.95
0.59
1.00
1.00
0.76
1.00
1.00
0.63
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.83
1.00
0.75
1.00
0.63
0.70
1.00
0.59
0.60
0.65
0.81
1.00
1.00
0.97
1.00
1.00
0.84
1.00
1.00
0.91
1.00
1.00
0.60
0.75
0.80

NM_001491

GCNT2

NR_003267
NR_003503
NM_004122
NM_130759
NM_015660
NM_018326
NM_018384
NM_024711
NM_153236
NM_175571
NM_144669
NM_001001413
NM_022036

GGT3P
GGT8P
GHSR
GIMAP1
GIMAP2
GIMAP4
GIMAP5
GIMAP6
GIMAP7
GIMAP8
GLT1D1
GOLGA6L1
GPRC5C

NM_000831

GRIK3

NM_000845
NM_001080476
NM_033423
NM_004133
NM_000860
NM_000415
NM_001002915
NM_017416
NM_173178
NM_000632
NM_138693
NM_057162
NM_000892
NM_152643
NM_000226
NM_173464
NM_033277
NR_003061

GRM8
GRXCR1
GZMH
HNF4G
HPGD
IAPP
IGFL2
IL1RAPL2
IL36B
ITGAM
KLF14
KLHL4
KLKB1
KNDC1
KRT9
L3MBTL4
LACRT
LILRP2

NR_024090
NR_024160
NM_005577
NM_052886

LINC00320
LINC00626
LPA
MAL2

NM_006770
NM_004994
NM_001044370
NM_005797
NM_144765
NM_024021
NM_021201
NM_001033602

MARCO
MMP9
MPPED1
MPZL2
MPZL2
MS4A4A
MS4A7
MTUS2

NM_152423
NM_003970
NM_021963
NM_002500

MUM1L1
MYOM2
NAP1L2
NEUROD1

glucosaminyl (N-acetyl) transferase 2, I-branching
enzyme (I blood group)
gamma-glutamyltransferase 3 pseudogene
gamma-glutamyltransferase 8 pseudogene
growth hormone secretagogue receptor
GTPase, IMAP family member 1
GTPase, IMAP family member 2
GTPase, IMAP family member 4
GTPase, IMAP family member 5
GTPase, IMAP family member 6
GTPase, IMAP family member 7
GTPase, IMAP family member 8
glycosyltransferase 1 domain containing 1
golgin A6 family-like 1
G protein-coupled receptor class C group 5
member C
glutamate ionotropic receptor kainate type subunit
3
glutamate metabotropic receptor 8
glutaredoxin and cysteine rich domain containing 1
granzyme H
hepatocyte nuclear factor 4 gamma
hydroxyprostaglandin dehydrogenase 15-(NAD)
islet amyloid polypeptide
IGF like family member 2
interleukin 1 receptor accessory protein like 2
interleukin 36, beta
integrin subunit alpha M
Kruppel like factor 14
kelch like family member 4
kallikrein B1
kinase non-catalytic C-lobe domain containing 1
keratin 9
l(3)mbt-like 4 (Drosophila)
lacritin
leukocyte
immunoglobulin-like
receptor
pseudogene 2
long intergenic non-protein coding RNA 320
long intergenic non-protein coding RNA 626
lipoprotein(a)
mal,
T-cell
differentiation
protein
2
(gene/pseudogene)
macrophage receptor with collagenous structure
matrix metallopeptidase 9
metallophosphoesterase domain containing 1
myelin protein zero like 2
myelin protein zero like 2
membrane spanning 4-domains A4A
membrane spanning 4-domains A7
microtubule
associated
tumor
suppressor
candidate 2
MUM1 like 1
myomesin 2
nucleosome assembly protein 1 like 2
neuronal differentiation 1
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0.90
1.00
0.69
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.82
1.00
1.00
1.00
1.00
0.98
1.00
1.00
1.00
0.72
0.62
0.88
0.84
0.71
0.71
1.00
0.97
0.87
0.74
0.85
0.50
0.84
1.00
0.63
0.95
0.94
0.88
0.87
1.00
0.65
0.92
1.00
1.00
1.00
0.59
0.96
0.81
1.00
1.00

NM_145007
NM_005123
NM_001105663
NM_002534
NM_003553
NM_001004739
NR_002171

NLRP11
NR1H4
NUDT7
OAS1
OR1E1
OR5L2
OR7E156P

NM_001079935
NM_207320
NM_178129
NM_130467
NM_000277
NM_022843
NM_031856
NM_031882
NM_001077358
NM_016953
NM_006210
NM_002625

OR7E24
OTUD6A
P2RY8
PAGE5
PAH
PCDH20
PCDHA8
PCDHAC1
PDE11A
PDE11A
PEG3
PFKFB1

NM_016112

PKD2L1

NM_004572
NM_005084
NM_024829
NM_000301
NM_002763
NM_002864
NM_138453
NM_006744
NM_021026
NM_005615
NM_198085
NM_025236
NM_005621
NM_022136

PKP2
PLA2G7
PLBD1
PLG
PROX1
PZP
RAB3C
RBP4
RFPL1
RNASE6
RNF148
RNF39
S100A12
SAMSN1

NM_145168

SDR42E1

NM_001080451
NM_001085
NM_006215
NM_000354
NM_012435
NM_001010846
NM_001040153
NM_003037

SERPINA11
SERPINA3
SERPINA4
SERPINA7
SHC2
SHE
SLAIN1
SLAMF1

NM_021181
NM_005835
NM_001039752
NM_021977
NM_016615

SLAMF7
SLC17A2
SLC22A10
SLC22A3
SLC6A13

NLR family pyrin domain containing 11
nuclear receptor subfamily 1 group H member 4
nudix hydrolase 7
2'-5'-oligoadenylate synthetase 1
olfactory receptor family 1 subfamily E member 1
olfactory receptor family 5 subfamily L member 2
olfactory receptor family 7 subfamily E member 156
pseudogene
olfactory receptor family 7 subfamily E member 24
OTU deubiquitinase 6A
purinergic receptor P2Y8
PAGE family member 5
phenylalanine hydroxylase
protocadherin 20
protocadherin alpha 8
protocadherin alpha subfamily C, 1
phosphodiesterase 11A
phosphodiesterase 11A
paternally expressed 3
6-phosphofructo-2-kinase/fructose-2,6biphosphatase 1
polycystin 2 like 1, transient receptor potential
cation channel
plakophilin 2
phospholipase A2 group VII
phospholipase B domain containing 1
plasminogen
prospero homeobox 1
PZP, alpha-2-macroglobulin like
RAB3C, member RAS oncogene family
retinol binding protein 4
ret finger protein like 1
ribonuclease A family member k6
ring finger protein 148
ring finger protein 39
S100 calcium binding protein A12
SAM domain, SH3 domain and nuclear localization
signals 1
short chain dehydrogenase/reductase family 42E,
member 1
serpin family A member 11
serpin family A member 3
serpin family A member 4
serpin family A member 7
SHC adaptor protein 2
Src homology 2 domain containing E
SLAIN motif family member 1
signaling lymphocytic activation molecule family
member 1
SLAM family member 7
solute carrier family 17 member 2
solute carrier family 22 member 10
solute carrier family 22 member 3
solute carrier family 6 member 13
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1.00
0.58
0.64
1.00
1.00
1.00
1.00
1.00
1.00
0.64
1.00
0.88
1.00
1.00
0.75
0.54
0.60
1.00
0.54
0.66
0.89
0.65
0.67
1.00
0.76
0.90
0.72
0.79
1.00
1.00
1.00
0.65
0.57
1.00
0.66
1.00
0.89
1.00
1.00
0.89
0.71
0.60
0.76
1.00
0.67
0.91
0.52
0.60

NM_006446

SLCO1B1

NM_019844

SLCO1B3

NM_180991

SLCO4C1

NM_001034852
NM_152989
NM_153189
NM_003122
NM_021015
NM_020225
NM_014465
NM_016524
NM_016945
NM_003225
NM_138379

SMOC1
SOX5
SPAM1
SPINK1
SSX5
STOX2
SULT1B1
SYT17
TAS2R16
TFF1
TIMD4

NM_018487
NM_014020
NM_001123376
NM_003701
NM_001080430
NM_022445
NM_012471

TMEM176A
TMEM176B
TMEM72
TNFSF11
TOX3
TPK1
TRPC5

NM_173485
NM_178562
NM_004616
NR_026547
NM_000371
NM_006001
NM_019076
NM_001075
NM_001073
NM_001076
NM_001077
NM_053039
NM_021139
NM_001074
NM_018974
NM_206933
NM_013452
NM_022479
NM_182758
NM_016373
NM_052898
NM_003446
NM_001037735

TSHZ2
TSPAN33
TSPAN8
TSPEAR-AS2
TTR
TUBA3C
UGT1A8
UGT2B10
UGT2B11
UGT2B15
UGT2B17
UGT2B28
UGT2B4
UGT2B7
UNC93A
USH2A
VCX
WBSCR17
WDR72
WWOX
XKR4
ZNF157
ZNF630

solute carrier organic anion transporter family
member 1B1
solute carrier organic anion transporter family
member 1B3
solute carrier organic anion transporter family
member 4C1
SPARC related modular calcium binding 1
SRY-box 5
sperm adhesion molecule 1
serine peptidase inhibitor, Kazal type 1
SSX family member 5
storkhead box 2
sulfotransferase family 1B member 1
synaptotagmin 17
taste 2 receptor member 16
trefoil factor 1
T-cell immunoglobulin and mucin domain
containing 4
transmembrane protein 176A
transmembrane protein 176B
transmembrane protein 72
tumor necrosis factor superfamily member 11
TOX high mobility group box family member 3
thiamin pyrophosphokinase 1
transient receptor potential cation channel
subfamily C member 5
teashirt zinc finger homeobox 2
tetraspanin 33
tetraspanin 8
TSPEAR antisense RNA 2
transthyretin
tubulin alpha 3c
UDP glucuronosyltransferase family 1 member A8
UDP glucuronosyltransferase family 2 member B10
UDP glucuronosyltransferase family 2 member B11
UDP glucuronosyltransferase family 2 member B15
UDP glucuronosyltransferase family 2 member B17
UDP glucuronosyltransferase family 2 member B28
UDP glucuronosyltransferase family 2 member B4
UDP glucuronosyltransferase family 2 member B7
unc-93 homolog A (C. elegans)
usherin
variable charge, X-linked
Williams-Beuren syndrome chromosome region 17
WD repeat domain 72
WW domain containing oxidoreductase
XK related 4
zinc finger protein 157
zinc finger protein 630
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0.92
0.91
1.00
0.85
0.97
1.00
0.94
0.51
0.85
0.78
0.77
1.00
1.00
1.00
1.00
0.89
0.55
0.55
0.97
0.95
0.92
0.63
0.80
0.95
1.00
1.00
1.00
0.61
0.87
1.00
1.00
1.00
1.00
1.00
0.75
1.00
0.77
1.00
1.00
1.00
0.89
0.99
0.51
0.69

Table 4-5. Heterochromatic genes with enhanced activation after siRNA against
SUV39H1 or RBMX/L1.
List of 364 genes in strucHC domains that are significantly upregulated (adjusted p < 0.05)
by SUV39H1 siRNA and/or RBMX/L1 siRNA, in the presence of hiHep factors. Foldchanges relative to control siRNA are shown. The data here are used in Figure 4-7C.
gene symbol

NR1H4
SPINK1
PKIB
TSPAN8
MYO3B
SLAMF7
CRP
CLIC5
LOC101930452
COL6A5
SMIM10L2A
UPP2
FAT2
BEND4
DSG2
GLP2R
FAM134B
IGSF1
MAFB
SLC17A3
CNGA3
GCNT2
ACMSD
NOX1
NUGGC
UCA1
BRINP2
MOB3B
PADI2
MIR3945HG
DOCK8
SERPINI1
RAPGEF5
NEBL
VNN1
GCNT3
CCND2
CHD7
PIK3AP1
ANO2

Significantly
upregulated in
si-SUV39H1?
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1

Significantly
upregulated in
si-RBMX/L1?
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
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Fold-change:
si-SUV39H1 vs
control
17.1
14.2
11.2
8.8
8.2
7.6
7.5
6.4
5.8
5.8
5.5
5.0
5.0
4.7
4.7
4.6
4.2
4.2
4.1
4.1
4.0
4.0
4.0
3.9
3.8
3.6
3.3
3.3
3.3
3.1
3.0
3.0
3.0
3.0
2.9
2.9
2.8
2.8
2.8
2.8

Fold-change:
si-RBMX/L1 vs
control
15.2
11.9
26.0
6.0
10.0
12.6
18.3
5.6
7.3
3.5
7.2
6.0
2.4
3.9
5.8
3.7
3.7
4.0
3.4
4.3
1.7
1.6
7.8
3.4
2.4
4.9
3.7
4.2
3.9
3.3
2.2
1.6
1.8
3.9
3.8
2.4
5.4
2.2
2.6
2.3

AKR1C3
LOC286297
LIPH
MPZL3
LOC100133920
PDZD2
ELOVL7
PLA1A
GOLGA8M
UGT1A7
IQGAP2
DDX11L16
TMEM27
FAM3D
HRG
ULBP3
SORBS1
WIPF3
DCX
FER1L6
EFHD1
UGT1A8
UGT1A9
DDX11L2
TEKT4P2
NLRC4
GOLGA8J
GOLGA8K
SPTBN2
PTGFRN
ZFAND2A
ABCC11
PCSK5
KLHL4
TGM5
PROS1
APOD
ALDOB
HNF4A
SULT1C2
KIAA1161
RNF44
MFAP3L
RAB6B
FOXA3
RASGRF2
AQP7P1
ACAA1
HNF1A
GLIDR
PCDH1
FUT6
SLC6A20
GOLGA8S

signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1

signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1

162

2.8
2.7
2.7
2.7
2.7
2.6
2.6
2.6
2.6
2.6
2.6
2.6
2.6
2.5
2.5
2.5
2.5
2.4
2.4
2.4
2.4
2.4
2.4
2.3
2.3
2.3
2.3
2.3
2.2
2.2
2.2
2.2
2.1
2.1
2.1
2.0
2.0
2.0
2.0
1.9
1.9
1.9
1.9
1.8
1.8
1.8
1.8
1.7
1.7
1.6
1.6
1.6
1.6
1.6

1.7
2.7
1.8
3.3
2.8
1.7
3.4
2.0
1.6
1.8
3.2
3.8
2.4
2.3
2.9
1.8
2.5
3.1
18.5
1.8
1.7
1.8
1.8
3.1
2.7
2.3
1.6
1.7
1.9
2.1
1.4
2.1
2.0
3.0
2.5
1.7
2.3
1.3
1.4
1.7
1.7
1.4
1.5
1.8
1.4
1.5
1.6
1.2
1.4
1.6
2.4
2.0
2.1
1.6

ZNF578
NATD1
PRODH2
SERPINC1
DYSF
ZBTB7B
GPR108
LINC00504
TREML3P
STOX2
TESPA1
SYT3
TMEM71
TNMD
MYH16
LOC102723769
SLC30A2
RRAGD
NPPB
FATE1
FPR3
TRIM67
TNFRSF11A
PADI3
DHRS2
DRGX
LINC01234
CLSTN2
COBL
LRRC31
ATP8A1
ASPA
LYPD1
CYP2B6
CLMN
KLHL6
CHDH
ERICH2
AMN
CPEB1
AKR1C4
TBXAS1
HABP2
FGF14
PDGFB
CYP4F3
G6PC
LAMP3
GBA3
MYO1H
IL18R1
UNC13D
ACVR1C
AOC3

signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1

signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
signif in si-RBMX/L1
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1.6
1.5
1.5
1.5
1.4
1.4
1.3
1.3
28.2
10.1
9.9
9.0
8.2
8.1
7.5
7.1
6.9
6.4
6.0
5.9
5.6
5.6
5.2
5.0
4.9
4.8
4.7
4.6
4.6
4.5
4.4
4.2
3.9
3.8
3.8
3.8
3.7
3.6
3.6
3.6
3.4
3.4
3.4
3.3
3.3
3.2
3.2
3.2
3.1
3.1
3.1
3.0
3.0
3.0

1.5
1.5
1.6
1.6
2.1
1.5
1.4
1.3
1.0
7.4
24.5
1.2
2.5
3.7
2.8
6.7
5.1
3.3
1.2
2.3
3.0
2.5
4.8
2.3
0.5
3.2
2.8
4.2
1.9
1.6
2.0
1.3
1.5
1.2
1.3
2.8
1.3
2.2
1.5
1.9
2.5
1.1
1.2
1.2
1.1
1.6
1.0
1.2
1.5
2.5
2.1
1.1
2.3
1.4

CRCT1
TSPAN33
ALDH1L1
CDH26
IFITM10
ATP1A2
KEL
SPIRE2
SLC7A9
PANX2
SDK1
NKAIN1
C1orf106
BMP8B
GOLGA8IP
NR1I3
BMP8A
MOGAT3
MTSS1
ZNF208
CYP4F12
PMEPA1
ZMYND15
RAET1K
IL17RB
CCDC64
DISP2
CACFD1
SERPINA6
GPX3
SPINT1
KIAA0040
AZGP1
URAHP
PAPPA2
TMEM37
ZBTB46
UGT1A6
GOLGA8T
SERPINA1
ADCK3
TRAPPC6A
CLU
ALS2CL
SLC6A13
GOLGA8H
PCSK6
TM6SF2
CTSD
SLC26A11
GLYAT
NEU1
TMEM133
GOLGA2P5

signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
signif in si-SUV39H1
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CHAPTER 5. PERSPECTIVES AND FUTURE DIRECTIONS
The packaging of DNA into repressive heterochromatin is a crucial process for the
maintenance of genome stability (Peng and Karpen, 2008) and for lineage commitment in
the early embryo (Fadloun et al., 2013a), and it has emerged as a major barrier to the
reprogramming of differentiated cell identity (Soufi et al., 2012; Becker et al., 2016).
Classically, heterochromatic structures were discerned on the basis of their physical
compaction, such as by the density of DNA under the microscope (Heitz, 1928; Brown,
1966), and early biophysical studies reported that heterochromatin is resistant to
mechanical shearing and sediments more rapidly during centrifugation (Frenster et al.,
1963; Doenecke and McCarthy, 1975). Modern genome-wide mapping of histone
modifications such as H3K9me3 and H3K27me3, which are enriched over known wellcharacterized heterochromatic regions such as pericentromeric repeats (Nakayama et al.,
2001; Lehnertz et al., 2003) and the inactive X chromosome (Plath et al., 2003), have
allowed global assessment of heterochromatic domain positions in the genome and their
dynamics across development lineages (Hawkins et al., 2010; Zhu et al., 2013; Xu et al.,
2014a). However, emerging evidence of H3K9me3 and H3K27me3 in active chromatin
regions (Piacentini et al., 2003; Vakoc et al., 2005; Blahnik et al., 2011; Riddle et al., 2012)
suggests that these marks may lack sufficient sensitivity and specificity to reveal domains
that are physically condensed and transcriptionally silent. I developed a method, called
Gradient-seq, to allow genome-wide mapping of heterochromatic domains on the basis of
their compacted structure, as reflected in their resistance to fragmentation. This approach
involves isolation of heterochromatic regions as intact chromatin, enabling our team to
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characterize the proteins physically associated with these regions, including novel
heterochromatin proteins we show to be functional regulators of gene silencing.

5.1 Gradient-seq as a method to map the human heterochromatin landscape
I observed that H3K9me3-marked DBR domains, previously mapped on the basis of an
impediment to reprogramming factor binding (Soufi et al., 2012), were consistently
depleted in input sequencing tracks for ChIP-seq experiments (Figure 4-1A), which
suggested that resistance to sonication may be a widespread feature of heterochromatic
regions. This agreed with previous work showing that heterochromatin is resistant to
mechanical shearing (Frenster et al., 1963) and that highly sonication-sensitive regions
map to active gene promoters (Auerbach et al., 2009), but the genome-wide
correspondence between sonication resistance and heterochromatin was not initially
clear. I found that isolation of sonication-resistant chromatin fragments was sufficient to
enrich heterochromatic sequences in DBRs over euchromatic sequences by a magnitude
comparable to conventional H3K9me3 ChIP (Supp. Fig. 4-1C). Using next-generation
sequencing, I measured the relative representation of genomic sequences in the
sonication-resistant material versus the sonication-sensitive material, a method that I
termed Gradient-seq. The domains of sonication-resistant chromatin, which I refer to as
structural heterochromatin (strucHC), show striking overlap with most H3K9me3 ChIP-seq
domains (Figure 4-1F), contain genes with very low levels of gene expression by mRNAseq (Figure 4-2D), cover nearly 100% of most heterochromatic satellite repeat elements
(Figure 4-3F), show high rates of DNA methylation at CpG islands (Figure 4-2F), and are
globally resistant to DNase I digestion (Figure 4-4D). Thus, the regions of the genome
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purified by gradient sedimentation meet a variety of criteria traditionally associated with
heterochromatin (Richards and Elgin, 2002).
This technique for physically enriching heterochromatin was informed by previous
work using sucrose gradients to investigate chromatin structure (Gilbert et al., 2004;
Ghirlando and Felsenfeld, 2008; Ishihara et al., 2010). Bickmore and colleagues, whose
ultracentrifugation conditions were the basis for my own studies, showed gene-poor
regions tend to sediment more rapidly after MNase digestion (Gilbert et al., 2004).
Subsequent work showed that transcription of an inducible gene was inversely correlated
with sedimentation rate for crosslinked, sonicated chromatin fragments (Ishihara et al.,
2010). However, these studies detected DNA sequences using 1 MB interval microarrays
(Gilbert et al., 2004) or quantitative PCR (Ishihara et al., 2010), or compared specific
fragments excised by nucleases (Ghirlando and Felsenfeld, 2008), and thus rapidly
sedimenting regions of chromatin have never been mapped with genomic resolution. More
importantly, these studies all isolated fragments of the same size in order to investigate
changes in chromatin buoyancy (Gilbert et al., 2004; Ghirlando and Felsenfeld, 2008;
Ishihara et al., 2010), and thus their findings were unrelated to fragmentation resistance.
Meanwhile, my observations using input tracks for ChIP-seq suggest that sonication
resistance alone is a reliable indicator of heterochromatic regions. Furthermore, since our
method for detecting heterochromatin avoids an electrophoresis-based size-selection step
(Gilbert et al., 2004; Ishihara et al., 2010), it is compatible with subsequent analysis of
proteins co-purifying with heterochromatin (Figure 4-5). For the purposes of genomic
mapping of heterochromatin, however, future work should investigate whether isolation of
large sonicated DNA fragments (by gel electrophoresis or bead selection), and thereby
eliminating the effects of differential buoyancy related to chromatin shape, is sufficient to
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produce genome-wide maps comparable to Gradient-seq. Such an adapted DNA-focused
method might facilitate the generation of heterochromatin maps for diverse cell and tissue
types, to gain insight into heterochromatin dynamics across development.
The finding that heterochromatic regions are depleted from highly sonicated
chromatin highlights an important bias in some ChIP-seq studies. All ChIP-seq data
presented here was normalized to a corresponding input sample on a bin-by-bin basis or
per-basepair basis for track generation. However, normalization by input-subtraction or
input-division is not a routine part of the bioinformatics workflow for public consortia such
as Roadmap Epigenomics (Zhu et al., 2013; Roadmap Epigenomics Consortium et al.,
2015) or ENCODE (ENCODE Project Consortium, 2012), which make ChIP-seq signal
tracks available in unnormalized form. Studies based on these public resources, without
normalizing for input, have claimed that large H3K9me3 domains in human cells are
dependent upon serum used for cell culture (Zhu et al., 2013). However, my re-analysis
of the same datasets revealed that H3K9me3 domains can be detected with comparable
abundance across a range of cell and tissue types, in vitro and in vivo, but this detection
requires input normalization (Supp. Fig. 4-1B). Thus, although it is possible that serum
affects the magnitude of the H3K9me3 ChIP signal, neither the existence of large
H3K9me3 domains nor the sonication resistance of those domains are culture artifacts.
Recently, the Roadmap consortium published a chromatin state segmentation that
consistently assigned small fractions of the genome to the “Heterochromatin” state
(Roadmap Epigenomics Consortium et al., 2015). The algorithm used in this analysis did
account for local enrichments in input but assumed a minimum background signal based
on the genome average (Roadmap Epigenomics Consortium et al., 2015). My results
suggest that these widely used genomic tools might warrant revision to account for regions
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consistently depleted from input chromatin. Furthermore, in light of other recent studies
mapping domains domains resistant to MNase digestion (Mieczkowski et al., 2016), which
generally agree with the sonication-resistant strucHC domains (Supp. Fig. 4-4B,C)
(exceptions discussed below), local normalization to input should be applied to ChIP-seq
datasets produced by sonication and MNase digestion alike.

5.2 Heterochromatic versus euchromatic subtypes of H3K9me3 domains
Overall, the strucHC domains enriched by Gradient-seq show a high rate of agreement
with conventional H3K9me3 ChIP-seq (Figure 4-1F, 4-2A), and 96.8% of the H3K9me3
domain coverage falls into either the strucHC or intermediate domain categories (Figure
4-2C), which have low rates of gene transcription (Figure 4-3B). However, the remaining
31 MB of H3K9me3-marked chromatin overlaps with structurally euchromatic domains,
defined by a depletion of sequencing signal in the strucHC fraction compared to the
euchromatin fraction (see plot in Figure 4-4A). This euchromatic subtype of H3K9me3
domains has remarkable selectivity for specific gene classes (Table 4-1), in particular
KRAB-ZNF genes (Figure 4-3A,C), which form large gene clusters on chromosome 19
(Vogel et al., 2006). Earlier work shows that these genes are expressed from both alleles
and are co-marked by H3K9me3 and the elongation-associated mark H3K36me3 (Blahnik
et al., 2011), and similarly I find that the euchromatic H3K9me3 domains as a whole
contain mostly active genes (Figure 4-3B) and are enriched for H3K36me3 (Supp. Fig. 43A). The fact that KRAB-ZNF gene clusters also form large domains of HP1 binding (Vogel
et al., 2006) rules out the possibility that H3K9me3 detection in these regions is an artifact
of poor antibody specificity. The sonication-sensitive structure of these regions, combined
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with the fact that more than three-quarters of the genes they contain have mRNA-seq
signal (Figure 4-3B), is arguably sufficient to justify labeling such regions of H3K9me3 as
“euchromatic.” However, I note that the classification of these regions as distinct from
heterochromatin is further supported by the hypomethylation of CpG islands in these
regions (in stark contrast to strucHC, see Figure 4-4B), as well as the reduction in contact
with the nuclear lamina (Figure 4-4C, Supp. Fig. 4-4D), which is a conserved property of
heterochromatic regions (Towbin et al., 2013).
A previous analysis of three-dimensional genome contacts by Hi-C found that
KRAB-ZNF genes have a unique pattern of interactions compared to other H3K9me3marked regions, warranting their separate classification as subcompartment B4 (Rao et
al., 2014) and supporting the idea that these regions are structurally distinct. However,
this analysis was performed at low resolution (100-kb), and there was only sufficient
sensitivity to detect subcompartment B4 when the analysis was performed on
chromosome 19 alone (Rao et al., 2014), meaning that it was not possible to detect similar
regions elsewhere in the genome. I have generated the first genome-wide map of
H3K9me3 domains with these euchromatic properities, which can be found on all 24
chromosomes and have three-times more genomic coverage than was mapped for
subcompartment B4 (Rao et al., 2014). I find that genes other than KRAB-ZNFs, such as
the transcribed protocadherin gamma cluster that is involved in intercellular
communication (Chen and Maniatis, 2013), are also found in this chromatin subtype
(Figure 4-3C). It is notable that H3K9me3 overlapping euchromatin appears so selective
for genes that exist as reiterated gene clusters, including HOX genes (Figure 4-3C). It is
tempting to speculate H3K9me3 is recruited to these gene bodies, despite the fact that
they are transcribed in this cell type, in order to prevent illicit recombination between the
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similar sequences of these nearby genes, as has previously been suggested (Blahnik et
al., 2011). Indeed, it was shown that an isolated 3’ ZNF exon, a unit shared by many ZNF
genes, is sufficient to recruit H3K9me3 when integrated elsewhere in the genome (Blahnik
et al., 2011). However, this model should be further tested by investigating whether
depletion of H3K9me3, HP1, or other heterochromatin components leads to increased
recombination or mutagenesis at genes in euchromatic H3K9me3 domains. It will also be
informative to compare genes and repeat classes in humans euchromatic H3K9me3
domains to those on Drosophila chromosome 4, which was also shown to have
transcriptionally permissive H3K9me3 domains (Riddle et al., 2012), to see if any
overarching principles can be discerned.
Although the H3K9me3 domains overlapping euchromatin represent a small
fraction the total fibroblast H3K9me3 domains in the genome (31 of 968 MB), these
regions have been instrumental to the study of H3K9me3 regulation, without widespread
recognition of their unique properties. KRAB-ZNF gene clusters are the major sites where
chromatin binding by KAP1/TRIM28 depends on its recruitment by KRAB-ZNF proteins
(Iyengar et al., 2011), as part of a potential autoregulatory mechanism (O’Green et al.,
2007; Frietze et al., 2010). In light of my findings, KAP1 recruitment by KRAB-ZNFs, which
previously has been suggested as a model for heterochromatin domain formation (Groner
et al., 2010), is compatible with both gene transcription and a sonication-sensitive
chromatin structure, and is therefore not sufficient for heterochromatin establishment. The
H3K9me3 signal over ZNF genes is in fact so prominent that a major study associated
with the Roadmap Epigenomics consortium (Zhu et al., 2013) used these sites to
standardize their H3K9me3 ChIP-seq datasets across cell types. The fact that sonicationsensitive H3K9me3 sites were used to define positive signal, combined with the lack of
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normalization to an input control, may have suppressed the detection of sonicationresistant heterochromatic domains in this study (Zhu et al., 2013).
In addition to KAP1, our finding of H3K9me3 domains with euchromatic structure
is also important for study of the three-protein HUSH complex, which regulates SETDB1
recruitment and H3K9me3 deposition (Tchasovnikarova et al., 2015). Although
euchromatic H3K9me3 domains are comparatively rare, they account for a majority of
reported HUSH-regulated sites in fibroblast H3K9me3 domains (Figure 4-3D), including
the strongest sites (Supp. Fig. 4-3C) and sites highlighted in the original report
(Tchasovnikarova et al., 2015) at ZNF and non-ZNF genes. My data suggest that HUSH
complex binding promotes H3K9me3 deposition without significant chromatin compaction,
challenging the use of the term “heterochromatin” to describe such sites (Timms et al.,
2016). Nonetheless, my observations are compatible with published model that the HUSH
complex “dims” the expression of transcribed genes but does not silence them fully
(Tchasovnikarova et al., 2015; Timms et al., 2016). Future work should investigate the
contribution of HUSH binding to chromatin accessibility as opposed to merely the readout
of the H3K9me3 mark.
A major outstanding question is what chromatin components or mechanisms
distinguish euchromatic from heterochromatic H3K9me3 domains. Although the HUSH
complex seems to preferentially act in the euchromatic subtype (Figure 4-3D), the loss of
this complex leads to increased gene expression and reduced H3K9me3 in these regions
(Tchasovnikarova et al., 2015), meaning that HUSH is not converting regions that would
otherwise be heterochromatic H3K9me3 to euchromatin. An attractive experimental
strategy would be to perform H3K9me3-directed IP from of the euchromatic gradient
fraction, followed by mass spectrometry, to identify more proteins associated with these
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regions. I indeed performed such IPs using the euchromatin fraction (analysis of DNA in
Supp. Fig. 4-1D, sequencing track in Figure 4-3A); however, I found that the amount of
chromatin obtained was too low to yield informative proteomic data (data not shown). An
additional challenge of such a purification strategy is that the second step, the H3K9me3
IP, also re-enriches the heterochromatic H3K9me3 domains (which are depleted <2-fold,
but still present, in the euchromatic fraction – see Figure 4-1C), and the much greater
genomic abundance of the heterochromatic regions would presumably cause them to
overwhelm the signal from the rarer euchromatic regions. A more viable strategy might be
to perform careful proteomic comparisons between a traditional H3K9me3 ChIP-MS and
H3K9me3 ChIP from the strucHC fraction, seeking to identify proteins enriched in the
former compared to the latter, which would be candidates for binders of euchromatic
H3K9me3 chromatin. Alternatively, to directly purify regions of euchromatic H3K9me3,
future work could use a protocol called “proteomics of isolated chromatin segments”
(PICh) (Déjardin and Kingston, 2009), which uses nucleic acid probes to pull down specific
loci in chromatin and has been used to identify major satellite-associated proteins
(Saksouk et al., 2014), perhaps directed at an H3K9me3-marked KRAB-ZNF exon.
Identifying proteins that preferentially promote a euchromatic or heterochromatic structure
within H3K9me3 domains would be useful for efforts to increase chromatin accessibility
during cell reprogramming. Such findings may also prove relevant to the chromatin state
of pluripotent cells, which have H3K9me3-marked regions but lack compacted
heterochromatin structures by electron spectroscopic imaging and electron microscopy
(Meshorer and Misteli, 2006; Ahmed et al., 2010; Fussner et al., 2011; Underwood et al.,
2016).
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5.3 Diversity of chromatin structure among H3K27me3 domains
The literature has been conflicted about whether the term “heterochromatin” includes
H3K27me3-marked regions, with some authors using the term synonymously with
H3K9me3-marked and HP1-bound domains (Beisel and Paro, 2011). Indeed, analysis of
select H3K27me3-marked sites reveals accessibility to binding by general transcription
machinery (Breiling et al., 2001; Dellino et al., 2004), suggesting that such regions may
constitute a “lesser” form of heterochromatin. Meanwhile, paradigmatic examples of
facultative heterochromatin, such as Barr body of the inactive chromosome, are marked
by H3K27me3 (Plath et al., 2003; Heard, 2005) and also have condensed ultrastructure
(Rego et al., 2008). Yet H3K9me3-marked chromatin too is dynamic in development
(Hawkins et al., 2010; Soufi et al., 2012; Becker et al., 2016; Figure 2-1), and thus the
functional descriptor “facultative” is inadequate to distinguish between the chromatin
states associated with H3K27me3 versus H3K9me3. Clearly, greater understanding is
needed on the relationship between H3K27me3-marked domains and structurally
compact heterochromatin.
I find that 49% of the H3K27me3 domains in human fibroblasts (327 of 672 MB;
Figure 4-2C) fall into domains we map as strucHC by Gradient-seq. The quantitative
enrichment of these regions in the strucHC fraction compared to the euchromatin fraction
is actually similar to the H3K9me3-marked strucHC domains (Figure 4-4A, compare red
plots between H3K9me3 and H3K27me3 subtypes). Thus, H3K9me3- and H3K27me3marked forms of strucHC have a chromatin structure that is comparably resistant to
sonication, supporting the notion that H3K27me3 is a bona fide heterochromatin mark
(Trojer and Reinberg, 2007). However, compared to H3K9me3, H3K27me3 was less
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predictive of a heterochromatic or intermediate state, as 29% of H3K27me3 domains (193
MB; Figure 4-2C) preferentially migrated to the euchromatin fraction (versus 3.2% or 31
MB of H3K9me3). The euchromatic nature of this H3K27me3 subtype is supported by a
variety of metrics, including increased gene expression (Figure 4-3B), decreased DNA
methylation at CpG islands (Figure 4-4B), and marked sensitivity to DNase I digestion
(Figure 4-4D). The euchromatic subtype of H3K27me3 includes all four major HOX gene
clusters (Figure 4-3C,E), which have been model loci for the study of Polycomb-regulated
regions over decades (Lewis, 1978; Duncan, 1982; Xu et al., 2014b), without widespread
acknowledgement that these regions have an atypical chromatin structure compared to
more heterochromatic H3K27me3 regions. These findings highlight the challenges of
generalizing from specific H3K27me3-marked loci to all PRC targets. Future work might
investigate whether the accessibility of H3K27me3-marked chromatin to transcription
factor binding (Breiling et al., 2001; Dellino et al., 2004) is different between the strucHC
and euchromatic subtypes mapped in this study.

5.4 Relationship between chromatin subtypes and hallmark properties of repressive
chromatin
A variety of proprieties have been associated with H3K9me3-marked chromatin or
repressive regions of the genome–such as DNA methylation (Lehnertz et al., 2003),
localization with the nuclear periphery (Csink and Henikoff, 1996; Guelen et al., 2008;
Poleshko et al., 2013; Towbin et al., 2013), late replication (O’Keefe et al., 1992; Chandra
et al., 2012), and resistance to nuclease digestion (Gottesfeld et al., 1975; Wallrath and
Elgin, 1995; Hamid et al., 1996)—and they have generally have been studied separately.
It has been unclear whether these properties are directly associated with H3K9me3
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deposition, compacted chromatin structure, or both, and our identification of H3K9me3
domains inside and outside of strucHC (as well as strucHC regions lacking H3K9me3 or
H3K27me3 enrichment) provided an opportunity to test these questions. We find that,
within CpG islands, the frequency of DNA methylation per CpG shows remarkable
correlation with the structural classifications from Gradient-seq (Figure 4-4B). Island CpGs
are consistently methylated in strucHC, regardless of histone mark, and are consistently
hypomethylated in euchromatin, with and without H3K9me3 or H3K27me3. The highest
rates of methylation are, in fact, seen at strucHC domains with neither mark enriched. The
nature of this “third” heterochromatin state, distinct from H3K9me3 and H3K27me3
domains, remains mysterious at present. Performing gradient sedimentation before and
after 5-azacytosine treatment, to inhibit DNA methyltransferases, would allow
determination of whether the observed hypermethylated state is required for
heterochromatic compaction in these regions. Overall, the patterns of CpG island
methylation, similar to gene transcription (Figure 4-3B), show a direct relationship with
genome structure as measured by Gradient-seq. However, since, outside of CpG islands,
DNA methylation is high in all chromatin categories (Supp. Fig. 4-4A), bisulfite sequencing
cannot be used to map the full territory of heterochromatin regions.
In contrast to CpG island methylation, DNA replication timing is most accurately
predicted by histone mark rather than extent of chromatin compaction. The strucHC and
euchromatic subtypes of H3K9me3 replicate similarly late in S phase, while all forms of
H3K27me3 replicate much earlier (Figure 4-4E). These striking associations for
H3K9me3- and H3K27me3-marked chromatin were described in some previous studies
(Chandra et al., 2012), while other groups report weak associations between replication
timing and histone marks based on genome segmentation models (Dileep et al., 2015),
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perhaps related to issues of input-normalization discussed above. My data suggest that
late replication might be conferred by chromatin complexes that localize to H3K9me3marked domains, rather than being a direct byproduct of a compacted chromatin structure,
and that late replication and active gene transcription can co-occur (at euchromatic
subtypes of H3K9me3). Meanwhile, association of chromatin with the nuclear lamina is
predicted by specific combinations of structural and histone mark classifications (Figure
4-4C, Supp. Fig. 4-4D). H3K9me3 domains generally have higher levels of lamin B1
binding compared to H3K27me3 domains, but within both histone mark categories,
strucHC and intermediate subtypes showed greater lamin association than euchromatic
subtypes.
Resistance to nucleases like DNase I and MNase is typically interpreted as a
measure of chromatin structure (Wallrath and Elgin, 1995; Hamid et al., 1996; Thurman
et al., 2012). It is reassuring that that there is a strong overall concordance between the
classifications from Gradient-seq and nuclease-based datasets, with euchromatin regions
showing higher rates of DNase I cleavage (Figure 4-4D) and sensitivity to MNase (Supp.
Fig. 4-4B). In particular, fibroblast strucHC domains overlap strikingly with domains of
increased resistance to MNase, determined based on MNase titration in K562 leukemia
cells (Mieczkowski et al., 2016), particularly among regions with similar H3K9me3 and
H3K27me3 signals in both cell types. Thus, my findings can be generally corroborated by
independent approaches not involving sonication or gradient sedimentation. However, a
key distinction between these methods occurs at the regions of H3K9me3 that are
euchromatic by Gradient-seq, but remain largely resistant to DNase I (Figure 4-4D) and
MNase (Supp. Fig. 4-4B,C). Inspection of regions co-marked by H3K9me3 and
H3K36me3 in both fibroblasts and K562 cells reveals a highly sonication-sensitive
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chromatin structure by Gradient-seq but resistance to MNase (Supp. Fig. 4-4C). Since
these two “structural” approaches are discordant regarding the accessibility of such
regions, independent methods should be used to adjudicate the discrepancy, such as this
late breaking paper (Risca et al., 2016) that uses correlations in radiation-induced DNA
cleavage to investigate chromatin structure. However, in the meantime, given that
euchromatic H3K9me3 domains (according to Gradient-seq) are permissive to gene
transcription (Figure 4-3B) and DNA hypomethylation (Figure 4-4B), it is likely that there
is at least some increased chromatin accessibility in these regions compared to other
types of H3K9me3-marked chromatin. It is possible that something about the local
environment of H3K9me3-marked chromatin or the chromatin complexes bound to these
sites that inhibits DNA cleavage reactions, including at more euchromatic sites, and that
the structure of such regions is better probed by a non-enzymatic method involving sound
waves/cavitation. Although it remains to be established whether Gradient-seq is a superior
readout of chromatin structure compared to nuclease-based methods, we note that only
Gradient-seq allows separation of transcriptionally silent H3K9me3 domains from
transcriptionally active ones prior to proteomics, which was a principal goal of our study.

5.5 Heterochromatin impedes direct conversion between differentiated
lineages
The impediment of genes to be activated during reprogramming is a property, like lamin
B1 binding, that also appears to be related to both structural state of chromatin and histone
mark enrichment. Previous transcriptomic analysis showed that, after fibroblasts are
converted to human induced hepatocytes (hiHeps), large numbers of genes expressed in
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native liver cells remain aberrantly repressed in the reprogrammed hiHep cells (Huang et
al., 2014). However, properties of chromatin that predict whether a hepatic gene will be
properly induced were not identified. I found that, among hepatic genes that are initially
silent in fibroblasts, H3K9me3-marked genes have a profound defect in activation (Supp.
Fig. 4-1A), with the majority of genes showing little to no activation above fibroblast levels
at the conclusion of hiHep reprogramming. This defect was not apparent in H3K27me3marked chromatin (Supp. Fig. 4-1A). These findings are consistent with prior evidence
that H3K9me3-marked chromatin, in particular, presents an impediment to reprogramming
to pluripotency (Soufi et al., 2012; Matoba et al., 2014). Moreover, these results suggest
that H3K9me3-marked chromatin poses a general barrier to cell fate reprogramming that
is not contingent on specific factor combinations (such as OSKM) (Soufi et al., 2012, 2015)
or the reprogramming being towards a state like pluripotency that has more limited
heterochromatin (Meshorer and Misteli, 2006; Ahmed et al., 2010; Fussner et al., 2011;
Underwood et al., 2016).
The differential effects of H3K9me3 versus H3K27me3 on hepatic gene activation
during reprogramming persist even when the comparison is restricted to within strucHC
(red plots in Figure 4-6A). Thus, even among regions with a similarly sonication-resistant
chromatin structure, H3K9me3-marked chromatin is uniquely refractory to gene activation,
revealing an important functional difference between these two heterochromatic marks.
Moreover, this finding further justifies the study of H3K9me3-associated heterochromatin
proteins as a means to understand barriers to cell conversion (Becker et al., 2016).
However, among H3K27me3-marked regions, the strucHC subtype has the lowest levels
of

hepatic

gene

induction

(Figure

4-6A),

suggesting

that

sonication-resistant

heterochromatic structure also impedes reprogramming independent from the H3K9me3
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mark. Moreover, whereas the strucHC and intermediate subtypes of H3K9me3 domains
are refractory to gene activation by hiHep factors, the euchromatic subtype of H3K9me3
is not (Figure 4-6A). Consequently, the depletion of such sonication-sensitive regions by
gradient sedimentation is an important step in order to purify only H3K9me3-associated
proteins that are relevant to reprogramming resistance.
In contrast to human iPS reprogramming, which proceeds at low efficiency (Hanna
et al., 2009; Vierbuchen and Wernig, 2012; Papp and Plath, 2013), a high fraction of cells
(10-15%) at the conclusion of hiHep reprogramming process express the hepatocyte
marker genes albumin and alpha-1-antitrypsin (Huang et al., 2014) (Supp. Fig. 4-6A),
which represents as much of half the cells infected with all three lentiviruses at MOI ~1
per virus. Thus, there is limited dynamic range to observe improvements of the efficiency
of hiHep reprogramming, whereas the main concern is the low fidelity of the conversion.
We show that knockdown of SUV39H1 or RBMX/L1 enhances the induction of a variety
of hepatic genes, marked by H3K9me3 in the starting fibroblasts, both early in
reprogramming (Figure 4-6D) and at the conclusion of the process (Supp. Fig. 4-6E).
These findings confirm, first, that the resistance of these heterochromatic H3K9me3
regions to hiHep reprogramming is dependent on the H3K9me3 methyltransferase
SUV39H1, similar to the impediment to iPS factor activity (Soufi et al., 2012). Second, this
shows that siRNA against SUV39H1 or RBMX/L1 enhances the fidelity of conversion at
the genes most refractory to reprogramming. Ongoing work in the laboratory is
investigating whether these perturbations also enhance hiHep reprogramming fidelity from
a functional standpoint, by testing whether the reprogrammed cells have a greater ability
to engraft in and repopulate the livers of FAH-deficient mice (Azuma et al., 2007).
Alternatively, one might consider testing whether the siRNA treatments affect the
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performance of the reprogrammed cells in in-vitro assays of hepatocyte function, such as
P450 drug metabolism, considering that such activity is typically limited in programmed
hepatocytes (Vallier, 2014) and given that CYP450 genes are repressed in fibroblast
H3K9me3 domains (Figure 4-6B).
We note that the activation of these heterochromatinized hepatocyte genes after
SUV39H1 or RBMX/L1 knockdown is generally modest in comparison to native
hepatocytes. This suggests that these regions of chromatin are still refractory to activation
even in the presence of these perturbations, and it may be useful to try enhancing the
extent of heterochromatin disruption. One strategy might be to use CRISPR-mediated
gene deletion instead of RNAi, to produce cells with complete loss of these
heterochromatin proteins. Alternatively, combinations of heterochromatin perturbations
should be tested, such as RNAi/CRISPR against multiple H3K9me3-associated proteins,
or combining SUV39H1 knockdown with HDAC inhibitions in order to simultaneously
disrupt multiple mechanisms of chromatin compaction.

5.6

Proteomics

reveals

functional

regulators

of

H3K9me3-marked

heterochromatin
Our identification of 172 heterochromatin proteins by quantitative proteomics (Figure 45B) was based on analysis of H3K9me3 IPs performed using the strucHC fraction,
compared to the euchromatin fraction (Figure 4-5A). Thus, our strategy resembles
traditional ChIP-MS approaches in terms of its specificity for components of H3K9me3marked chromatin (Soldi and Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015), but has
the advantage of first depleting transcriptionally active H3K9me3 domains during the
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gradient sedimentation step. As expected, the list of identified heterochromatin proteins
includes known structural components of heterochromatin, such as linker histone and
lamin B1, as well as a variety of known mediators of gene silencing (Figure 4-5D). Our
results also overlap significantly, but not completely, with the only previous H3K9me3
ChIP-MS dataset performed for differentiated cells (Soldi and Bonaldi, 2013) (Figure 45E). Furthermore, the strong agreement between proteins enriched in the strucHC fraction
and those enriched in the H3K9me3 IP off of the strucHC fraction (Figure 4-5C) is
consistent with H3K9me3-marked chromatin being the major component of the strucHC
fraction. The fact that 22 of the heterochromatin proteins have previously been shown to
impede iPS reprogramming (Supp. Fig. 4-5B) suggests that this should be a rich dataset
for revealing new factors involved in restricting cell fate conversion.
A surprising finding is the large number of heterochromatin proteins with RNA
binding activity (119 of 172). However, this subset of heterochromatin proteins actually
has an improved rate of overlap with other H3K9me3-related proteomic studies (Figure 45F) (Vermeulen et al., 2010; Soldi and Bonaldi, 2013), indicating that this observation is
not particular to our approach or method of analysis. The presence of RNA-binding
proteins in heterochromatin is consistent with previous evidence that RNA-binding by HP1
is required for its heterochromatin localization (Muchardt et al., 2002), that some
constitutive heterochromatin regions generate RNA (Saksouk et al., 2015), and that
particular noncoding RNAs are important for heterochromatic compaction after escape
from pluripotency (Savić et al., 2014). Specific RNA-binding proteins like HNRNPK, which
we

also

find

in

heterochromatin,

have

been

shown

to

regulate

H3K9me3

methyltransferases and reprogramming (Bao et al., 2015; Thompson et al., 2015).
Nonetheless, the role of RNA in mammalian heterochromatin remains controversial, as
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RNAi-dependent mechanisms for heterochromatin establishment discovered in yeast
have not been verified in mammals (Saksouk et al., 2015). Since our two-step method for
heterochromatin purification (gradient sedimentation followed by H3K9me3 IP) achieves
high purity for heterochromatic regions (Supp. Fig. 4-1C), a major outstanding question is
which RNAs are present in this sample. Indeed, we have performed RNA-seq from these
samples, in collaboration with Roberto Bonasio’s laboratory, and analysis of this data is in
process.
We show that two RNA-binding proteins have functional roles in heterochromatic
gene silencing. First, we show that TARDBP (also known as TDP-43), which is the least
enriched among six ALS-related proteins in heterochromatin (Figure 4-5G) but the most
comprehensively studied (Lee et al., 2012), suppresses expression of genes in strucHC
domains (Supp. Fig. 4-5C,D), using microarray data form human patient-derived
fibroblasts. This large number of strucHC genes shows modest but widespread
upregulation in fibroblasts from TARDBP-mutant ALS patients, compared to healthy
controls, but not in sporadic ALS cases with wild-type TARDBP (Supp. Fig. 4-5C,D).
Second, we studied the role of RBMX (together with the related protein RBMXL1) in
regulating gene expression genome-wide, with and without the presence of hiHep
reprogramming factors. Indeed, RBMX/L1 knockdown led to significant upregulation of 67
strucHC genes in the absence of exogenous factors (Figure 4-7E, Supp. Fig. 4-7C).
However, the most striking result was observed in the context of hiHep reprogramming,
where the effects of SUV39H1 siRNA in enhancing activation of strucHC genes were
closely mirrored by RBMX/L1 siRNA (Figure 4-7C; Table 4-5). Thus, RBMX/L1 contributes
to the observed impediment in activating heterochromatic liver genes during hiHep
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reprogramming, consistent with what was observed at candidate transcripts by RT-PCR
(Figure 4-6D).
The mechanisms by which RBMX/L1 and TARDBP function in heterochromatic
silencing is currently unclear. A crucial question is whether the RNA-binding activity of
these proteins is required for the localization to or activity in strucHC. Previous work shows
that the RNA-recognition motif (RRM) of RBMX is dispensable for both its binding to
chromatin and its role in regulating centromeric cohesion (Matsunaga et al., 2012), a
function that has been shown for other heterochromatin proteins like SUV39H1 (Peters et
al., 2001). Thus, RBMX’s role in strucHC may not require RNA interaction at all. This
question should be investigated by testing if an RRM-deletion mutant of RBMX
phenocopies RBMX deletion in terms of enhancing the activation of H3K9me3-marked
hepatic genes during reprogramming. A similar strategy can be pursued for TARDBP and
other RNA-binding proteins in our heterochromatin dataset, to investigate the wider
functional relevance of the observed enrichment for RNA-binding domains among these
proteins. In addition, to gain insight into the mechanism of RBMX function, it will be useful
to identify RBMX-interacting proteins by IP and mass spectrometry, to see if RBMX binds
HP1 or H3K9me3 methyltransferases, as was previously shown for HNRNPK (Bao et al.,
2015; Thompson et al., 2015).

5.7 Monitoring reprogramming impediments to screen heterochromatin
proteins
Our studies with the canonical H3K9me3 regulator SUV39H1 as well as RBMX illustrate
that perturbation of heterochromatin does not immediately induce widespread de187

repression of silenced genes. This agrees with previous genetic studies of SUV39H1/H2
(Bulut-Karslioglu et al., 2014), it may indicate the existence of redundant silencing
mechanisms or simply the requirement for targeted transcriptional activators to upregulate
these cell-type specific genes (Figure 4-6D). In light of this data, testing putative
heterochromatin regulators for whether they are directly required for gene silencing may
be an inappropriate criterion for establishing functionality. The key functional property of
heterochromatin

is

not merely

transcriptional repression

but dominance

over

transcriptional activating mechanisms, as seen for classic studies of position effect
variegation (Wallrath and Elgin, 1995; Elgin and Reuter, 2013), as well as, more recently,
resistance to reprogramming (Soufi et al., 2012). Our experiments in the context of hiHep
conversion (Figure 4-6D) show that monitoring activation of sentinel heterochromatinized
genes following ectopic addition of alternative-lineage transcription factors is a powerful
assay for revealing the action of novel heterochromatin regulators.
Given that we’ve identified multiple hepatic genes that show an H3K9me3dependent impediment to activation during hiHep reprogramming (Figure 4-7C,D), it is
possible to leverage such sites in order to screen a wider set of proteins for functional
roles in heterochromatin. Specifically, we are conducting an siRNA screen of
approximately 100 heterochromatin proteins, from our proteomic analysis as well as select
candidates from the literature. Similar to the experimental design in Figure 4-7A (top), we
have transduced cells with hiHep transcription factors followed by independent siRNAs
against each candidate heterochromatin protein. The endpoint of the assay is RT-PCR for
hepatic genes in strucHC, such as DSC2, CRP and NR1H4 (Figure 4-6D, 4-7D), with the
goal of identifying proteins whose knockdown enhances the reprogramming of these
genes, similar to RBMX. This approach can be extended beyond the hepatic lineage, by
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using transcription factor combinations for iPS reprogramming (Takahashi and
Yamanaka, 2006), conversion to neurons (Vierbuchen et al., 2010), or reprogramming to
diverse other lineages. Our major goal is to identify additional components of the
heterochromatin proteome that, like RBMX, oppose the induction of H3K9me3-marked
genes for other fates. Of particular interest would be proteins that are involved in impeding
conversion to specific lineages but not others. Such findings could help shed light on the
cell type-specific mechanisms of heterochromatin establishment that help to guard against
changes in cell identity, but that so far have remained elusive.
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Appendix A. Bookmarking by specific and nonspecific
binding of FoxA1 pioneer factor to mitotic chromosomes
This appendix contains a manuscript to which I contributed during my graduate work,
which was published in Genes and Development (Vol. 27(3), p. 251-260), and in which I
am listed as the third author. The large majority of the work in this manuscript was
performed by Juanma Caravaca, Ph.D., under the guidance of Dr. Zaret. I performed the
RNA polymerase II immunofluorescence experiments as well as the ethynyl uridine RNA
labeling experiments that are presented in Supplementary Figure 5, and which supported
the choice of RT-PCR timepoints used in Figure 6. The manuscript was written by Dr.
Caravaca and Dr. Zaret, and I assisted in editing the manuscript.
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While most transcription factors exit the chromatin during mitosis and the genome becomes silent, a subset of
factors remains and ‘‘bookmarks’’ genes for rapid reactivation as cells progress through the cell cycle. However,
it is unknown whether such bookmarking factors bind to chromatin similarly in mitosis and how different
binding capacities among them relate to function. We compared a diverse set of transcription factors involved in
liver differentiation and found markedly different extents of mitotic chromosome binding. Among them, the
pioneer factor FoxA1 exhibits the greatest extent of mitotic chromosome binding. Genomically, ~15% of the
FoxA1 interphase target sites are bound in mitosis, including at genes that are important for liver differentiation.
Biophysical, genome mapping, and mutagenesis studies of FoxA1 reveals two different modes of binding to
mitotic chromatin. Specific binding in mitosis occurs at sites that continue to be bound from interphase.
Nonspecific binding in mitosis occurs across the chromosome due to the intrinsic chromatin affinity of FoxA1.
Both specific and nonspecific binding contribute to timely reactivation of target genes post-mitosis. These
studies reveal an unexpected diversity in the mechanisms by which transcription factors help retain cell identity
during mitosis.
[Keywords: mitosis; bookmarking; pioneer factor; FoxA1; chromatin; chromosomes]
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When cells enter mitosis, chromosomes condense
(Caravaca et al. 2005) and the genome becomes silent
(Prescott and Bender 1962; Spencer et al. 2000). Only a
fraction of transcription factors are retained on mitotic
chromosomes (Martinez-Balbas et al. 1995; Michelotti
et al. 1997; Burke et al. 2005; Yan et al. 2006; Egli et al.
2008), and a subset of these facilitate rapid gene reactivation post-mitosis (Young et al. 2007; Blobel et al.
2009; Dey et al. 2009; Kadauke et al. 2012). The basis for
the marked differential in transcription factors’ binding
to mitotic chromatin and how it reflects the factors’ roles
in genome reactivation is not clear.
In liver development, binding sites for FoxA and GATA
factors are occupied on the silent liver gene alb1 in
undifferentiated embryonic endoderm (Gualdi et al. 1996;
Bossard and Zaret 1998). Upon hepatic induction, nearby
binding sites for NF-1, C/EBP, and other factors become
3
Corresponding author
E-mail zaret@upenn.edu
Article published online ahead of print. Article and publication date are
online at http://www.genesdev.org/cgi/doi/10.1101/gad.206458.112.

occupied, and the liver gene is activated. Among the
factors that promote liver development, only FoxA proteins can bind their target sites on nucleosomes and
enable the other factors to bind (Cirillo and Zaret 1999;
Cirillo et al. 2002); hence, FoxA factors have been called
‘‘pioneer factors’’ (Cirillo et al. 2002; Zaret and Carroll
2011). While GATA4 is dependent on FoxA for binding
nucleosomes (Cirillo and Zaret 1999), it can bind to
compacted chromatin that is inaccessible to the other
factors (Cirillo et al. 2002) and hence can be considered
a subordinate pioneer factor. The structure of the
DNA-binding domain (DBD) of FoxA resembles that
of linker histone (Clark et al. 1993; Ramakrishnan
et al. 1993), and the FoxA C-terminal domain, which
is unlike that of linker histone, interacts with core
histones and promotes local chromatin opening (Cirillo
et al. 2002). The highly related FoxA1 and FoxA2 are
encoded by unlinked genes and both are necessary for
the activation of the hepatic program (Lee et al. 2005);
FoxA1 has been shown to remain bound to mitotic
chromosomes in adult liver cells (Zaret et al. 2011). We
therefore sought to investigate the mechanism and

GENES & DEVELOPMENT 27:251–260 ! 2013 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/13; www.genesdev.org

217

251

Downloaded from genesdev.cshlp.org on February 7, 2013 - Published by Cold Spring Harbor Laboratory Press

Caravaca et al.

role of FoxA binding to the mitotic genome in hepatic
cells.
Results
Pioneer factors bind more strongly than other factors
to mitotic chromatin
We previously assessed the interphase chromatin binding
and mobility of GFP-tagged versions of FoxA1, GATA4,
C/EBPa, NF-1, and other proteins that are expressed in
the liver and contain different DBD structures (HMGB1,
c-Myc, and linker histone H1o). Notably, FoxA1 moves
much more slowly in chromatin than the other factors,
correlating with its high nucleosomal binding ability,
although not as slow as H1o (Sekiya et al. 2009). Here,
we expressed the constructs in HUH7 adult human
hepatoma cells that had been blocked in mitosis with
nocodazole and visualized GFP fluorescence in live cells
by high-resolution deconvolution microscopy (Agard
1984). GFP-FoxA1 was seen almost exclusively bound to
chromosomes in the metaphase-arrested cells as well as
in drug-free control cells passing through mitosis, mimicking the pattern of GFP-H1o (Fig. 1A). We estimate that
the GFP transfected cells expressed ;10-fold more of the
respective amounts of the transcription factor than the
endogenous protein (data not shown). When we used 20fold lower amounts of transfected GFP-FoxA1 plasmid

DNA, we observed much fainter signals but still marked
binding to mitotic chromosomes (Supplemental Fig. 1a).
GFP-GATA4 and GFP-HMGB1 fluorescence was seen
both on the mitotic chromosomes and in the cytoplasm
(Fig. 1B), while GFP-C/EBPa gave fainter signals on
mitotic chromosomes than the other factors. Western
blotting of endogenous C/EBPa showed it to be severalfold less stable in mitotic hepatoma cells, whereas FoxA1
was equal in abundance in mitotic and asynchronous
cells (Supplemental Fig. 1b). GFP-c-Myc and GFP-NF1
exhibited background fluorescence on the mitotic chromosomes, reflecting factor exclusion (Fig. 1B). Cells released from the metaphase mitotic block and fixed at
anaphase and telophase showed that GFP-FoxA1 remained
bound to chromosomes throughout mitosis, while a GFP
protein fused to a nuclear localization sequence was
excluded (Supplemental Fig. 2a). Endogenous FoxA1
exhibited similar properties but with a more diffuse
signal that is typical of fixed cells, compared with that
seen when live cells are imaged (Supplemental Fig. 2b).
GFP fused to the FoxA1 DBD was sufficient to bind
mitotic chromosomes (Fig. 1A).
Thus, within this group of regulatory factors for the
liver lineage, the earliest pioneer factor in development is
the most strongly bound to mitotic chromatin; the subordinate pioneer factor GATA4 is partially bound, similar
to that seen for GATA1 elsewhere (Kadauke et al. 2012);
and later developmental factors are either partially
bound, bound yet unstable in mitosis, or excluded from
the mitotic chromosomes altogether.
Highly transcribed gene targets of FoxA1 remain
specifically bound in mitosis

Figure 1. Diverse modes of hepatic transcription factor binding
to mitotic chromosomes. (A,B) GFP fluorescence in live HUH7
hepatoma cells visualized by deconvolution microscopy with or
without nocodazole for mitotic arrest. (A) GFP and GFP/brightfield (BF) views showing that GFP-FoxA1, GFP-FoxA1 DBD, and
GFP-H1o remain quantitatively bound to mitotic chromosomes.
(B) A portion of the cellular GATA4 and HMGB1 is released
from mitotic chromosomes in nocodazole-treated cells; C/EBPa
becomes unstable, yet a portion remains bound; and c-Myc and
NF1 are excluded from the mitotic chromosomes.
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To assess where endogenous FoxA1 binds the genome
in mitotic cells compared with asynchronously cycling
cells, we performed chromatin immunoprecipitation
(ChIP) coupled with deep sequencing (ChIP-seq) on triplicate cell populations, with and without nocodazole
treatment (Supplemental Fig. 3a,b). More than 94% of
the nocodazole-arrested cells were in mitosis, as assessed
by cell morphology and H3Ser10 phosphorylation, while
<2% of the asynchronously cycling wells were in mitosis
(Supplemental Fig. 3a). Using model-based analysis of
ChIP-seq (MACS) (Zhang et al. 2008) to assign peaks, we
discovered 546 FoxA1-bound sites in mitotic cells and
3509 sites in asynchronous cells (Fig. 2A). Eighty-seven
of the called FoxA1 peaks were specific to mitotic cells,
but visual inspection of the unique sequence reads and
quantitative PCR (qPCR) analysis of independent chromatin preparations indicated that the FoxA1-bound sites
in mitotic cells are also bound in asynchronous cells
(e.g., Fig. 2B [intergenic site on ch. 5 and MIPEP site at
+92.7 kb, red arrowheads], B [ChIP-qPCR validations are
of mitotic and asynchronous cell chromatin]). Certain
weak FoxA1 peaks in mitosis that were not called by
MACS were significant by ChIP-qPCR (Fig. 2B, AFP !4.1and !2-kb sites and TTR promoter), similar to the weaker
mitotic site at the HNF4a !7-kb site and unlike a negative
control site on ch. 13 (Fig. 2B). ChIP for histone H3 at
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Figure 2. FoxA1 in mitosis occupies the most
strongly expressed and strongly bound genes in
asynchronous HUH7 cells. (A) Peaks were pooled
from three replicate ChIP-seq samples, revealing
3509 asynchronous FoxA1-binding sites, of which
546 are also bound in mitosis. (B) FoxA1 ChIP-seq
data tracks and ChIP-qPCR confirmation in independent chromatin samples with signals normalized
to input and per million sequence reads. Red arrowheads depict sites of mitotic binding, and those that
were verified by qPCR are shown on the right. The
circle indicates the negative control site. The break
in the HNF4a and TTR bar graphs is to accommodate different scales for the asynchronous (as.) and
mitotic (mi.) data. (C) FoxA1 ChIP-seq signals over
all sites bound in mitotic and asynchronous cells
compared with all sites bound only in asynchronous
cells; the signal is normalized to input DNA quantity and the total number of aligned sequence reads.
FoxA1 binding is much stronger to sites in mitotic
and asynchronous cells than to sites bound in
asynchronous cells only. (D) Common FoxA-binding
motif at sites bound in mitosis versus asynchronous
only. (E) Nearly all of the FoxA1-bound sites in
mitosis are associated with genes either within the
transcribed region or <20 kb upstream. (F) Box and
whisker plots showing that genes bound by FoxA1 in
mitotic and asynchronous cells correspond to those
more highly expressed genes in hepatoma cells; (***)
P < 10!15. (G) FoxA1 remains bound to hepatic
transcription factor genes in mitosis.

these sites showed comparable signals between the asynchronous and the mitotic chromatin (Supplemental Fig. 3c),
demonstrating that differences seen for FoxA1 were specific to the factor and not the preparations of chromatin.
FoxA1 peaks that occurred in both mitotic and asynchronous cells were, on average, markedly stronger in
asynchronous cells than the FoxA1 peaks that occurred
only in asynchronous cells (Fig. 2C, where overlapping
peaks were merged). De novo motif analysis of FoxA1
peaks in mitosis revealed a Fox consensus sequence that
was essentially the same as that seen at asynchronousonly sites (Fig. 2D). We found 601 genes bound by FoxA1
in both asynchronous and mitotic cells and 2722 genes
bound by FoxA1 only in asynchronous cells (Fig. 2E).
Triplicate microarray analyses of HUH7 cells showed
that mitotic and interphase FoxA1 target genes represent
those that are among the most highly expressed in interphase (Fig. 2F). Mitotic FoxA1 targets include transcription factor genes that are important for hepatic differenti-

ation, such as HNF4a and FOXA1 itself (Fig. 2G), and genes
for kinase signaling pathways (Supplemental Fig. 3d). In
summary, we estimate that ;15% of the FoxA1 sites that
are bound in interphase cells are also bound in mitosis,
corresponding to the strongest bound sites at the more
highly expressed genes in interphase.
FoxA1 target sites that remain bound in mitosis
have a higher intrinsic nucleosome occupancy score
(INOS) than sites bound only in asynchronous cells
To further characterize potential differences between
target sites for FoxA1 that remain bound in mitosis
compared with sites bound only in asynchronous cells,
we first compared the binding events with available
histone modification data in the human ENCODE database. No substantial differences were observed to be
centered over the FoxA1-binding sites (data not shown).
Given the extensive prior data documenting the ability
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of FoxA1 to bind nucleosomal DNA (Cirillo et al. 1998;
Cirillo and Zaret 1999; Chaya et al. 2001), we compared
the FoxA1 mitotic and asynchronous binding data with
a computational model that predicts how well a nucleosome could form at underlying 147-base-pair (bp) lengths
of DNA (Kaplan et al. 2009; Tillo and Hughes 2009; Tillo
et al. 2010). Figure 3 shows the average INOS for FoxA1
ChIP-seq peaks in mitotic and asynchronous cells across
1500 bp spanning each binding event. In both cases, there
is a peak in INOS near the center of DNA binding. Peaks
in INOS of ;300 bp have been observed at binding events
for other transcription factors (Tillo et al. 2010). A difference here is that the absolute value of INOS for FoxA1 is
low, indicating that the protein does not generally bind
to CG-rich regions of the genome. Indeed, the target
sequence for FoxA1 is relatively AT-rich (Fig. 2D).
Interestingly, the INOS for FoxA1 in mitotic cells is
significantly higher than that in asynchronous cells (P =
9.5 3 10!6). The higher INOS for mitotic peaks suggests
that the underlying nucleosome is typically more stable
at chromosomal sites where FoxA1 remains bound in
mitotic cells compared with that seen at sites where
FoxA1 binds only in asynchronous cells. This possibility
is consistent with the aforementioned features of FoxA1
binding its target site on nucleosomes in vitro and in vivo
and suggests that more stable nucleosomal targets help
predict mitotic chromosome binding.
Substantial nonspecific mitotic chromosome binding
by FoxA1
We next addressed the apparent conundrum that FoxA1
is stable in mitosis (Supplemental Fig. 1b) and retained
globally on the chromosomes (Fig. 1A) yet dissociates
from many specific interphase binding sites (Fig. 2A).
To investigate changes in the chromatin-binding properties of FoxA1, we performed fluorescence recovery after
photobleaching (FRAP) assays in unfixed cells on GFPFoxA1, with GFP-H1o as a control. GFP-H1o in HUH7
cells exhibited a threefold increase in FRAP half-time in
metaphase compared with interphase (Fig. 4A); a similar
increase was seen for H1c-GFP in other cells (Chen et al.

Figure 3. FoxA1-bound sites in mitotic cells have higher
predicted nucleosome occupancy compared with sites bound
only in asynchronous cells. Average INOS for FoxA1 3509 ChIPseq peaks seen only in asynchronous HuH7 cells and 544 peaks
seen in mitotic cells within 6750 bp from the center of the
peak; also shown are 100,000 sequences selected at random
from human genome (hg18). The average INOS profiling of
FoxA1 in mitotic HuH7 cells is higher than seen in asynchronous cells (t-test, P = 9.5 3 10!6).
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2005). Thus, linker histone moves more slowly in metaphase chromatin, consistent with the chromosomes’ high
degree of compaction. In marked contrast, GFP-FoxA1
exhibited a more than twofold decrease in FRAP half-time
in metaphase (Fig. 4A). Thus, the dramatic compaction of
chromatin in mitosis is associated with an increase in the
mobility of FoxA1 compared with interphase.
We questioned whether the increased mobility of FoxA1
in mitosis could be visualized in the genomic ChIP-seq
data as an increase in nonspecific DNA-binding signals.
Indeed, when viewed at the chromosomal level, there was
a greater background of nonpeak FoxA1 ChIP-seq reads in
mitotic cells compared with asynchronous cells (Fig. 4B,
blue lines below red arrowheads; Supplemental Fig. 4).
Thus, the increased mobility of FoxA1 in mitosis is associated with significant amounts of FoxA redistributing
from specific sites to the flanking chromosomal domains.
We questioned whether the nonspecific binding at the
chromosomal level in mitotic cells was dependent on
FoxA1 interactions with DNA. To address this, we transfected HUH7 cells with GFP-tagged variants of FoxA1
that perturb nonspecific DNA binding (FoxA1-RR) or
specific DNA binding (FoxA1-NH) (Sekiya et al. 2009).
FoxA1-RR has alanine substitutions at two residues that
make phosphate contacts with the DNA backbone (Fig.
5A). The FoxA1-RR mutant exhibits a marked decrease in
overall and nonspecific DNA binding but still recognizes
FoxA target sites, albeit more weakly than wild type
(Sekiya et al. 2009). FoxA1-NH has alanine substitutions
at two residues that make base contacts with DNA (Fig.
5A). The FoxA1-NH mutant exhibits normal nonspecific
DNA binding but no longer recognizes FoxA target sites
(Sekiya et al. 2009). Strikingly, when observed in live
mitotic cells, much of the GFP-FoxA1-RR mutant was
cytoplasmic (Fig. 5B). In contrast, the GFP-FoxA1-NH
mutant was largely retained on the mitotic chromosomes
(Fig. 5B), demonstrating that specific binding is not necessary for bulk mitotic retention. From these data, we
conclude that much of the FoxA1 in mitotic chromatin
is bound nonspecifically to the DNA.
To assess the contributions of specific and nonspecific
binding to target site binding in mitosis, we performed
ChIP for the GFP tag in cells transfected with GFP-FoxA1
and the variants (Fig. 5C; Supplemental Fig. 5a). As
expected, wild-type GFP-FoxA1 bound to endogenous
FoxA1 targets in both asynchronous and mitotic cells
(Supplemental Fig. 5b). Of three target sites that possess
a FoxA-binding motif, binding by the GFP-FoxA1-RR
mutant at the AFP !4.1-kb site and the TTR promoter
was diminished, but still significant, in comparison with
the IgG ChIP control (Fig. 5C, red arrowheads). In contrast, the GFP-FoxA-NH mutant exhibited a loss of
binding to all of these sites (Fig. 5C). Therefore, despite
a loss in nonspecific DNA binding and significant release
from chromosomes, the FoxA-RR mutant can still bind in
mitosis to sites with FoxA1 motifs. We conclude that
binding by FoxA1 in mitotic chromosomes can take two
forms: nonspecific binding that is not reflected in specific
peaks in the ChIP-seq data and specific binding at a subset
of asynchronous cell FoxA1 target sites.
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Figure 4. Increased mobility and nonspecific binding
of FoxA1 in mitotic cells. (A) Relative fluorescence
intensity (RFI) analysis showing that while GFP-H1o
moves threefold more slowly in mitotic chromatin
compared with interphase nuclei, GFP-FoxA1 moves
2.5-fold more quickly. Error bars denote standard error
of the mean (SEM). Primary FRAP data for RFI analysis.
White circles indicate the bleached area. (B) Unique
FoxA1 ChIP-seq signals from two to 10 reads per
million per 25-bp interval mapped to the left arm of
human ch. 7 depicting higher nonspecific, background
binding in mitotic cells (red arrows) and many more
peaks in asynchronous cells. Input DNA is shown at
two to 20 reads per 25-bp interval.

Specific and nonspecific mitotic binding promotes
target gene reactivation post-mitosis
Previous knockdown studies of Brd4 (Dey et al. 2009),
MLL (Blobel et al. 2009), and GATA1 (Kadauke et al. 2012)
found that these mitotic bookmarking factors are required for the timely reactivation of genes to which they
bind in mitosis and are not required for the initial
reactivation of genes to which they are bound only in
interphase. To assess FoxA1 in this context, we compared
the target gene reactivation after mitotic release in cells
transfected for 2 d with a FOXA1 knockdown siRNA
versus a control siRNA (Supplemental Fig. 5c,d). The
relatively short time period is sufficient for determining
effects on nascent transcript induction (see below) but, in
our hands, not long enough for marked effects on steadystate levels of mRNA. By immunofluorescence, RNA
polymerase II was absent from metaphase chromosomes
in blocked HUH7 cells and then rebound chromatin 80
min after release in some cells (Supplemental Fig. 5e).
Incorporation of ethynyl uridine (EU) (Jao and Salic 2008)
into nascent RNA was undetectable in arrested cells;
sparse staining appeared in some cells by 80 min after
release and was more uniform across the nucleus by 90–
100 min post-release in late telophase (Supplemental Fig.
5e), similar to other cell types (Prasanth et al. 2003). Based

on these findings, we collected triplicate RNA time
points before and after transcriptional reactivation and
analyzed genes by RT-qPCR with primer sets that span
intron–exon junctions to exclusively detect nascent
mRNA. Many genes exhibited a continual increase in
nascent transcripts for hours after mitotic release, while
others exhibited an initial burst of expression (Fig. 6A;
Supplemental Fig. 6).
Regardless of the initial re-expression pattern, most of
the genes that were bound by FoxA1 in mitosis exhibited
a statistically significant dependence on FoxA1 for their
initial activation in late telophase (Fig. 6A; Supplemental
Fig. 6, top rows), demonstrating that FoxA1 functions as
a bookmarking transcription factor. None of the genes
that were not bound by FoxA1 in mitosis or interphase
were dependent on FoxA1 for early reactivation, demonstrating selectivity for FoxA1 target genes (Fig. 6A;
Supplemental Fig. 6, bottom rows). Interestingly, many
of the genes that were bound by FoxA1 in interphase but
not in mitosis were also dependent on FoxA1 for their
initial activation post-mitosis, although with a wider
variation in response (Fig. 6A; Supplemental Fig. 6, middle rows). When we grouped all genes assayed in each
category at the earliest time point and assessed the
average fold induction in the presence of FoxA1 siRNA
over that with the control siRNA, both the mitotic-bound
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Figure 5. FoxA1 mutants that perturb specific or nonspecific
DNA binding reveal significant nonspecific binding to mitotic
chromatin. (A) Crystal structure view of the FoxA DBD depicting residues mutated to perturb specific (NH) and nonspecific
(RR) DNA binding (Sekiya et al. 2009). (B) The FoxA1 mutant
with impaired nonspecific DNA binding is partially released
from mitotic chromosomes, while the FoxA1 mutant with
impaired specific DNA binding is mostly retained. (C) ChIPqPCR assays on transfected HUH7 cells in mitosis showing that
the FoxA1-RR nonspecific binding mutant can still recognize
the Afp !4.1-kb and Ttr promoter target sites that contain
FoxA-binding motifs (shown in the top row, red arrowheads),
whereas the FoxA1-NH specific binding mutant cannot. Thus,
even when loss of nonspecific binding results in most of the
FoxA1 being lost from mitotic chromosomes (B), FoxA1 can
bind specifically to target sites in mitotic cell chromatin (C).

and asynchronous-only-bound FoxA1 target genes exhibited
a significant difference from the genes not bound by FoxA
(Fig. 6B). Similar results were obtained with a less extensive study using a different siRNA to knock down FoxA1
(Supplemental Fig. 7). We conclude that FoxA1’s increased mobility in mitotic chromatin (Fig. 4A) yet high
nonspecific chromatin-binding capacity (Figs. 5, 6) keep
the factor on chromatin and facilitate rapid reactivation
during mitotic exit. The most highly expressed FoxA1
targets retain FoxA1 binding in mitosis, whereas most
other FoxA1 targets appear to be dependent on nonspecific binding to mitotic chromatin. Importantly, FoxA1
does not indirectly enhance the reactivation of genes to
which it is not bound in interphase. We conclude that the
pioneer factor FoxA1 has mitotic chromatin-binding
features that distinguish its activity from other bookmarking factors that have been characterized.
Discussion
In this study, we demonstrated that FoxA1, a pioneer
factor involved in early steps of liver development, also
bookmarks targets genes during mitosis. FoxA1 employs
two different modes of mitotic binding that contributes
to gene reactivation during exit from mitosis. The
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specific binding mode is responsible for mitotic marking
of genes that are highly expressed in interphase, including
important liver genes, and the nonspecific binding mode
keeps FoxA1 in the vicinity of other target genes by
random site retention on mitotic chromosomes. The
nonspecific chromatin binding occurs via the high intrinsic affinity of FoxA1 for nucleosomal DNA (Cirillo
and Zaret 1999; Sekiya et al. 2009) and the factor’s increased chromatin mobility in mitosis (Fig. 4). By retaining
FoxA1 on the DNA in mitosis, albeit nonspecifically, the
factor has initial access to its specific target sites that
would precede what would be observed for factors that do
not bind mitotic chromatin and thus could facilitate early
gene reactivation during mitotic exit (Fig. 7).
What determines whether a transcription factor will
remain bound to a particular site in mitosis? The answer
to this question has eluded the field, and there may be
different mechanisms employed by different factors. As
seen by other factors (Kadauke et al. 2012), the binding
sequence motif for FoxA1 is essentially the same at
mitotic-bound sites compared with sites bound only in
interphase (Fig. 2D). We failed to discover histone modifications at FoxA1 target sites in asynchronous cells that
would predict mitotic binding. However, this negative
result could be due to a limitation of the available
chromatin modifications currently in the online databases or to a lack of correspondence between the cell
lines that have been assayed and HUH7 cells in which
we performed our experiments. Importantly, we were
able to discern that predicted INOSs (Kaplan et al. 2009)
are sufficient to distinguish the subset of sites that
remain bound by FoxA1 in mitosis; i.e., the sites that
retain FoxA1 binding in mitosis had significantly higher
INOSs. While nucleosome mapping in vivo will be required to assess the validity of these predictions, they are
striking in light of FoxA1 having a markedly lower off rate
for its target sites on nucleosomes compared with free
DNA (Cirillo and Zaret 1999). Furthermore, sequential
ChIP studies showed that FoxA1 binds a nucleosomal target
site in vivo (Chaya et al. 2001). Because many, but not all,
other transcription factors lack the high intrinsic affinity for
nucleosomal DNA, it seems unlikely that the INOS will be
a general predictor of mitotic chromosome binding. However, for this class of protein, it could be useful.
How is nonspecific DNA binding by FoxA1 more
prominent in mitosis than in interphase? Our FRAP
experiments revealed that despite linker histone moving
more slowly in mitotic chromatin, in agreement with
prior studies (Chen et al. 2005), the mobility of FoxA1 in
chromatin is increased compared with interphase. This
observation, coupled with the high intrinsic nucleosome
and chromatin-binding capacity of FoxA1, could be
sufficient to explain a decrement in specific target residence time with a concomitant increase in nonspecific
chromatin binding. As for what causes an increased
mobility of FoxA1 in mitotic chromatin, we speculate
that a mitosis-specific modification of the protein could
play a role, the overall compaction of chromatin could
help exclude many specific sites, and/or an altered
modification of the chromatin itself could contribute.
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Figure 6. FoxA1 is necessary for timely reactivation
of target genes as cells exit mitosis. (A) RT-qPCR
analysis of primary transcripts in HUH7 cells treated
with siRNAs for FoxA1 (si6689) or a control siRNA
blocked in mitosis and released for various time points.
Data are normalized to Gapdh and to the ‘‘block’’ time
point prior to mitotic release. The first two genes in
each row exhibited a net increase in synthesis over
time, while the others exhibited an initial burst of
synthesis. The top row depicts genes that are bound by
FoxA1 in mitosis; these are dependent on FoxA1 for
late telophase reactivation. The middle row depicts
genes that are bound by FoxA1 only in asynchronous
cells, many of which depend on FoxA1 for its initial
activation. The bottom row depicts genes that are not
bound by FoxA1 and are independent of FoxA1 for early
reactivation. See Supplemental Figure 5 for more genes
of each type. Error bars denote SEM; asterisks indicate
significance by a one-tailed Student’s t-test: (*) P < 0.05;
(**) P < 0.01. (B) The average nascent transcript induction at 105 min post-mitotic block release is shown
as a ratio of that in the presence of the FoxA1 siRNA
over that for the control siRNA for genes in the three
categories in A and Supplemental Figure 5. Error bars
denote SEM, and asterisks indicate significance by a
one-tailed Student’s t-test: (*) P < 0.05; (**) P < 0.01.
A separate Mann-Whitney test, not shown, revealed
that the FoxA siRNA selectively perturbed mitotic
FoxA1-bound versus unbound to P < 0.00013 and
asynchronous-only bound versus unbound to P < 0.022.
The data show that FoxA1 facilitates the early reactivation of genes bound in mitosis as well as genes bound
solely in interphase cells and does not indirectly enhance
the reactivation of genes to which it does not bind.

By assaying in parallel diverse types of factors critical
for a single cell lineage, we discovered a diversity of
mitotic chromatin-binding types, including total occupancy, specific and nonspecific binding, partial or total
chromosome exclusion, and differential mitotic stability.
We note that the earliest transcription factors in liver
development, including FoxA1 and HNF1b (Lokmane
et al. 2008), are necessary in the endoderm for hepatic
induction and exhibit high-level binding to mitotic chromosomes (Verdeguer et al. 2010). In contrast, the other
hepatic transcription factors tested exhibit successively
less mitotic binding capacity. This raises the possibility
that the diverse modes of transcription factor binding in
mitosis may mimic binding hierarchies in development.
The mitotic binding hierarchy could be a way to ensure
the initial exclusion of factors that would otherwise
promote an alternate cell fate when a given cell type exits
mitosis.

24 h, cells were washed three times with PBS and released into
medium containing 0.06 mg/mL fresh nocodazole (Sigma, M1404).
After 18 h, ;94% of the cells were blocked in metaphase
(Supplemental Fig. 3a) and used for imaging or ChIP. Drug
washout experiments showed that the cells remained viable and
proliferative. For mitotic block release studies, arrested cells
were either (1) harvested by gentle shaking and replated into
fresh medium or (2) washed three times with PBS, and fresh
medium was added to the cells. Cells were allowed to proceed for
the periods indicated.
Fluorescence imaging of HUH7 cells
HUH7 cells were plated in glass-bottomed microwell dishes
(Mat Tek Corporation) and transfected on the next day with

Materials and methods
Mitotic arrest of HUH7 cells
HUH7 cells were plated in fresh DMEM High Glucose with
L-glutamine (Invitrogen, 11965), 10% FBS (HyClone), and 1%
penicillin–streptomycin (Invitrogen) and grown overnight to
75% confluence. Cells were blocked in S phase by addition of
fresh medium containing 2 mM thymidine (Sigma, T1895). After

Figure 7. Specific and nonspecific modes of FoxA1 binding to
the mitotic genome allow rapid reactivation of FoxA target
genes during mitotic exit.
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GFP-tagged fusion proteins (Sekiya et al. 2009) with FuGENE 6
(Roche). After 48 h of mitotic arrest, asynchronous and
nocodazole-blocked cells were photographed at 1003 using
a Deltavision Core Deconvolution microscope (Applied Precision) from an Olympus IX70 microscope equipped with a
Photometrics CoolSNAP HQ 12-bit monochrome cooled CCD
camera. We used a 1003 1.4 NA oil immersion PlanSApo lens
(Olympus, #UPLSAPO 100XO) objective with epi-illumination
provided by a 300 W xenon arc lamp. The resulting images were
deconvoluted using the constrained iterative algorithm with
softWoRx (Applied Precision) acquisition software.
For conventional fluorescence microscopy, cells were fixed
with 3.7% formaldehyde (Fisher Scientific) for 20 min, washed
twice with PBS, permeabilized for 10 min in methanol (Fisher
Scientific) at !20°C, and then rinsed three times with PBS. Cells
were stained with 4,6-diamidino-2-phenylindole (DAPI) for 1 min.
After three washes with PBS, the samples were imaged at 403
using a Nikon Optiphot microscope with an Optronics CCD
camera. Alternatively, after the first PBS washes, cells were
incubated with a monoclonal antibody against H3phospho-S10
(Abcam, ab14955) diluted 1/375 in 3% FBS, 5 mM KCl, 100 mM
NaCl, 0.2% Triton X-100%, 1% BSA, and 10 mM Tris-HCl (pH
7.5) for 2 h at 4°C, then rocked 33 with PBS for 10 min at room
temperature and incubated with a secondary antibody conjugated to Alexafluor 488 (Invitrogen; A21202) at 1/500 in dilution
buffer for 1 h at room temperature. After rinsing twice with PBS,
cells were stained with DAPI and imaged as above. For RNA
polymerase II, cells were fixed for 30 min in PBS containing 4%
paraformaldehyde and permeabilized for 20 min in PBS containing 0.5% Triton X-100. Blocking was in PBS, 0.1% Triton X-100
(PBS-T), and 10% goat serum (Sigma, G9023) for 1 h. 8WG16
(Abcam, ab817) was diluted 1:1000 in PBS-T and applied overnight at 4°C. Cells were washed three times with PBS for 10 min
each and then treated with Alexa Fluor 488 goat anti-rabbit IgG
(1:10,000 in PBS-T; Invitrogen, A11001) for 1 h at room temperature. Cells were washed three times with PBS. DAPI (Sigma,
D9542) at 0.5 mg/mL PBS was applied to the cells for 2 min. Cells
were washed with PBS and imaged at 603 using an Eclipse
TE2000-U inverted microscope (Nikon) and CoolSNAP EZ
camera (Photometrics).
For immunostaining of endogenous FoxA1, HuH7 cells were
washed twice with PBS before fixation in PBS with 4% paraformaldehyde for 12 min at room temperature and then rehydrated in cold PBS, 0.5% Triton X-100 for 10 min. After rinsing
twice with PBS, cells were treated with blocking solution
containing PBS-T, 4% FBS, 10% glycerol, and 0.1 M glycine for
1 h at room temperature. Primary incubation was done with a
goat antibody against FoxA1 (Abcam, ab5089) diluted 1/200 in
blocking solution for 1 h at room temperature. Cells then were
rocked three timeswith PBS-T for 5 min and incubated with
Alexa Fluor 488 anti-goat (1/1000 in blocking solution; Invitrogen, A11055) for 1 h at room temperature. Finally, after rocking
the cells three times with PBS-T for 10 min, cells were stained
with DAPI and imaged as for H3phospho-S10.
To visualize new RNA synthesis after release from a mitotic
block, HUH7 cells were synchronized by thymidine–nocodazole
block and released into fresh medium. One hour before the desired
time point for fixation, EU was added to 0.5 mM (Jao and Salic
2008). After this 1-h pulse, the cells were fixed and permeabilized
as for RNA polymerase II. Cells were washed once with PBS, and
the 30-min ‘‘click’’ reaction to Alexa Fluor 594-azide was initiated
and later quenched as specified (Click-It RNA Alexa Fluor 594
imaging kit; Invitrogen, C10330). Cells were then washed three
times with PBS while protected from light and counterstained
with DAPI, washed with PBS, and imaged at 603.
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ChIP
Asynchronous and nocodazole/thymidine-blocked cells were
cross-linked with 1% formaldehyde for 20 min at room temperature followed by addition of glycine to 125 mM. After two
washes with PBS, cells were collected and frozen. Cell pellets
were lysed, and genomic chromatin was sonicated to 200–500 bp
(Diagenode Bioruptor). For ChIP-qPCR, 25 mg (for GFP-ChIP) or
35 mg (for FoxA1-ChIP) were precleared with salmon sperm DNA
and protein A agarose (Millipore, #16-157). Samples were split,
the first aliquot was incubated with 2 mg of rabbit IgG (Abcam,
ab46540), and the second aliquot was incubated with 2 mg
of rabbit polyclonal to GFP (Abcam, ab290), FoxA1 (Abcam,
ab23738), or Histone H3 (Abcam, ab1791). Samples were rotated
overnight at 4°C and immunoprecipitated with salmon sperm
DNA–protein A agarose and low- and high-salt wash steps.
Cross-linked products were reversed, RNase-treated, and DNApurified. Samples were analyzed on an iCycler iQ multicolor
real-time PCR (Bio-Rad) using SYBR Green (Bio-Rad). PCR
primer sets are listed below. We used two biological replicates
for the GFP-ChIP and three independent replicates for the FoxA1
and H3-ChIP.
ChIP-seq
ChIP was performed on triplicate chromatin samples of 335 mg
divided for FoxA1 and IgG immunoprecipitations, and products
were used to generate libraries (Illumina, IP-102-1001) of 100–
200 bp (Bioanalyzer, Agilent) on an Illumina Sequencer. Additionally, one DNA input library each was made from mitotic and
asynchronous chromatin. Sequence reads were aligned to the
human genome (NCBI Build 36) with ELAND using default
parameters. We uniquely mapped 40,002,286 and 43,176,234
reads for mitotic and asynchronous cells, respectively. Peaks
were called for each lane separately with MACS (Mfold parameter 16; false discovery rate [FDR] 5% for mitotic peaks and
0.05% for asynchronous peaks) using the input lanes as background. A more lenient FDR was used to assess mitotic peaks
because the majority of reads fell into regions of nonspecific
binding (see Fig. 3C), making peak identification for this ChIP
more difficult. The trends observed in Figure 2, C and F, are also
observed when both peak sets are filtered at 5% FDR (data not
shown). Peak sets from each replicate were intersected, and
peaks that share $50% sequence were merged to define distinct
binding sets. RefSeq transcripts were classified as targets if a
FOXA1 peak was present in the gene body or within 20 kb
upstream of the transcription start site. Data track images of
peaks were constructed by pooling sequence reads from all
replicate lanes, assessing tag counts at each position, normalizing the count per million aligned reads, and subtracting input.
These counts were written into a wiggle file and uploaded to the
University of California at Santa Cruz Genome Browser. Wholechromosome views were created similarly, except that sequence
tags were binned at 25-bp intervals prior to normalization.
Motifs were discovered using MEME and TOMTOM. The
presence or absence of the human FoxA1-binding sequence
was assessed using the available site matrix from JASPAR
(MA0148.1). ChIP-seq and gene expression array data have been
uploaded to Gene Expression Omnibus.
Intrinsic nucleosome occupancy calculation
The INOS based on the Lasso algorithm (Kaplan et al. 2009; Tillo
and Hughes 2009; Tillo et al. 2010) was calculated for evaluation
of intrinsic nucleosome occupancy. For each 1500-bp sequence,
we calculated the INOSs for each slide window of 147 bp and
moved the window base by base to get the profiling of INOSs.
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The control set was 100,000 sequences randomly selected from
hg18.
Gene expression microarrays
Total RNA was collected from three different plates of asynchronous Huh7 cells using the RNeasy minikit (Qiagen). Expression microarrays were performed with a Human Gene 1.OST
array (Affymetrix) at the University of Pennsylvania Microarray
Core Facility and were evaluated using Partek.

Nascent mRNA of target genes were analyzed by real-time PCR
using SYBR Green (Applied Biosystems). Primer sets (see below)
were designed to detect primary transcript, nonspliced mRNA
by spanning intron–exon junctions and the adjacent exon.
Expression levels were normalized to the levels of spliced
GAPDH. The data are represented as fold induction over time
0 h: 2DDCt = 2Ctgene_t ! CtGapdh_t/2Ctgene_t0 ! CtGapdh_t0. Error bars
indicate SEM. One asterisk denotes P < 0.05 and two asterisks
represent P < 0.01, calculated using a one-tailed Student’s t-test.
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Western blot analysis
Primary antibodies used were as follows: FoxA1 (0.001 mg/mL;
Abcam, ab23738), C/EBPa (1:400; Santa Cruz Biotechnology,
sc-61), and vinculin antibodies (1:5000; Sigma-Aldrich, V-9131).
Secondary antibodies used were as follows: goat anti-rabbit
IgG (H+L)-HRP (1:5000; Bio-Rad, 1706515) and goat anti-mouse
IgG-HRP (1:5000; Santa Cruz Biotechnology, sc-2005).
FRAP assays
Cells cultured in glass-bottomed microwell dishes were transfected with GFP-tagged proteins and arrested in mitosis. The
dishes were mounted onto a spinning-disk confocal microscope
with a Yokogawa CSU X1 scan head and an Olympus IX 81 microscope. The cells were kept at 37°C using an Okolab Uno incubator. Acquisition and hardware were controlled by MetaMorph,
version 7.7 (Molecular Devices). An Andor iXon3 897 EMCCD
camera (Andor Technology) was used for image capture. Solidstate lasers for excitation (488 nm for GFP) were housed in a
launch constructed by Spectral Applied Research. An Olympus
1003, 1.4 NA UPlanSApo oil immersion objective was used for
all experiments.
FRAP was performed using the iLas2 system (Roper Scientific),
using a 50-mW diode-pumped crystal laser at 405 nm (CrystaLaser, model DL405-050-O) controlled by MetaMorph. Laser
power for bleaching was attenuated to 7.5%. For each experiment, four to six single-prebleach images were acquired before
an area of 1.5 mm2 was bleached. Images were collected over 150
sec (FoxA1) or 227 sec (H1) every 0.3 sec. At least nine cells were
analyzed for each time.
To calculate the relative fluorescence intensity (RFI) in the
bleached area at time t, we used the equation RFI (t) = [IB (t) ! IBG
(t)/IB (t0) ! IBG (t0)] [IU (t0) ! IBG (t0)/IU (t) ! IBG (t)]. IB (t) is the
fluorescence intensity in the bleached region at time t, IBG (t) is
the fluorescence intensity in an area containing no cells (background) at time t, IU (t) is the fluorescence intensity in a
nonbleached region in the same cell at time t, IB (t0) is the
fluorescence intensity of the bleached region before bleaching,
IBG (t0) is the fluorescence intensity in the region containing no
cells before bleaching, and IU (t0) is the fluorescence intensity in
the nonbleached area before bleaching. Curve fitting was performed using Prism 5 (Graphpad Software). Error bars from
individual time points represent standard error of the mean
(SEM).
FoxA1 knockdown
Huh7 cells at 30% confluence were reverse-transfected with
3 nM siRNA (FoxA1 ID: si6689) (Fig. 6; Supplemental Figs. 5, 6)
or s6687 (Supplemental Fig. 7) and negative control #1 Silencer
Select siRNAs (Ambion) using RNAiMAX (Invitogen, 13778075). After 58 h, mitotic arrested cells were harvested by shakeoff and plated with fresh medium. Total RNA was collected at
the time points indicated using the RNaEasy microkit (Qiagen).
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